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ABSTRACT 
 
Endometrial cancer (EC) is the most common gynecologic malignacy in the United States. In 
2010, 43,470 cases were newly diagnosed with 7,950 deaths reported. Certain subtypes of EC are 
responsible for a disproprtionate number of deaths each year. Specifically, high-grade Type I, 
papillary serous (PS), and clear cell (CC) tumors account for 60% of all deaths, despite 
accounting for only 20% of new cases. The molecular mechanisms related to poor survival in 
these subtypes are unknown. The tumor microenvironment refers to the complex milieu of 
supporting cells, i.e. stromal cells, which co-exist with the primary tumor. Broad classes of 
stromal cells including inflammatory cells, endothelial cells, and fibroblasts, support the growth 
and dissemination of the primary tumor through their interactions with cancer cells. The primary 
goal of this research was to determine the prognostic roles of two stromal-related pathways 
[CXCL12 and CXCR4; hepatocyte growth factor (HGF), c-Met, and basic fibroblast growth 
factor (bFGF)] in a sample of EC cases (N=216) treated at Magee-Womens Hospital. Paraffin-
embedded tissue blocks were retrieved from the Pathology Department at Magee-Womens 
Hospital and protein expression was measured using immunohistochemistry (IHC). Chi-square 
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tests, Kaplan-Meier plots, log-rank tests, and Cox proportional hazards models were used to 
examine the relationship between tumor and stromal protein expression, clinicopathologic 
factors, overall survival (OS), and recurrence-free survival (RFS). In the first 
microenvironmental pathway, positive CXCL12 expression was significantly associated with 
better OS (hazard ratio, HR: 0.17 95% CI 0.05, 0.59) and RFS (HR: 0.10 95% CI 0.02, 0.57) in 
high-grade Type I cases. In the second pathway of interest, better OS was detected in HGF 
positive, stromal bFGF positive patients compared to HGF positive, stromal bFGF negative 
patients (HR: 0.14, 95% CI 0.03, 0.60). Additionally, worse RFS was observed in HGF positive, 
tumor bFGF positive patients compared to patients with negative expression of both markers 
(HR: 9.88, 95% CI 2.63, 37.16). This study provides evidence that tumor microenvironmental 
proteins can serve as independent prognostic biomarkers in EC. The public health implications 
include a better understanding of the biology of EC and potential targets for molecularly-targeted 
treatments in EC. 
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1.0  INTRODUCTION 
Despite being a highly curable cancer, endometrial cancer (EC) accounts for a large proportion 
of cancer-related deaths each year. In 2010 the American Cancer Society estimated that 43,470 
cases of EC were newly diagnosed and approximately 7,950 deaths occurred. Risk factors related 
to estrogen exposure are implicated in the etiology of the majority of ECs (Type I), with obesity 
showing the largest relative risk. Other important estrogen-related risk factors include early 
menarche, late menopause, hormone replacement therapy, nulliparity, polycystic ovary 
syndrome, and diabetes. The mechanism describing the association between estrogen exposure 
and EC risk is the unopposed estrogen hypothesis. This hypothesis states that estrogen, when 
unopposed by progesterone, has mitogenic effects on the endometrium which can result in a 
higher incidence of oncogenic mutations. In general, survival associated with estrogen-driven EC 
is favorable. 
A subgroup of ECs appears to be estrogen-independent (Type II) and little is known about 
the etiology of these tumors. Identification of risk factors associated with development of Type II 
EC is limited by the low incidence of these tumors, which precludes effective prevention of these 
tumors. Patients with Type II tumors are more likely to experience poor outcomes such as 
recurrence, metastasis, and death compared to their Type I counterparts. Additionally, the 
molecular pathways associated with poor outcomes in these patients are unknown. 
Understanding the molecular epidemiology of poor-prognosis tumors could potentially lead to 
better treatment options and reduce morbidity and mortality associated with these cancers, while 
adding to the general body of knowledge regarding these tumors.  
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The tumor microenvironment refers to the extracellular matrix and the supporting cast of 
cells that are genetically normal but phenotypically altered due to their interaction with 
neoplastic cells. In normal tissue homeostasis, stromal cells provide supportive functions to 
epithelial cells and facilitate communication between cells. Following the carcinogenesis of a 
primary tumor, the tightly regulated interactions between transformed epithelial cells and stromal 
cells become dysregulated. Cancer cells are able to co-opt the multiple functions of stromal cells 
to serve their metabolic needs and migratory ambitions. Evidence from other common cancers 
suggests that the tumor microenvironment contributes to the invasive and aggressive phenotypes 
seen in cancers with poor survival. 
Two microenvironmental pathways have been examined in other common cancers. The first, 
CXCL12 and CXCR4, is involved in directional migration of cells and therefore may contribute 
to metastasis, a common cause of cancer-related death. The second pathway, hepatocyte growth 
factor (HGF), c-Met, and basic fibroblast growth factor (bFGF) is associated with angiogenesis, 
the formation of new blood vessels from preexisting vessels. The initiation of angiogenesis is a 
requirement for the growth of tumors as well as distant metastasis. 
The goals of this research are to further describe Type I and Type II ECs through completion 
of the following three primary aims: 1.) explore risk and prognostic factors associated with Type 
I and Type II EC patients, 2.) examine the association between CXCL12/CXCR4 expression, 
clinicopathologic factors, and survival in EC, and 3.) examine the association between HGF/c-
Met/bFGF expression, clinicopathologic factors, and survival in EC. 
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2.0  LITERATURE REVIEW 
2.1 ENDOMETRIAL CANCER (EC) EPIDEMIOLOGY 
2.1.1 EC incidence and mortality 
EC is the most common gynecological malignancy in the United States; an estimated 43,470 
cases were newly diagnosed in 2010 [1]. Joinpoint analyses using data from the Surveillance, 
Epidemiology End Results (SEER) program indicate that EC incidence rates in the U.S. declined 
significantly between 1975 and 1988 and increased between 1988 and 1998. More specifically, 
between 1988 and 1998, the annual percentage change (APC), a statistic which describes the rate 
of change for a particular cancer statistic, increased yearly at a rate of 0.6% [2]. Thereafter, the 
APC decreased at a rate of 1% per year between 1998 and 2004.  
Analyses of EC incidence rates by race indicate important trends over time (Figure 1). In the 
early 1970’s, Caucasian women had a two-fold higher incidence of EC compared to African-
American and women of other race. Following the peak in 1975, age-standardized incidence 
rates in Caucasian women began to decline dramatically. By 1989, the difference in incidence 
between Caucasian and African-American women was less than 3 cases per 100,000 persons 
(White: 14.1 cases per 100,000 women; African-American: 11.4 cases per 100,000 women). 
Joinpoint analyses stratified by race indicate that African-American, Asian or Pacific Islander, 
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and American Indian/Alaska Native women had positive APC’s of 1.0%, 0.7%, and 2.2% 
respectively between 1995 and 2004, whereas Caucasian women had a statistically significant 
APC decline of 0.5% during the same time period [2]. 
 Regardless of race, as women transition into menopause, the incidence of EC increases 
dramatically (Figure 2). Age-specific incidence rates show that EC incidence begins to 
dramatically increase at age 50 which coincides with the menopausal transition for most women. 
The highest incidence of EC among Caucasian and African-American women occurs between 
ages 75 and 79, with approximately 54 cases per 100,000 women being diagnosed in each race. 
American Indian/Alaska Native women experience bimodal peaks in incidence rates at ages 65-
69 and 75-79. Finally, Asian or Pacific Islander women experience their highest age-specific EC 
incidence at age 55-59, with 27.5 cases per 100,000 women occurring. Subsequently, incidence 
rates gradually decline over the next twenty years of life for Asian or Pacific Islander women. 
Although 75% of ECs are diagnosed early in the disease process, mortality from EC has 
increased dramatically over the past 20 years [3]. Likely contributors to this increase include an 
increasing life span in the U.S. and coexisting medical co-morbidities [3]. Historically, EC 
mortality rates have been higher in African-American women compared to Caucasian women, 
despite a two-fold higher incidence of EC in white women. The disparity in incidence has 
narrowed between the two races in the last decade, but the disparity in mortality has not. Espey 
et al. [2] reported the EC mortality rate to be 7.1 per 100,000 African-American women while 
the mortality rate for Caucasians was 3.9 per 100,000 women between 2000 and 2004. Several 
plausible explanations exist for this disparity in mortality: 1) differences in stage, grade, and 
histology at time of diagnosis 2) lower socioeconomic status of African-American women 3) 
greater clinical co-morbidities and 4) differences in treatment [4].  
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EC mortality rates among other ethnic minorities appear to be increasing as well. 
Tammemagi [5] reported the age-adjusted mortality rates from EC to be 2.2, 2.6, and 3.2 per 
100,000 women for Asian Pacific Islanders, American Indian/Alaska Native, and 
Hispanic/Latino women, respectively, during the 1992-2002 time period, indicating an increase 
in cancer associated mortality. 
2.1.2 Factors related to EC survival  
Survival following EC diagnosis and treatment is generally favorable, however survival 
decreases significantly with increasing stage at diagnosis. Using data from SEER, the relative 
survival for EC in the U.S. is plotted in Figure 3. Between 1996 and 2006, women diagnosed 
with localized tumors had a relative survival of 94% after 9 years of follow-up. Patients with 
regional spread had a relative survival of 60% after 9 years of follow-up, while patients with 
distant metastases present at diagnosis had poor survival rates throughout the 8-year duration 
follow-up period. In the SEER cohort, unstaged patients had a relative survival slightly lower 
than patients with regional endometrial tumors.  
In addition to stage, age and tumor histology have a significant impact on survival in EC [6]. 
Compared to patients less than 45 years of age at the time of diagnosis, Zaino et al. [7] reported 
that patients 55 years of age or older had a two-fold higher risk of EC death while patients 65 
years of age had a 3.40 times higher risk, and patients greater than 75 years of age had a 4.70 
times higher risk. Poor prognosis associated with increasing age may be due to a variety of 
factors including: 1.) older patients may develop more aggressive histology subtypes of EC 
which carry a worse prognosis, 2.) older patients may have a weaker immunologic capacity 
against cancer, and 3.) less aggressive therapeutic options are used in elderly patients [8, 9]. 
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Finally, numerous studies show that tumor histology is an important independent predictor in EC 
survival. Clear cell (CC) and papillary serous (PS) histology subtypes comprise between 10% 
and 20% of all EC cases, however they account for approximately half of all EC-related deaths, 
signifying an important disparity in EC survival [10]. 
 
Figure 1 EC incidence among U.S. women by race, SEER*Stat, 1973-2005 
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Figure 2 Age-specific endometrial cancer incidence rates among U.S. women by race, SEER*Stat, 
2000-2004 
 
 
Figure 3 Relative survival following endometrial cancer diagnosis by stage, 1996-2006, SEER*Stat 
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2.2 EC RISK FACTORS 
The etiology of EC is multifactorial and varies considerably based on the histology of the tumor. 
Two classes of endometrial tumors are recognized: Type I, also referred to as endometrioid, is 
associated with the estrogen pathway, often arises from atypical hyperplasia, and presents as a 
low-grade, well-differentiated tumor [11]. Typically, estrogen and progesterone receptors are 
expressed in these tumors [12]. Type II endometrial tumors, also known as the nonendometrioid 
type, arise from an atrophic endometrium and appear to be unresponsive to estrogen stimuli. The 
two histology subtypes of Type II EC are PS and CC [13]. Patients with these tumors are usually 
diagnosed in advanced stages with relatively low 5-year survival rates compared to patients with 
Type I endometrial tumors [13]. 
Many of the commonly cited risk factors for Type I EC contribute to a chronic low-level 
increase in circulating estrogen exposure that is not counterbalanced by progesterone [14]. 
Namely, obesity, unopposed estrogen therapy, and reproductive characteristics, such as parity, 
age at menarche and menopause, and oral contraceptive use are strongly associated with EC risk. 
Recent studies have implicated other lifestyle risk factors, particularly diet and the metabolic 
syndrome, in the carcinogenic process related to Type I EC. Conversely, the risk factor profile 
for those who develop Type II endometrial tumors is unknown. Relatively fewer studies have 
explored the epidemiologic profile of Type II patients, however these patients tend to be African-
American, multi-parous, and of normal weight [15]. 
In addition to the environmental component of EC risk, a genetic basis for EC has been 
described. Hereditary non-polyposis colorectal cancer syndrome (HNPCC), also known as Lynch 
syndrome, is caused by mutations in one of five DNA mismatch repair genes, MLH1, MSH2, 
MSH6, PMS1 and PMS2; mutations in MLH1 and MSH2 account for the majority of cases, 
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whereas MSH6 mutation is implicated in 15% of cases [16]. Germline mutations in these genes 
result in microsatellite instability (MSI) which is a progressive accumulation of alterations at 
microsatellite loci [17]. EC is the most common phenotype of this cancer syndrome following 
colorectal cancer [17]. Some studies even report EC to be the most common malignancy for 
women with HNPCC, not colon cancer [18]. Females with HNPCC have a ten-fold increased 
lifetime risk of developing EC compared to women not belonging to HNPCC families. 
Hereditary EC is more likely to occur at a younger age and is characterized by high stage and 
poor differentiation [17]. 
 The increasing prevalence in many of the known risk factors for EC, such as obesity, 
highlights the potential for an increased future burden of EC in the U.S. The modifiable nature of 
many of these risk factors underscores the need for public health interventions.  
2.2.1 Endogenous estrogens and EC 
Endometrial tissue is one of the many target tissues responsive to sex steroid hormones [14]. Sex 
steroid hormones share a basic chemical structure, and include androgens, estrogens, and 
progesterone [19]. Important regulatory properties maintained by these hormones include 
apoptosis, cellular proliferation, and differentiation; processes that are frequently dysregulated in 
malignant transformation. The unopposed estrogen hypothesis describes the relationship between 
steroid hormones and EC risk. Estrogen, when unopposed by progesterone, has proliferative 
effects on the endometrium. Consequently, women with high levels of bioavailable estrogens and 
low plasma progesterone have an increased risk of EC. This hypothesis resulted from two 
important observations: 1.) endometrial proliferation rates are greater during the follicular phase 
of the menstrual cycle when progesterone levels are low and estrogen levels are at normal 
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concentrations and 2.) the risk of EC is higher for women using exogenous estrogen therapy 
without a progestin component [14]. Factors associated with high circulating levels of estrogen 
are described below. 
2.2.1.1 Obesity 
The role of obesity in endometrial carcinogenesis has been documented extensively. In fact, EC 
is the cancer most commonly associated with obesity [19]. Many epidemiologic studies show a 
substantially greater risk with increasing weight. In obese pre- and post-menopausal women the 
increase in risk of EC ranges from two to five-fold [14]. In a meta-analysis of international 
cohorts, Renehan et al. [20] reported the overall relative risk of EC to be 1.59 times higher for 
each 5 kg/m2 increase in body mass index (BMI). Although this association has been 
demonstrated convincingly, the exact mechanisms through which increased adiposity confers a 
higher EC risk are not fully understood. Implicated in the disease process are two interrelated 
hormonal pathways: the estrogen/progesterone pathway and the insulin and insulin-like growth 
factor 1 (IGF-1) axis pathway. 
 Following menopause, the major source of estrogen is from the conversion of adrenal 
androgens (androstenedione) to estrogen (estrone) by aromatization in adipocytes [21]. In 
postmenopausal women, excess weight can potentially affect the bioavailability of estrogen 
through two mechanisms. First, adiposity raises plasma levels of aromatase and 17β-
hydroxysteroid dehydrogenase, enzymes responsible for conversion of androstenedione and 
testosterone into estrone and estradiol, respectively. In fact, BMI is positively associated with 
levels of estradiol and estrone in healthy control women [22]. The second mechanism through 
which excess weight influences the availability of estrogen is by increasing circulating levels of 
both insulin and IGF1 [19]. Excess weight is associated with insulin resistance due to increased 
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concentrations of fatty acids which are released from adipose tissues [14]. Elevated levels of 
fatty acids lead to metabolic changes that limit the ability of hepatic and muscular tissue to 
absorb and utilize glucose in energy metabolism. Consequently, a reduction in insulin receptors 
occurs, leading to a state of insulin resistance. Insulin resistance causes plasma levels of IGF-1 to 
increase, which lower hepatic synthesis of sex-hormone binding globulin (SHBG). SHBG is 
responsible for binding estradiol in women, with lower levels of this protein resulting in greater 
amounts of bioavailable estrogens [19]. 
2.2.1.2 Metabolic conditions 
Metabolic conditions, particularly diabetes, have been shown to be positively related to an 
increased EC risk. Although excess weight has played a mediating role in this association, recent 
analyses show that EC risk is associated with diabetes independent of weight. Weiderpass et al. 
[23] explored this association in a population-based case-control study in Sweden. Adjusted for 
age, hormone replacement therapy use, parity, age at menarche, and recent BMI, EC cases were 
1.70 times more likely to have diabetes compared to randomly selected population controls. 
Furthermore, this study examined if hypertension, another component of the metabolic disorder, 
modified the risk of EC associated with diabetes. When adjusted for recent BMI, history of 
hypertension was not significantly associated with EC risk (Odds Ratio (OR): 1.10, 95% CI 0.90, 
1.30). Hypertension did modify the risk of EC in obese patients; cases were 1.40 times more 
likely to be obese and hypertensive compared to controls (95% CI 1.00, 2.20) [23]. Among 
normal weight women no increase in risk of EC for hypertensive women was observed (OR: 
1.00, 95% CI 0.70, 1.20). 
Two potential mechanisms exist for the increased EC risk in relation to diabetes. As 
previously mentioned, increased levels of circulating insulin can result in decreased synthesis of 
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SHBG which is associated with increased circulating estrogen. Conversely, insulin may act as a 
direct growth factor on the endometrium, irrespective of changes in sex steroid hormone levels 
[23].  
2.2.1.3 Parity 
Related to unopposed estrogen exposure, nulliparity has consistently been shown to be a risk 
factor for EC. Most studies report a 10-40% reduction in EC risk for parous vs. nulliparous 
women [24-28]. Pregnancy is a time when progesterone levels are high which may account for 
the reduced EC risk through opposition of estrogen [29]. In a population-based case-control 
study, Brinton et al. [30] reported that Polish women who ever had a full-term pregnancy were 
half as likely to be cases compared to women who never had a full-term birth (OR: 0.51, 95% CI 
0.40, 0.70). Additionally, a statistically significant trend in the number of full-term births was 
observed; women with 3 or more full-term births had a 70% lower risk of EC compared to 
nulliparous women. Furthermore, this study examined the potential relationship between timing 
of pregnancy and EC. Age at last birth and intervals since last birth variables were constructed to 
examine the effect on EC risk. Although the findings did not support a role for such a 
relationship, other studies have reported important relationships between timing of pregnancy 
and EC risk [29, 31]. Parrazzini et al. [29] and Lambe et al. [31]  reported that protection of 
pregnancy against EC risk decreased significantly with longer time since last birth.  
Several studies have examined whether infertility is associated with risk of EC. The World 
Health Organization defines infertility as not being able to conceive within one year of trying; 
however, many disorders could be at the root of this condition which makes infertility a difficult 
risk factor to study [32]. Furthermore, infertility is usually treated with fertility drugs that 
stimulate multiple ovulations per cycle. As these drugs increase serum levels of hormones, these 
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agents may underpin the reported associations between infertility and EC risk [33]. Two large 
studies examined the risk of EC in cohorts of infertile patients [34, 35]. In a cohort of Australian 
women, no significant difference in EC risk was observed for women who utilized in vitro 
fertilization (IVF) compared to the general population (SIR 1.09, 95% CI, 0.45-2.61) [34].  In 
women who did not receive ovarian stimulation, the observed incidence of EC was significantly 
higher compared to the expected incidence (SIR: 2.47, 95% CI 1.18, 5.18). This study implies 
that untreated IVF patients have an increased risk of EC. Importantly, this study only controlled 
for age; factors that may confound the relationship between infertility and EC risk were not taken 
into account.  
Modan et al. [35] studied the risk of EC in a cohort of women diagnosed as infertile between 
1964 and 1974. In unadjusted analyses, the incidence of EC was significantly greater than 
expected (SIR: 4.80, 95% CI 3.00, 7.40). The role of ovulation induction treatments was also 
assessed in this study. Women treated with fertility drugs had a SIR of EC two times greater than 
women not treated with fertility drugs (6.80 vs. 3.10), however this was not statistically 
significant. Because of the conflicting evidence, carefully planned studies are needed to 
understand this relationship in the presence of potential confounders. 
2.2.1.4 Polycystic ovary syndrome 
Polycystic ovary syndrome (PCOS) is a relatively common disorder in pre-menopausal women 
that is characterized by anovulation and progesterone deficiency. In 1990 the National Institutes 
of Health (NIH) established diagnostic criteria for the disorder: chronic anovulation and presence 
of hyperandrogenism (diagnosed either clinically or biochemically) with the exclusion of other 
causes of hyperandrogenism such as adult-onset congenital adrenal hyperplasia (CAH), 
hyperprolactinemia, and androgen-secreting neoplasms [36]. More recently, the 2003 Rotterdam 
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consensus workshop revised the previous guidelines to include polycystic ovaries as a diagnostic 
criterion [37]. Because PCOS is a heterogeneous syndrome, the Rotterdam consensus concluded 
that 2 out of 3 of these criteria are sufficient for diagnosis. An association between PCOS and EC 
was first suggested in 1949 by Speert from the observation that women with EC had a high 
incidence of cystic ovaries [38]. Since then, several studies have been conducted to further 
explore this relationship, however design issues have precluded a definitive answer regarding 
this relationship [39]. Many studies have examined whether EC risk was elevated in women with 
anovulatory infertility, which is one of the presenting symptoms of the syndrome and may occur 
from causes unrelated to PCOS. Others have observed an association between risk of 
endometrial hyperplasia and PCOS [39]. 
 In a cross-sectional study, the prevalence of polycystic ovaries, a marker of PCOS, was 
similarly distributed in patients with EC and patients with benign gynecological conditions. 
When stratifying by age, PCOS was more common in EC cases less than 50 years of age 
compared to similarly aged women with benign gynecological conditions (62% vs. 27%, p= 
0.03) [39]. Although this cross-sectional study cannot establish the timing of events, i.e. if cystic 
ovaries preceded EC, this study does lend favorable support to the association. Prospectively 
planned studies, where PCOS is defined based on diagnostic criteria, are needed to determine the 
relationship between PCOS and EC risk. Based on biological plausibility it would appear 
reasonable to suggest that women with PCOS have a higher probability of EC as anovulation is 
associated with decreased circulating levels of progesterone, which would lead to higher levels 
of unopposed circulating estrogen [40].  
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2.2.2 Exogenous estrogens and EC 
2.2.2.1 Estrogen replacement therapy 
Risk of EC is strongly associated with unopposed estrogen replacement therapy (ERT). ERT use 
rose dramatically in the United States from the mid 1960’s until 1975 for the relief of 
menopausal symptoms. During this time period, EC rates increased at an alarming rate, which 
prompted investigations into an association between ERT and EC risk [41]. In a meta-analysis of 
29 observational studies, the combined relative risk (RR) for EC was 2.30 times higher for ERT 
users compared to non-users. Additionally, EC risk increased as the duration of ERT usage 
increased [42].  
 In a meta-analysis including 7 observational studies exploring the association between 
estrogen plus progestin therapy and risk of EC found no association (RR: 0.80, 95% CI 0.60, 
1.20), further supporting a role for unopposed estrogen and EC risk [42]. Similarly, the Women’s 
Health Initiative trial reported no statistically significant increase in the incidence of EC after 5 
years of follow-up in women who used estrogen plus progestin therapy (HR: 0.83, (95% CI 0.29, 
2.32) [43]. 
2.2.2.2 Selective estrogen receptor modulators 
Selective estrogen receptor modulators (SERMs) have been used in the treatment of hormonally 
related cancers. SERMs resemble the chemical structure of estrogens and compete for binding at 
estrogen receptors, antagonizing the effects of endogenous estrogen [44]. Two major SERMs, 
tamoxifen and raloxifene, have been commonly used in the treatment of breast cancer. Although 
tamoxifen antagonizes estrogen receptors in the breast, it is associated with EC risk via 
stimulation of endometrial estrogen receptors. The estrogenic effects of tamoxifen in the uterus 
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are associated with a two to seven-fold increased risk of EC [45]. In a large cohort of women 
who developed endometrial tumors after being diagnosed with breast cancer, Hoogendoorn et al. 
[46] reported that EC was significantly more likely to occur in the women treated with 
tamoxifen. Additionally, tamoxifen-treated patients had unfavorable prognostic characteristics 
and worse survival compared to EC patients not treated with tamoxifen.  
Conversely, raloxifene has anti-estrogenic effects in both the breast and uterus. DeMichele 
et al. [44] reported a 50% reduction in the odds of EC associated with raloxifene use compared to 
never users. Moreover, raloxifene is associated with a 33% reduction in EC risk adjusted for age, 
race, BMI, and family history of breast cancer.   
2.2.2.3 Oral contraceptive use 
The risk of EC associated with oral contraceptive use varies based on the formulation of the 
drug. Sequential oral contraceptive (SOC) formulations, although commonly used until the 
1970’s, were discontinued when an increased risk of EC was observed [47]. Sequential 
formulations deliver high doses of estrogen for up to 16 days of the monthly cycle, consequently 
increasing circulating levels of unopposed estrogen [14]. Use of the SOC Oracon, was seven-fold 
more frequent in women with EC than women from the same population without EC [48].  
 Similar to estrogen plus progestin treatments, combination oral contraceptive (COC) 
formulations contain estrogen and progesterone, and are given for approximately 22 days of the 
monthly cycle [14].Sixteen case-control studies and three cohort studies have examined the 
relationship between COC therapy and risk of EC [47]. The results of these studies show that 
risk of EC is essentially halved for women who use COC formulations [47]. Moreover, duration 
of use was associated with a decreased risk of EC. In the Cancer and Steroid Hormone Study, 
women who used COC formulations for less than one year had the same risk of developing EC 
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as those women who had never used COCs. Compared with never-users, women who used 
COCs for more than 5 years were 0.40 times as likely to develop EC [49]. 
2.2.3 Age and EC 
Increasing age is a risk factor for many cancers. The two distinct types of EC, Type I and Type 
II, have different age distributions, which may point out important differences in the etiologies of 
the two types of EC. The median age for Type I EC onset  is 61 years of age, with 90% of cases 
occurring in women older than 50 years of age [3]. Mean age at diagnosis of Type I EC is 61 
years whereas women with Type II EC are typically diagnosed five to ten 10 years later than 
their Type I counterparts [50]. Age-specific graphs for EC incidence, regardless of type, illustrate 
the dramatic increase in diagnoses as women age that appears to coincide with the menopausal 
transition (Figure 2).  
EC in women less than 50 years of age is uncommon. Studies vary regarding the incidence 
of EC in this demographic but most report between 5% and 30% of cases occur in women 
younger than 50 years of age [51]. In general, women younger than 50 years of age are 
premenopausal. Several epidemiologic studies have examined risk factors associated with EC 
development in patients younger than 50 years of age, as well as prognostic factors and survival 
rates in these cases [52-55]. In general, young EC cases are more likely to be obese and have 
advanced stage disease at the time of diagnosis compared to older EC cases, while hypertension 
and diabetes are reportedly more common in older EC cases [52, 53]. Furthermore, survival was 
generally better for young cases in these two case-series; at the end of follow-up almost all EC 
cases designated as “young,” were alive at the end of follow-up. Lu et al. [54] examined the 
frequency of germline mutations in MLH1, MSH2, and MSH6 in a cohort of EC cases younger 
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than 50 years at the time of diagnosis. MSI and immunohistochemistry (IHC) analyses revealed 
9% of young EC cases to carry a germline mutation in one of three DNA repair genes. Notably, 
all patients with germline HNPCC syndrome mutation had a first-degree relative with an 
HNPCC-related cancer [54]. In this setting, family history as well as age at diagnosis can play an 
important role for clinicians in recommending DNA testing for HNPCC.  
In a Danish case-control study, Parslov and colleagues [55] compared EC cases to age-
matched non-cancer controls. In the multivariable model, family history of EC (OR: 2.10, 95% 
CI 1.10, 3.80), having two or more children (OR: 0.30, 95% CI 0.20, 0.60), increasing age at first 
birth (OR: 0.10, 95% CI 0.04, 0.10), induced abortion (OR: 0.50, 95% CI: 0.30, 0.90), oral 
contraceptive use between 1-5 years (OR: 0.20, 95% CI 0.10, 0.30), and hormone replacement 
therapy use between 1-5 years (OR: 3.10 95% CI 1.40, 7.00) were significantly associated with 
EC risk in women younger than 50 years of age.  
 Schmeler et al. [51] examined the incidence of EC in young, normal weight women. While 
obesity is a major risk factor for EC, a substantial proportion of young women with EC is normal 
weight. In their cohort of young premenopausal women who developed EC before the age of 50, 
25% had a BMI less than 25kg/m2, which was defined as normal weight in this study [51]. 
HNPCC status was assessed using the revised Amsterdam criteria and patient medical records. 
Among the normal weight cases, 4% were identified as having HNPCC compared to 14% in the 
overweight group. Nulliparity was most prevalent in the normal weight and obese groups 
compared to the overweight group. Infertility was higher among normal weight patients 
compared to overweight and obese cases (17% vs. 7% and 14%, respectively). Diabetes was 
least frequent in the normal weight cases (4% vs. 13% and 35% for overweight and obese cases, 
respectively). Irregular menses was more common among obese cases compared to normal 
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weight cases (61% vs. 30%). Histology subtype, differentiation, and stage of the tumors were 
similar between normal weight, overweight, and obese EC cases. 
2.2.4 Diet and EC 
Although the evidence for an association between dietary factors and EC is somewhat 
contradictory, studies suggest that consumption of soybean-containing foods (phytoestrogens), 
fruits, vegetables, diets low in fat and high in fiber are protective against EC [56]. In a case-
control study using a diet history questionnaire to determine food intake, Goodman et al. [57] 
reported that EC cases were less likely to consume legumes, dietary fiber, and fruit fiber 
compared to healthy controls. Compared to the lowest quartile of vegetable and fruit intake, 
those in the highest quartile had ORs of 0.47 and 0.54, respectively, after adjustment for 
pregnancy history, oral contraceptive use, ERT use, and history of diabetes. High consumption 
of soy products was associated with a decreased risk of EC (OR: 0.46, 95% CI 0.26, 0.83) for the 
highest quartile compared with the lowest quartile of soy intake. Conversely, energy intake from 
fat sources was associated with an increased risk in EC, adjusted for total energy intake.  
 The reduced risk of EC as a result of dietary soy and fiber is biologically plausible. Soy diets 
provide high doses of phytoestrogens which share a similar chemical structure to estrogen. 
Therefore, phytoestrogens may antagonize estrogen by binding at the estrogen receptor [57]. 
Furthermore, high dietary intake of fiber is positively associated with plasma levels of SHBG, 
which may reduce the amount of circulating estrogen [57]. 
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2.2.5 Smoking and EC 
Although a risk factor for many human cancers, cigarette smoking has an inverse relationship 
with EC risk. A meta-analysis including 10 prospective and 24 case-control studies found that 
women who reported ever-smoking had a significantly reduced risk of EC in prospective studies 
(RR: 0.81, 95% CI, 0.74,0.88) and case-control studies (OR: 0.72, 95% CI, 0.66, 0.79) [58]. An 
even greater reduction in risk was evident for current smokers; the overall summary estimate 
from prospective studies was 0.74 (95% CI 0.64, 0.84) while the summary estimate from case-
control studies was 0.63 (95% CI 0.55, 0.72). When stratifying women based on menopausal 
status, a reduction in EC risk remained for postmenopausal women (RR: 0.71, 95% CI 0.65, 
0.78), but not in pre-menopausal women (RR: 1.06, 95% CI, 0.88, 1.28). 
Mechanistically, several explanations may account for an association between smoking and 
a reduced risk of EC. Michnovicz et al. [59] reported that cigarette smoking induces an increase 
in estradiol 2-hydroxylation. This pathway yields 2-hydroxyestrogens, which possess minimal 
peripheral estrogenic activity and are cleared rapidly from the circulation, thereby reducing the 
bioavailability of estrogen. Others have suggested that smoking may negatively affect ovarian 
function. Pre-menopausal women who smoke have fewer ovarian follicles which may result in 
earlier menopause and consequently reduce lifetime estrogen exposure [60]. This hypothesis was 
not supported by the meta-analysis findings by Zhou et al. [58], as no decreased risk of EC was 
reported among pre-menopausal women who smoke. As the mechanism for an association 
between smoking and EC risk is unknown, further study into this relationship is warranted.  
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2.3 CLINICAL FEATURES OF ENDOMETRIAL TUMORS 
2.3.1 Histopathology 
The major EC histology subtype is Type I (endometrioid), which accounts for 75-80% of all ECs 
[61]. Adenocarcinoma is the most commonly diagnosed histology subtype among Type I EC 
patients, however adenocarcinoma with squamous differentiation occurs in approximately 25% 
of cases [62]. The next most common EC histology subtypes, CC and PS, account for less than 
20% of all endometrial tumors, and are collectively referred to as Type II EC. Finally, mucinous, 
squamous, and undifferentiated tumors comprise the remaining EC histology subtypes [61]. 
2.3.2 Precursor Lesions 
2.3.2.1 Type I EC: Endometrial intraepithelial neoplasia (EIN) 
Endometrial intraepithelial neoplasia (EIN) is the precursor lesion of Type I EC [3]. The 
histological appearance of this lesion is characterized by a glandular area that exceeds the 
stromal area; left untreated, these precursors progress to invasive carcinoma [63]. EIN arises 
from a hyperplastic endometrium. Endometrial hyperplasia (EH), a noninvasive proliferation of 
the uterine lining, occurs in the setting of unopposed estrogen stimulation [64]. Unopposed 
estrogens produce a disordered proliferative endometrium and over time an increasingly irregular 
distribution of endometrial glands results [65]. Classification of EH is defined by architectural 
complexity (simple or complex) and cytological atypia (present or absent) [65]. Hyperplasia with 
atypia is the least common type of hyperplasia and is strongly associated with EIN and further 
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progression to Type I EC. In fact, women diagnosed with atypical hyperplasia are ten times more 
likely to develop EC compared to women diagnosed with non-atypical hyperplasia [63]. 
2.3.2.2 Type II EC: Endometrial glandular dysplasia (EmGD) 
Endometrial intraepithelial carcinoma (EIC) was previously thought to be the precursor lesion in 
PS EC, however recent studies have suggested that a newly identified lesion, endometrial 
glandular dysplasia (EmGD), is the precursor to both EIC and PS. Morphologically and 
clinically, EIC resembles an early form of PS rather than a precursor [66]. EIC is characterized 
by a complete replacement of surface epithelium by glands that resemble the PS cells with high 
grade nuclei [66]. EmGD on the other hand appears to represent the earliest morphologically 
identifiable precursor lesion in PS development for several reasons: first, EmGD transitions 
frequently into EIC, and EIC transitions into PS, however there is no direct transition from 
EmGD to PS. Second, in PS tumors, areas of EmGD are usually noncontiguous with the main 
tumor mass, however EmGD lesions are proximal to EIC. Finally, p53 overexpression, the most 
common molecular alteration in PS tumors, ranges on a continuum in various endometrial 
tissues: p53 overexpression scores are lowest in the benign endometrium, moderately high in 
EmGD lesions, and more frequent in EIC [66].    
2.3.3 Staging of EC 
Guidelines for the staging of EC have been defined by the International Federation of 
Gynecology and Obstetrics (FIGO). Stage I refers to cancer confined to the corpus uteri; stage II 
involves the corpus and the cervix but has not extended outside the uterus; stage III extends 
outside of the uterus but is confined to the true pelvis with or without lymph node involvement; 
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stage IV involves the bladder or bowel mucosa or has metastasized to distant sites [12]. In order 
to properly stage EC a hysterectomy and lymphadenectomy should be performed [61]. 
 Stage of presentation varies based on the histology subtype of the tumor. In Type I tumors, 
roughly 72% of ECs are stage I, 12% are stage II, 13% are stage III, and the remaining 3% are 
diagnosed at stage IV [3]. Type II tumors are usually diagnosed at an advanced stage compared 
to Type I tumors. Approximately 54% of Type II tumors are stage I, 8% are stage II, while the 
remaining 38% are either stage III or IV [15]. Five-year survival rates for stage I-IV ECs are as 
follows: stage I: 81-90%; stage II: 72-80%; stage III: 39-63%; and stage IV: 17-20% [3].  
2.4 EC TREATMENT 
Several thorough reviews have been written regarding the treatment of EC [67-70]. Typically, 
women between 55 and 65 years of age presenting with bleeding unrelated to the menstrual cycle 
and/or pelvic pain have an endometrial biopsy or dilation and curettage [61]. After identifying 
cancerous cells, most patients will undergo a hysterectomy with bilateral salpingo-oophorectomy 
as the initial treatment. Contraindications to surgery (old age, morbidly obese, poor health, etc) 
occur in a minority of cases, which precludes surgical intervention. At the time of surgery, lymph 
node sampling (i.e. lymphadenectomy) is usually performed to inform adjuvant treatment 
options [67]. In patients with Type I (endometrioid) tumors, surgery alone is sufficient for stage 
IA, grade 1 or 2 disease and stage IB, grade 1 disease due to the low risk of recurrence and death 
[67]. 
Intermediate risk Type I EC patients are a heterogeneous group and typically have a 
combination of one or more of the following pathologic risk factors: any degree of myometrial 
 24 
invasion and moderately to poorly differentiated grade, lymphovascular invasion, and age older 
than 70. The efficacy of adjuvant radiotherapy in this subgroup was addressed in the 
Gynecological Oncology Group (GOG) trial 99 which concluded that adjuvant radiotherapy in 
this subgroup decreases the risk of recurrence (HR: 0.42, 95% CI 0.25, 0.73), but not all-cause 
mortality [71].  
The role of adjuvant therapy in high-risk EC cases (stage III and IV, any histology) was 
examined in the GOG trial 122, which scrutinized the role of whole-abdominal irradiation vs. 
doxorubicin and cisplatin chemotherapy. Chemotherapy significantly improved progression-free 
survival (PFS) and overall survival (OS) compared with whole-abdominal irradiation in this 
high-risk subgroup. Although toxicities were more commonly reported in patients in the 
chemotherapy arm they appeared to be well-tolerated [72].  
By definition, CC and PS ECs of any stage are considered to be at high risk for recurrence 
and death. The initial treatment for these tumors is similar to intermediate and high-risk Type I 
tumors; surgical resection of the uterus, removal of the ovaries, and lymph node dissection 
followed by chemotherapy and/or radiotherapy is generally employed. Only one prospective trial 
has examined the role of radiotherapy in early stage CC and PS cases; due to a large proportion 
of recurrences in the irradiated areas, the authors of this trial concluded that chemotherapy 
should be used in this subgroup of EC cases [73]. Several clinical phase III trials of 
chemotherapy have included patients with CC and PS EC subtypes [74-78]. Typically, these 
trials examine varying combinations and doses of doxorubicin, cisplatin, and paclitaxel. Fleming 
et al. [74] examined the efficacy of cisplatin and doxorubicin with or without paclitaxel in 263 
advanced or recurrent EC cases. Cases with CC and PS tumors made up 20% of the patient 
population. Treatment with all three therapies significantly improved response rates, PFS, and 
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OS compared to the two therapy regimen.   In 2009, a phase III clinical trial examined a protocol 
including surgery, volume-directed radiotherapy of the pelvic and para-aortic lymph nodes, and 
cisplatin/doxorubicin chemotherapy with or without paclitaxel [78]. In this trial, CC and PS 
histologies made up 18% of all cases. The addition of paclitaxel to cisplatin, doxorubicin, and 
radiotherapy did not improve recurrence-free survival (RFS), however significant toxicities were 
observed in this treatment arm. 
To date, no phase III clinical trials utilizing molecularly targeted therapies have been 
performed in EC. Dedes et al. [79] reviewed the phase II clinical trials that target specific 
alterations known to occur in EC. The PI3K/Akt/PTEN/mTOR signaling pathway (to be 
discussed in section 2.5) is the most comprehensively tested pathway; approximately 16 clinical 
trials have been completed or are ongoing. Other molecular treatment targets include epidermal 
growth factor receptors (EGFRs) and vascular endothelial growth factor (VEGF). In general, 
these trials have not shown significant improvements in complete response, partial response, or 
stabilization of disease, however this is likely due to the fact that patients in these trials 
previously underwent chemotherapy regimens and no stratification based on molecular subtype 
was performed.  
2.5 MOLECULAR ALTERATIONS IN EC 
2.5.1 Type I EC 
A dualistic model of endometrial carcinogenesis based on clinical and prognostic factors was 
first proposed by Bokhman in 1983 which led to the acceptance of two main types of EC, Type I 
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and Type II [80]. Epidemiological evidence suggests that the multi-step carcinogenic process of 
Type I endometrial tumors begins with complex EH and progresses to EIN which is the 
precursor lesion of this type [64]. The most commonly reported molecular alterations in Type I 
ECs occur in PTEN, K-ras, β-catenin, BRAF, DNA repair genes which result in MSI, and certain 
cell cycle genes. 
2.5.1.1 Tumor suppressor genes 
The phosphatase and tensin homolog (PTEN) is an important tumor suppressor gene commonly 
mutated in Type I ECs [17]. The PTEN gene product has both lipid and protein phosphatase 
activities which confer different functions [81]. The lipid phosphatase activity of PTEN causes 
cell cycle arrest at the G1/S checkpoint while the protein phosphatase activity of PTEN 
modulates signal transduction pathways by acting on the second messenger, phospholipid 
phosphatidylinositol-(3,4,5)-triphosphate (PIP3). Inactivation of PTEN results in an increase in 
PIP3 which leads to phosphorylation and upregulation of AKT. The overall result is an increase 
in cell proliferation and survival [17].  
Between 40% and 83% of Type I endometrial tumors have altered PTEN expression [82]. 
Additionally, 55% of precancerous lesions have altered PTEN expression, signifying that loss of 
PTEN function is an early event in EC formation [17]. Mutation and loss of heterozygosity 
without mutation result in loss of PTEN [50]. IHC studies have examined the association 
between PTEN expression and prognostic variables; based on semi-quantitative scoring, loss of 
PTEN expression was significantly associated with poor differentiation, positive lymph node 
involvement, and shorter OS compared to tumors with positive PTEN expression [83].  
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2.5.1.2 Oncogenes 
The K-ras gene is a cellular GTPase belonging to the ras gene family [84]. K-ras functions as a 
molecular switch during cell signaling and plays an important role in tumor growth and 
differentiation [11]. When K-ras is present in its constitutively active state, i.e. GTP-bound state, 
continual propagation of intracellular signaling occurs, which allows the cell to proliferate. 
Mutations in the K-ras gene have been reported in 10-30% of Type I tumors, however this 
alteration is rarely seen in Type II tumors [11]. Importantly, K-ras mutations occur in 
approximately 16% of EHs indicating an early event in the carcinogenic process [50]. A single 
amino acid change is responsible for an activating mutation in this gene [84]. 
β-catenin is an adherens junction protein, involved in the maintenance of epithelial layers in 
coordination with E-cadherin [84]. By mediating adhesions between cells, communicating with 
neighboring cells, and anchoring the cytoskeleton of the cell, β-catenin plays a major role in 
normal cell growth and tissue architecture [84]. Mutations in β-catenin lead to overexpression of 
the protein in the nucleus due to the inability of the ubiquitin proteasome to degrade β-catenin 
[11]. Consequently, constitutive activation of target genes such as cyclin D1 occurs which favors 
cell transformation [12]. Additionally, β-catenin is an activator of the downstream Wnt signaling 
pathway; disturbances in Wnt signaling promote human cancers [81]. Nuclear expression of β-
catenin ranges from 31-47% in Type I endometrial tumors. Similar to K-ras and PTEN 
mutations, β-catenin mutations are present in approximately 10% of endometrial hyperplasias, 
signifying β-catenin loss as an early event in tumorigenesis [85]. 
BRAF belongs to the raf family of cytoplasmic serine/threonine protein kinases [84]. The 
BRAF protein plays a role in the mitogen-activated protein kinase (MAPK) pathway which 
affects cell division, differentiation, and secretion [84]. Feng et al. [86] conducted an 
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experimental study to assess the frequency of BRAF mutations in normal endometrial tissues, 
atypical hyperplastic tissues, and EC. Direct sequencing of DNA samples demonstrated that 
BRAF mutations were present in 23%, 11%, 11%, and 0% of Type I, Type II, atypical 
hyperplastic lesions, and normal endometria respectively. The low percentage of BRAF 
mutations in the precursor lesion suggests that the BRAF gene mutation may be important for 
cancer progression rather than the early stages of carcinogenesis in Type I EC.  
HER2/neu is a proto-oncogene that encodes for a transmembrane receptor tyrosine kinase 
which is involved in various cell signaling pathways, notably MAPK and phosphatidylinositol-3 
kinase (PI3K) [84]. These pathways play major roles in cellular functions such as proliferation, 
survival, and aging [84]. Although less prevalent in Type I endometrial tumors, overexpression 
of HER2/neu has been reported in 10 to 30% of high-grade Type I tumors suggesting this 
alteration is an important event in tumor progression rather than tumor initiation [50]. 
2.5.1.3 Microsatellite instability 
MSI refers to a progressive accumulation of alterations at microsatellite loci. Specifically, frame 
shift mutations in short segments of repetitive DNA are found throughout noncoding DNA [81]. 
These alterations arise due to DNA repair errors made during replication. Between 20 and 45% 
of Type I endometrial tumors have MSI and these tumors are also more likely to have PTEN, K-
ras, and β-catenin mutations [12]. In EC, the most commonly inactivated mismatch repair genes 
are MSH2 and MLH1. MLH1 inactivation occurs due to hypermethylation of CpG islands in the 
promoter region of the gene. Moreover, this is the most common cause of MSI in Type I EC, 
however the mechanism of MSH-2 inactivation is still unknown [50]. 
Data on the clinicopathologic impact of MSI in EC were reported by An et al [87]. In a 
subset of Type I ECs, an MSI-high phenotype was denoted by the presence of MSI at 2 or more 
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loci while specimens were classified as “microsatellite stable” if no MSI or one MSI locus was 
present. Among MSI-high patients, 58% had positive lymphovascular invasion, 40% had deep 
myometrial invasion, and 50% had poorly differentiated tumors, signifying an aggressive 
phenotype. 
2.5.1.4 Cell cycle genes 
Cyclins and cyclin-dependent kinases (CDKs) are the regulatory subunits that govern 
progression through the mammalian cell cycle. Cyclins D1, E, A, and B1 form complexes with 
their respective CDK partners, and phosphorylate target substrates which leads to transcription 
and subsequently cell growth [88]. Overexpression of cyclins/CDKs is reported in many cancer 
phenotypes and upregulated cyclin/CDK protein levels are responsible for uncontrolled cell 
proliferation. 
In EC, aberrant expression of cell-cycle regulators has been reported. Compared to normal 
endometrial glands, endometrial tumors had significantly higher rates of immunostaining of 
cyclin D1, cyclin E, cyclin A, cyclin B1, CDK2, CDK4, CDC2, p53, p21, and p27. Analysis by 
stage indicates that cyclin D1, CDK4, and p53 expression were significantly higher in advanced 
stages compared to early stage tumors [88].  
 In terms of survival, cyclin A overexpression was found to be an important indicator of poor 
prognosis in a multivariable model. In patients with cyclin A-positive tumors, OS following 
diagnosis was 20 months less than patients with cyclin-A negative tumors [88]. Cyclin A acts 
during the late G1 phase through the M phase; amplification of the cyclin A gene has been 
shown to induce anchorage independence in cultured cells, which is an important characteristic 
of transformation. The authors concluded that the adverse prognosis associated with cyclin-A 
positivity may be due to the growth potential this regulator maintains [88].  
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2.5.2 Type II EC 
Type II EC comprises the remaining 10-20% of sporadic endometrial tumors. The two most 
common histologies of this type are CC and PS. Although these two histology types are 
commonly grouped together, IHC and genetic studies have shown that the alterations commonly 
observed in PS tumors are relatively infrequent in CC tumors [12]. 
Overall, the epidemiology and biology of Type II tumors are not well characterized, 
however the carcinogenic process appears unrelated to estrogenic stimuli. These tumors typically 
develop in women who are multiparous and normal weight, which contrasts with the 
tumorigenesis of Type I EC [15]. Moreover, Type II tumors generally develop from an atrophic 
endometrium in older women [14]. The clinical course of these tumors is generally more 
aggressive than Type I as five-year survival rates are significantly lower [13, 15]. Table 1 
summarizes the major clinicopathologic features present in Type I and Type II ECs and Table 2 
reports the frequency of genetic alterations that commonly occur in these two tumor types.  
2.5.2.1 Tumor Suppressor Genes 
The most commonly mutated tumor suppressor gene in Type II EC is p53. Approximately 71-
85% of Type II tumors carry mutations in this gene [50]. p53 is a nuclear protein which responds 
to cellular stress caused by DNA damage, hypoxia, and oncogene activation; following damage, 
nuclear p53 accumulates due to interactions between MDM2 and p14ARF [89]. High levels of 
p53 signal transcription of p21 which induces cell cycle arrest by inhibiting cyclin D1 
phosphorylation of the Retinoblastoma (Rb) gene [11]. Numerous cancers are associated with 
aberrant p53 signaling. Although p53 mutations occur in both types of EC however, this 
mutation is an early event in Type II tumorigenesis. p53 mutations occur in Type I tumors, but is 
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often described as a late event [90]. In contrast to other tumor suppressors, mutations in this gene 
result in an overexpression of the gene product. Mutant p53 protein is non-functional, however it 
resists degradation and exerts a dominant negative effect on wild-type p53 [17]. Positive p53 
staining in IHC analyses is often associated with advanced stage, lymph node metastases, and the 
Type II subtype [83]. 
Inactivation of p16 is another molecular alteration reported to occur in Type II endometrial 
tumors [81]. p16 is a tumor suppressor gene that binds to CDK4 and inhibits the cyclin-CDK 
subunit from progressing past the G1 checkpoint of the cell cycle [91]. Therefore, reduced 
expression of the p16 protein is associated with uncontrolled cell growth [81]. Engelsen et al. 
[91] reported loss of p16 expression occurs in approximately 25% of endometrial tumors; 
moreover, low expression of p16 was significantly associated with CC and PS histology and 
advanced stage. The mechanism of inactivation is poorly understood however the three 
mechanisms that alter the p16 gene in other common cancers are homozygous deletion, promoter 
hypermethylation, and rarely, point mutations [92]. Recently, Ignatov and colleagues [92] 
reported that loss of p16 expression by gene deletion and promoter hypermethylation was 
significantly associated with invasive tumor behavior and development of metastases. 
Approximately 93% of primary tumors with metastases had alterations in the p16 gene compared 
to 58% of primary tumors with no metastases. 
2.5.2.2 Oncogenes  
The HER2/neu protein is a transmembrane tyrosine kinase receptor, similar in function to EGF-R 
[17]. Importantly, this protein does not have its own ligand binding domain, however it binds 
tightly to other ligand-bound EGF-R family members [84]. Due to these interactions, HER2/neu 
is an important regulator in cell growth and differentiation. HER2/neu overexpression is 
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commonly reported in EC, however the frequency of overexpression varies considerably by 
study. Recently, HER2/neu gene amplification measured by fluorescence in situ hybridization 
(FISH) was conducted in a large cohort of Type I and Type II EC [13]. HER2/neu gene 
amplification was significantly higher in Type II EC when compared with Type I EC (17% vs. 
1%, p< 0.001). HER2 gene amplification was observed in 16% of the CC specimens and 17% of 
PS specimens. In Type II ECs HER2/neu and p53 are the most frequently studied molecular 
alterations. Other genes that have been recently explored in the carcinogenesis of Type II tumors 
are zinc-finger E-box-binding homeobox 1 (ZEB1) and folate receptor alpha [93, 94]. 
 
Table 1 Clinical and pathological features in Type I and Type II EC 
Characteristic Type I Type II 
Incidence 80%-90% 10%-20% 
Age Pre/peri-menopausal >65 years 
Primary exposure Unopposed Estrogen Unknown 
Background endometrium Hyperplastic Atrophic 
Histology Endometrioid Clear cell, papillary serous 
Grade Low or high grade High grade 
 
 
Table 2 Common genetic alterations in Type I and Type II EC 
Genetic Alteration Gene Type Type I EC (%) Type II EC (%) Reference 
PTEN inactivation Tumor Suppressor 55 
 
11 [95] 
p53 mutation Tumor Suppressor 16-40 80-90 [17, 95] 
p16 inactivation Tumor Suppressor 23 43 [91] 
K-ras mutation Oncogene 13-26 0-10 [95] 
β-catenin mutation Oncogene 25-38 rare [95] 
HER2/neu mutation Oncogene 10-30 45-80 [81] 
BRAF mutation Oncogene 20 rare [86] 
MSI DNA repair genes 17 5 [95] 
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2.6 TUMOR-STROMAL INTERACTIONS  
In normal tissues epithelial cells form fixed, ordered structures and perform tissue-specific 
functions [96], while the extracellular matrix (ECM) and stromal cells provide supportive 
functions to epithelial cells. The microenvironment of a particular tissue comprises a vast 
network of mobile cells that supply the epithelium with paracrine growth factors which control 
cellular responses [97]. Interactions between stromal cells (fibroblasts, endothelial cells, and 
inflammatory cells) and epithelial cells can occur either by direct cell contact or cytokine 
signaling. 
 EC originates in the epithelial cells either due to inherited mutations or an accumulation of 
somatic mutations in oncogenes and tumor suppressor genes. As endometrial epithelial cells 
acquire gene mutations, the ability of the local microenvironment to regulate cell growth 
becomes disrupted and results in an activated stroma, characterized by increased quantities of 
collagens, proteoglycans, and glycosaminoglycans [98]. Consequently, the activated stroma 
recruits inflammatory cells and fibroblasts which support the survival and proliferation of 
carcinoma cells due to abnormal paracrine signaling [97]. The relationship between tumor cells 
and stromal cells allows for the continued growth and invasion of the primary tumor mass.  
 Two stromal-related pathways have been studied in EC cell lines, in vivo mouse models, 
and human EC tissues: CXCL12/CXCR4 and hepatocyte growth factor (HGF)/c-Met/basic 
fibroblast growth factor (bFGF). Findings from experimental studies have yet to be replicated in 
large samples of patients with EC.  Furthermore, reported relationships between expression of 
these proteins and prognostic factors are inconsistent. Understanding the association between 
expression of these potentially important genes and clinical parameters may inform therapeutic 
protocols to improve survival outcomes. 
 34 
2.6.1 The CXCL12/CXCR4 pathway 
2.6.1.1 Physiological role 
CXCL12 (also called stromal cell-derived factor-1alpha), a chemokine of the CXC family and its 
receptor, CXCR4 (C-X-C motif receptor 4) are involved in proliferation, adhesion, chemotaxis 
and tumor metastasis in several malignancies [99]. Chemokines are a family of chemotactic 
cytokines that direct the movement of cells; cells which express the appropriate chemokine 
receptors migrate towards high concentrations of chemokines along a chemokine gradient [100]. 
Furthermore, chemokines are known to play an important role in immune responses, and recent 
evidence suggests that CXCR4 is the predominately expressed chemokine receptor in human 
cancers [101].  
The ability of CXCL12 to induce cancer cell migration has been reported in other cancers. 
Research in breast, ovarian, and thyroid cancer shows that CXCL12 directly stimulates cancer 
cell migration and angiogenesis by interacting with its cognate receptor, CXCR4 [102-104]. 
Similar to expression patterns in other human solid cancers, CXCL12 and CXCR4 are expressed 
in an inverse manner in ECs. Compared to EC tissue, expression of CXCL12 is significantly 
higher in the normal tissues of the endometria while expression of the CXCR4 receptor is 
significantly higher in EC compared to  normal endometrial tissue [105].  
2.6.1.2 In vitro and ex vivo studies of CXCL12/CXCR4 and EC 
Four studies have analyzed the CXCL12/CXCR4 axis in EC, but the conclusions regarding the 
prognostic role of these proteins are contradictory. Mizokami et al. [106] studied the relationship 
between tumor grade and expression of CXCL12 and CXCR4 in 41 Type I EC cases. Tissue 
resected from each case was analyzed using IHC and staining was classified on a 3-titered scale: 
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negative or weakly positive, moderately positive, and strongly positive. Both CXCL12 and 
CXCR4 expression were inversely related to tumor grade in the carcinoma compartment of the 
tissue [106]. In low-grade Type I tumors, CXCL12 expression was significantly higher compared 
to high-grade Type I tumors (p<0.05). Similarly, CXCR4 expression was significantly higher in 
low-grade Type I vs. high-grade Type I tumors (p<0.05) [106]. Stromal expression of CXCL12 
and CXCR4 were assessed, however due to weaker expression in the stromal compartment no 
significant difference in stromal CXCL12 or CXCR4 expression among different grade cancers 
was observed.  
Similarly, Kodama et al. [107] reported CXCR4 expression to be significantly lower in 
patients with characteristics of advanced EC. Fifty-five patients with Type I EC were evaluated. 
CXCR4 expression was analyzed by IHC and dichotomized as positive (more than 50% of cells 
stained) or negative (less than 50% of cells stained). CXCR4 was significantly lower in patients 
with advanced stage tumors (p=0.004), deep muscular invasion (p=0.05), lymph node metastasis 
(p=0.03), ovarian metastasis (p=0.003), and positive peritoneal cytology (p=0.001); all of which 
indicate an aggressive cancer phenotype. Additionally, survival following surgery was examined 
with a Cox multivariable model; CXCR4 expression was not an independent predictor of EC 
survival adjusted for other known prognostic factors [107]. Results from these two studies 
conflict with the notion that the SDF-alpha/CXCR4 pathway is involved in an aggressive EC 
phenotype, as tumors with poor prognostic traits were less likely to show positive staining. 
The third study to examine this pathway was performed by Tsukamoto et al. [108] who 
investigated the interaction between CXCL12 and CXCR4 on the ability of endometrial tumors 
to invade the muscular layer of the endometrium. Muscular infiltration is an important prognostic 
factor in EC; regional node metastases and distant organ metastases are significantly more likely 
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to occur as the depth of muscular invasion increases [105]. In this study, five human EC cell 
lines and EC tissues from 34 Type I EC were examined. CXCR4 protein expression was detected 
using IHC and scored on a 3-titered scale similar to Mizokami et al [106]. The outcome, 
muscular invasion, was classified on the basis of depth: invasion of more than half of the muscle 
layer vs. invasion of less than half of the muscle layer. CXCR4 expression was significantly 
higher in endometrial tumors that invaded more than half of the myometrium compared to 
tumors with superficial invasion. The in vitro assays revealed several key findings: 1.) the 
receptor, CXCR4 is expressed in both EC cell lines and EC tissue shown by Western blot 
analyses, 2.) tumor cells became migratory when cultured with uterine smooth muscle cells as 
measured by an in vitro migration assay, 3.) uterine smooth muscle cells produce the chemokine, 
CXCL12 as measured by an ELISA assay, 4.) CXCL12 activates the PI3K/Akt pathway as 
shown by Western blot analysis using a p-Akt-specific antibody, and 5.) Akt activation is 
required for uterine smooth muscle cell-induced EC cell migration and treatment with a PI3K 
inhibitor significantly impeded cell migration [108]. The findings from this study suggest that the 
CXCL12/CXCR4 axis plays a significant role in EC invasion. 
Most recently, Gelmini et al. [105] examined mRNA and protein expression of CXCR4 and 
CXCL12 in 41 Type I EC. Tumor samples and adjacent non-neoplastic tissues were analyzed by 
reverse transcriptase-polymerase chain reaction (RT-PCR) and IHC for the detection of mRNA 
and protein, respectively. The main prognostic factor in the ex vivo portion of the study was 
histological grade. CXCR4 mRNA expression was significantly higher in ECs compared to the 
paired normal tissue (median mRNA expression: 10.3 vs. 2.9, p=0.04). Conversely, CXCL12 
mRNA expression was significantly higher in normal tissues compared to corresponding EC 
tissues (median mRNA expression: 15.6 vs. 5.1, p=0.002).This relationship mirrors the paradigm 
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of expression noted in other cancers. Additionally, CXCR4 mRNA expression was significantly 
lower in grade 1 tumors compared to grades 2 and 3 tumors indicating that CXCR4 expression 
increases in undifferentiated cancers (p=0.04) [105]. CXCR4 protein expression did not 
significantly differ by tumor grade as all ECs showed a uniform and high expression, regardless 
of grade. 
2.6.1.3 In vivo studies of CXCL12/CXCR4 and EC 
In addition to exploring this pathway in human EC tissues, Gelmini et al. [105] further explored 
the invasive capacity of CXCR4 receptor expressing cells in an in vivo mouse model. Following 
intraperitoneal injection of the HEC1A human endometrium adenocarcinoma cell line, 
experimental mice developed distant metastases in the lung, liver, and peritoneum. Nude mice 
treated with an anti-CXCR4 antibody had complete regression of liver and lung metastases 
compared to the control mice. In anti-CXCR4 treated mice the metastatic index of the 
peritoneum was 2.5% compared to a metastatic index of 70% in the control mice, implying that 
treatment with chemokine antagonists may reduce distant metastases in patients where CXCR4 is 
highly expressed.  
2.6.1.4 Mechanism of action 
Although the results describing the association between CXCL12/CXCR4 expression and EC 
prognosis are conflicting, studies with growth and migratory assays confirm the ability of 
CXCL12 to stimulate cancer cell growth and invasion. Two mechanisms of action are 
downstream activation of two independent pathways: the PI3K/Akt pathway and the  
MAPK/ERK pathway [109]. Akt is a downstream target molecule of PI3K. PI3K is activated by 
growth factor receptor signaling cascades and once stimulated PI-3K phosphorylates and 
 38 
activates Akt. Akt targets many proteins involved in cellular functions such as growth, 
differentiation, cell cycle progression, and cell metabolism [109]. The MAPK pathway (also 
known as extracellular signal-regulated kinases, ERK) is also involved in cellular processes 
similar to Akt [84]. When activated by upstream kinases, MAPK/ERK translocates to the 
nucleus of stimulated cells and phosphorylates nuclear targets [84].  
EC in vitro studies have provided evidence that CXCL12 activates both the PI3K/Akt 
pathway and the MAPK/ERK pathway [109, 110]. Furthermore, activation of each pathway is 
correlated with PTEN and estrogen receptor expression status. Li et al. [110] used the PTEN-
deficient Ishikawa cell line to examine the effect of CXCL12 on signaling transduction and cell 
growth. PTEN was transfected back into Ishikawa cells to examine whether proliferation differed 
in PTEN-deficient vs. PTEN-present cell lines. Levels of pAKT were significantly lower in the 
PTEN-present cells compared to the PTEN-deficient cells, however the level of pERK was not 
significantly different between the two cell lines [110]. The growth-promoting effects of 
CXCL12 on PTEN-present cells were significantly less compared to the PTEN-deficient cells; 
when 50 ng/ml of CXCL12 was added to 96-well plates of both lines, the optical density 
(measured at wavelength 490 mm) was 1.4 in the PTEN-present cells and 0.6 in the PTEN-
deficient cells (p<0.05). The findings from this study imply that PTEN may inhibit CXCL12 
induced growth-promoting effects. As PTEN mutations are reported in 40-80% of Type I ECs, 
the role of CXCL12 in stimulating further growth and invasion in EC is highly relevant. 
 Zhao et al. [109] further investigated this mechanism by studying the role of estrogen 
receptor status of the tumor and the ability of CXCL12 to induce proliferation in EC cell lines. 
Using Ishikawa and HEC-1A EC cell lines, both of which differ with respect to ER and PTEN 
profiles, low concentrations of CXCL12 were able to produce cell proliferation in the Ishikawa 
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cell line but not the HEC-1A cell line. The Ishikawa cell line is positive for ER expression but is 
negative for the production of PTEN due to a mutation in the PTEN gene [110]. Conversely, the 
HEC-1A cell line is positive for PTEN expression and lacks ER expression [109]. A Western 
blot analysis showed that low concentrations of CXCL12 increased the level of ERK in HEC-1A 
cells without changing the level of Akt. Conversely, CXCL12 increased the level of Akt without 
changing the level of ERK in Ishikawa cells. When high concentrations of CXCL12 were 
administered, both Akt and ERK increased significantly in both cell lines. This study indicates 
that low concentrations of CXCL12 activate only the dominant signal transduction pathway. In 
EC cells that lack PTEN expression (Ishikawa), the Akt pathway is activated with CXCL12 
stimulation. In EC cells that lack ER expression (HEC-1A), the ERK pathway is stimulated 
following administration of CXCL12 to cells.  
2.6.2 The HGF/c-Met/bFGF pathway 
2.6.2.1 Physiological role 
Hepatocyte growth factor (HGF) (also called scatter factor, SF) is a stromal-derived growth 
factor with mitogenic and motogenic effects on various cell types [111]. HGF regulates cell 
growth, cell motility, and morphogenesis by activating a tyrosine kinase signaling cascade after 
binding to its proto-oncogenic receptor, c-Met [112]. HGF acts as a multi-functional cytokine on 
cells of mainly epithelial origin. Its ability to stimulate mitogenesis, cell motility, and matrix 
invasion gives it a central role in angiogenesis, tumorigenesis, and tissue regeneration. 
In normal epithelial cells, HGF is not expressed however carcinoma cells may acquire the 
ability to produce HGF. Additionally, various factors secreted by carcinoma cells can induce 
expression of HGF. Examples of these inducers include interleukin-1β, basic fibroblast growth 
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factor (bFGF), tumor necrosis factor (TNF)-α, and prostaglandin E2 [113, 114]. Similar to the 
CXCR4 receptor, the c-Met receptor is overexpressed in carcinoma cells. The proposed 
relationship of this pathway in EC is that HGF-inducers stimulate HGF secretion from stromal 
cells which can then bind to the c-Met receptor stimulating metastasis and invasion of the 
epithelial tumor in a paracrine fashion.  
2.6.2.2 In vitro and ex vivo studies of HGF/c-Met and EC 
In vitro studies in breast, bladder, lung, and pancreatic cancer cell lines verify the ability of HGF 
to stimulate invasion [115-117]. Additionally, the c-Met receptor is commonly overexpressed in 
these cancers indicating a paracrine relationship between HGF and c-Met. The findings 
published thus far on the role of this pathway in EC progression corroborate these results. 
In normal endometrial tissues, Sugawara et al. [118] demonstrated that HGF had stimulatory 
and migratory effects. In this in vitro study endometrial biopsy samples were obtained from 
women undergoing laparoscopy for benign gynecological conditions. All women were in the 
proliferative phase of the menstrual cycle when samples were taken. RT-PCR and Southern blot 
hybridization demonstrated that c-Met mRNA was present in purified endometrial epithelial cells 
and the normal human endometrium, whereas HGF mRNA was not observed in the isolated 
epithelial cells but was present in the normal endometrium [118]. This study hypothesized the 
cell type of origin for HGF to be stromal fibroblasts or infiltrated blood cells such as 
macrophages, however this was not further explored. An MMT proliferation assay showed that 
HGF stimulated a two-fold increase in the number of endometrial epithelial cells compared to the 
control culture where no HGF was added (p<0.05). Moreover, the potential motogenic effects of 
HGF were examined with a Boyden’s chamber assay; a significant increase in the number of 
migrated endometrial epithelial cells occurred when HGF was added to the medium compared to 
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the control experiment where no HGF was added. This study is important in clarifying the role of 
the HGF/c-Met pathway in the non-neoplastic endometrium. In this context, HGF promotes 
regeneration and repair that occurs normally during the menstrual period. Dysregulation of this 
pathway during malignant transformation has negative consequences, namely invasion and 
metastasis. 
Bae-Jump et al. [119] studied HGF and c-Met expression in ECs obtained from surgical 
specimens (N=4) and EC cell lines (KLE, RL-95, HEC-1A, and HEC-1B). After isolating 
endometrial stromal cells from normal human endometrial tissue, enzyme-linked immunosorbent 
assay (ELISA) was performed to demonstrate that stromal cells secrete the HGF protein. 
Additionally, EC tissues and EC cell lines showed positive staining for c-Met mRNA and protein 
using RT-PCR and Western blot analysis, respectively [119]. Importantly, these experiments also 
showed that endometrial stromal cells did not express the c-Met receptor, reinforcing the 
paracrine nature of this pathway. Different grade EC cell lines expressed various amounts of c-
Met, however the relationship was inconsistent with findings from other cancers. The KLE cell 
line, which was derived from a poorly differentiated endometrial adenocarcinoma, expressed the 
least c-Met protein; the RL-95 cell line, derived from a moderately differentiated tumor 
expressed an intermediate amount of c-Met protein; and the HEC-1A and HEC-1B cell lines, 
isolated from patients with well-differentiated stage 1A and 1B adenocarcinoma tumors, 
respectively, expressed the greatest amount of c-Met protein. Assuming that c-Met 
overexpression is a marker of advanced ECs, expression would be expected to increase with 
poorly differentiated tumors. Importantly, the sample size in this study consisted of four cell 
lines and four endometrial carcinoma tissue specimens.  
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In addition to HGF and c-Met, HGF-inducers play an important role in this pathway. As 
their name implies, these proteins induce the transcription and expression of HGF. Using the 
Ishikawa and HEC-1 EC cell lines, as well as tissue from neoplastic and non-neoplastic 
endometria, Yoshida et al. [111] characterized staining patterns of HGF, c-Met, and several 
possible HGF inducers by IHC and RT-PCR. EC tissue and normal tissue from benign 
endometrial cases were collected from patients and the stromal and carcinoma components were 
isolated in order to profile the components separately.  
HGF secreted from endometrial stromal cells (normal and cancer associated) promoted the 
proliferation and invasion of EC cells. HGF mRNA was not detected in the HEC-1 or Ishikawa 
EC cell lines however both normal endometrial stromal cells and cancer associated stromal cells 
expressed the HGF gene. HGF mRNA was six-fold higher in cancer stromal cells compared to 
the normal stromal cells. The effect of HGF on the invasive ability of EC cells was significant; 
addition of HGF to cell cultures of HEC-1 and Ishikawa cells increased the penetrance of these 
cells four times more than cells cultured in the absence of HGF as measured by the Matrigel 
invasion chamber assay (p<0.05) [111]. Proliferation of cancer cells measured by an MTT assay 
was promoted by the addition of HGF in the HEC-1 cancer cell line but not the Ishikawa. 
Additionally, the c-Met gene was expressed in both EC cell lines and in 8 of the 10 cancer cases. 
In order to further clarify the mechanism of interaction between carcinoma cells and the cancer 
stroma, several HGF inducers were investigated. bFGF, interleukin-6 (IL-6), TNF-α, and 
prostaglandin E2 were investigated as potential carcinoma-associated inducers of HGF. bFGF 
significantly increased HGF transcription three-fold.  The findings from this study indicate that 
carcinoma cells express the c-Met receptor as well as produce bFGF which acts upon stromal 
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cells. In turn, cancer associated stromal cells secrete HGF which then binds to the c-Met receptor 
activating a complex program of invasive growth [111, 112]. 
Two prognostic studies have examined HGF and c-Met expression in EC patients. 
Wagatsuma and colleagues [120] examined the association between HGF and c-Met expression, 
clinicopathologic factors, and OS in 93 surgically staged Type I EC patients. Protein expression 
was analyzed in 14 normal endometrial specimens: 5 in the proliferative phase of the menstrual 
cycle, 4 in the secretory phase of the menstrual cycle, and 5 atrophic specimens. IHC for HGF 
and c-Met was performed on paraffin-embedded blocks; staining of both proteins was 
dichotomized as focal (as less than one-third of the gland or cancer cells showing positive 
reactivity for HGF or c-Met) or diffuse (more than one-third of the gland or cancer cells showed 
positive staining for HGF or c-Met). In normal endometrial specimens, diffuse staining for HGF 
and c-Met was observed in 79% and 14% of specimens, respectively. Approximately 90% and 
63% of ECs showed diffuse staining for HGF and c-Met, respectively. Diffuse staining of c-Met 
was significantly associated with advanced surgical stage (stages III and IV, p=0.03) and poorly 
differentiated histology (p=0.002) compared to focal c-Met staining. Age, myometrial invasion, 
and vascular involvement were not significantly associated with diffuse c-Met staining at a 
p<0.05. HGF expression was significantly higher in stage III and IV endometrial tumors 
compared to stage I and II endometrial tumors (Mann-Whitney U-test, p=0.0013).  Multivariable 
analyses showed that OS was significantly associated with stage, differentiation, presence of 
myometrial invasion, and a microvessel count greater than 110; neither HGF or c-Met expression 
were independent predictors of prognosis. 
Similarly, Bishop et al. [121] reported positive HGF and c-Met staining in 100% (n=38) and 
87% (n=33) of PS EC patients, respectively. Furthermore, the level of expression was compared 
 44 
between PS cases and women with atrophic endometrial tissues, low-grade Type I cases, and 
high-grade Type I cases. Patients with cancer had more c-Met and HGF expression than those 
with atrophic endometrial tissues. Neither HGF nor c-Met was significantly associated with 
depth of invasion, stage, or lymph node status. Compared to patients with weak HGF expression, 
OS was significantly worse for patients with strong HGF expression (p=0.04). A similar trend 
for c-Met expression was observed, however this comparison did not reach statistical 
significance (p=0.10).  
The prognostic value of bFGF has also been examined in two small cohorts of EC cases. 
High expression of tumor-derived bFGF protein was significantly associated with poor 
differentiation, presence of tumor necrosis, and vascular invasion [122]. Similarly, Fujimoto et 
al. [123] showed that bFGF mRNA expression was significantly higher in poorly differentiated 
and advanced stage tumors. The association between bFGF expression and survival in EC has 
not been explored. 
The in vitro and ex vivo studies presented here demonstrate the following: 1.) the HGF 
ligand is expressed in the normal endometrium 2.) HGF has the ability to induce migration of 
endometrial epithelial cells as shown by migration assays 3.) the expression of c-Met is 
upregulated in ECs compared to normal endometrial tissues 4.) several inducers of HGF have 
been examined in EC studies however bFGF is the only factor that has been shown to 
significantly increase the transcription of HGF 5.)  the role of HGF, c-Met, and bFGF in EC 
prognosis is inconclusive based on the few studies that have examined these relationships. 
2.6.2.3 Mechanism of action 
Kanayama et al. [124] proposed that HGF stimulates anoikis resistance in EC cells by interacting 
with cyclooxygenase-2 (COX-2), an enzyme that has been implicated in the promotion of 
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carcinogenesis [124]. RL95-2 cells, a human EC cell line, were plated on tissue culture dishes in 
the presence and absence of HGF. A terminal deoxynucleotidyl transferase-mediated nick end-
labeling (TUNEL) assay, which reports the percentage of apoptotic cells, was performed. 
Treatment with HGF significantly decreased the number of apoptotic cells in the RL95-2 cell 
line compared to the cells incubated in the absence of HGF (23.0±2.7% vs. 33.6±3.4%, p<0.05).  
Additionally, activation of the ERK or PI3K/AKT signaling pathways was examined to 
determine the mechanism by which HGF induces anoikis resistance. Cells from the RL95-2 cell 
line were pretreated with ERK and PI3K inhibitors and incubated with HGF. TUNEL was used 
to count apoptotic cells. Compared to untreated cells, the number of apoptotic cells was 
significantly increased in the cells pretreated with PI3K inhibitors compared to cells incubated 
with HGF (34.9±3.4% vs. 23.0±2.7%, p<0.01), indicating this pathway is involved in HGF 
anoikis resistance. Conversely, cells pretreated with an ERK inhibitor failed to effectively inhibit 
anoikis resistance induced by HGF.  
Finally, this study demonstrated that Meloxicam, a COX-2 inhibitor, significantly blocked 
cellular viability.  In those cells treated with the highest concentration of Meloxicam, the percent 
of surviving RL95-2 cells was significantly decreased compared to those cells cultured in the 
absence of Meloxicam. Therefore, HGF may inhibit anoikis by activating the PI3K/AKT 
pathway which further induces COX-2 expression. Importantly, COX-2 inhibitors may play a 
role in the treatment of ECs which overexpress HGF as seen by the inhinbition of this pathway 
with Meloxicam. 
 Choi et al. [114] studied the hormonal influence of estrogen on HGF stimulation in EC cell 
lines. Although estrogen is known to be an important factor in endometrial carcinogenesis, its 
role in promoting the invasion and metastasis of EC has not been addressed. The HEC-1A (well 
 46 
differentiated) and KLE (poorly differentiated) EC cell lines were cultured either in an estrogen 
dominant environment, a progesterone dominant environment, or without ovarian hormones 
(control). Estrogen increased the invasion of both HEC-1A and KLE cells significantly 
compared to the control (p<0.05) whereas progesterone opposed invasion [114]. Importantly, 
when HEC-1A cells were cultured in the presence of estrogen without stromal cells present, little 
invasion was detected. When HGF was added to the culture, EC cells resumed an invasive 
presence, even in the absence of stromal cells. Furthermore, cell cultures showed that TNF-α was 
a potent mediator of the estrogen-stimulated stromal HGF secretion. When NK4, an HGF 
antagonist was added to the cell culture, estrogen-induced invasion was completely nullified. 
2.6.3 The role of estrogen signaling in tumor-stroma interactions 
Although the molecular mechanisms related to estrogen signaling in EC have not been fully 
clarified, epidemiologic evidence supports an association between increased estrogen exposure 
and the risk of developing EC. Several lines of evidence support a relationship between estrogen 
action and the stromal pathways presented here in the context of EC. First, Choi et al. [114] 
reported that EC cells cultured under estrogen dominant conditions induced TNF-α expression 
from carcinoma cells which subsequently induced HGF expression from stromal cells [114]. 
Furthermore, Zhao et al. [109] reported that CXCL12 is a direct target of estrogen action and a 
strong inducer of cell proliferation in EC. In this study, CXCL12 induced cell growth in a dose-
dependent manner in the Ishikawa cell line, a cell line known to express estrogen receptor, 
whereas the same effect was not achieved within the HEC-1A cell line which lacks estrogen 
receptor expression.  
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Additionally, stromal-derived pathways can directly contribute to the activation of estrogen 
receptor. CXCL12/CXCR4 and HGF/c-Met activate downstream kinases, notably MAPK and 
PI3K/Akt, which subsequently phosphorylate estrogen receptor on the transcriptional activation 
function domain, AF-1 [109, 114, 125, 126]. Ligand-independent stimulation of estrogen 
receptor by MAPK and PI3K/Akt results in conformational changes in estrogen receptor, 
recruitment of co-activators, and activation of target gene transcription, similar to estrogen 
activation of the receptor [127]. Therefore, a potent feedback loop is plausible: the targets of the 
HGF/c-Met and CXCL12/CXCR4 pathways activate estrogen receptor which can further 
stimulate production of HGF and CXCL12, binding to their cognate receptors (c-Met and 
CXCR4, respectively), and activation of downstream signaling events. 
Furthermore, stromal cells surrounding the primary tumor cells can contribute to the 
biosynthesis of estrogen. Estrogen metabolizing enzymes such aromatase and the 17β-
hydroxysteroid dehydrogenases are abundantly expressed in stromal cells and convert androgen 
precursors and inactive estrogens into the metabolically active estradiol. Consequently, the 
intratumoral concentration of E2 increases which may further promote EC progression through 
estrogen receptor activation [128]. 
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3.0  SUMMARY 
EC is a significant public health problem. In 2010, the American Cancer Society estimated that 
nearly 8,000 deaths from this cancer occurred. Two subtypes are commonly described in the 
literature, Type I and Type II EC. These two subtypes differ with respect to etiology, 
carcinogenic mutations, and prognosis. Type I EC is a highly preventable cancer; estrogen 
exposure mediated by obesity is the strongest risk factor for development of this subtype. 
Furthermore, a large proportion of Type I EC patients is cured by surgery and favorable 
prognosis is observed. Cancer initiating mutations of this subtype include PTEN inactivation, K-
Ras mutation, and MSI. Conversely, the risk factors associated with development of Type II EC 
are unknown; these patients are more likely to have an aggressive disease characterized by 
recurrence, metastasis, and high mortality. Typically, p53 and HER2/neu are the commonly 
described carcinogenic mutations in this subtype. 
Current treatments for the management of aggressive EC include radiotherapy and 
chemotherapy, which are limited in prolonging OS despite reducing the risk of recurrence. 
Furthermore, toxicities associated with these treatments are substantial. In recent years, cancer 
control treatments have moved away from traditional cytotoxic therapies to the use of small-
molecule inhibitors or antibodies, which provide a targeted treatment approach. The 
identification of prognostic biomarkers in epidemiologic studies is a necessary precursor to 
implementing such treatment.   
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The tumor microenvironment refers to the complex network of cells that surround and 
interact with the primary tumor. In normal tissue homeostasis, fibroblasts, endothelial cells, and 
inflammatory cells interact with tissue-specific epithelial cells to exert normal tissue function. 
Following endometrial carcinogenesis, the ability of the local microenvironment to regulate cell 
growth becomes disrupted and results in an activated stroma. Further recruitment of stromal cells 
to the primary tumor site supports the survival and proliferation of carcinoma cells due to 
abnormal paracrine signaling [97]. This altered relationship between tumor cells and stromal 
cells allows for an aggressive cancer phenotype, characterized by growth and invasion of the 
tumor. Recent studies in breast, colorectal, and lung cancers assert that tumor 
microenvironmental factors are associated with poor survival and can potentially serve as 
therapeutic targets. 
The in vitro and ex vivo literature suggests a role for two pathways, CXCL12/CXCR4 and 
HGF/c-Met/bFGF, to enhance EC progression and metastasis. CXCL12 and CXCR4 may 
influence survival though directional movement of tumor cells, while HGF, c-Met, and bFGF are 
angiogenic factors that enhance tumor growth and metastasis. In order to study how expression 
of these proteins relates to the etiology and prognosis of EC, these biomarkers need to be 
explored in large sets of existing data and tissue bank repositories. The main goal of this research 
is to add to the body of knowledge regarding EC prognosis by exploring the role of the tumor 
microenvironment. The three specific aims of this research are: 
1a.) Compare the characteristics of patients with Type I and Type II EC  
1b.) Identify prognostic factors for OS among patients with low-grade Type I, high-grade 
Type I, and Type II EC 
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2.) Evaluate the association between CXCR4 and CXCL12 protein expression, prognostic 
factors, and survival outcomes in a sample of Type I and Type II EC cases 
3.) Evaluate the association between HGF, c-Met, and bFGF protein expression, prognostic 
factors, and survival outcomes in a sample of Type I and Type II EC cases 
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4.1 ABSTRACT 
Objective: We investigated risk factors for Type II (N=176) vs. Type I (N=1,576) endometrial 
cancer (EC) in cases treated at Magee-Womens Hospital between 1996 and 2008.  
Methods: Clinical data were available from the University of Pittsburgh Medical Center 
(UPMC) Network Cancer Registry. Logistic regression was used to estimate the adjusted odds of 
having Type II EC vs. Type I EC. Risk factors of interest in this analysis were: age, race, body 
mass index (BMI), year of diagnosis, parity, menopausal status, and history of additional primary 
tumors.  
Results:  Relative to women with Type I EC, women with Type II EC were more likely to be 
older at diagnosis (OR: 1.03 per 1 year increase in age, 95% CI 1.01-1.05), of non-white race 
(OR: 2.95, 95% CI 1.66-5.27), have a history of additional primary tumors (OR: 1.56, 95% CI 
1.05-2.32), and less likely to be obese (OR: 0.45, 95% CI 0.29-0.70).  
Conclusion:  In this large retrospective cohort of patients with EC, the striking difference in risk 
factors associated with Type II vs. Type I tumors suggests that these subtypes represent different 
disease entities that require different treatment modalities. Currently, Type II cases have a 
significantly worse prognosis compared to Type I. Further characterization of risk factors 
associated with developing Type II tumors is needed to prevent this aggressive malignancy. 
 
Keywords: endometrial cancer, epidemiology, Type I, Type II  
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4.2 INTRODUCTION 
Endometrial cancer (EC) is a common malignancy in the US and around the world. The 
incidence of EC exceeds the incidence of cervical, ovarian, vaginal, and vulvar cancers 
combined [129]. Despite being a common cancer, the mortality rates from this disease (4.1 
deaths per 100,000 women) are relatively low, which is mainly attributed to early detection. 
Between 75% and 80% of cases are diagnosed with tumors confined to the uterus (stage 1), 
which are effectively treated with hysterectomy [130]. Since the 1960’s, EC-related mortality has 
declined significantly, although recent data suggest that the number of EC deaths may be on the 
rise [3, 131-133].  
Prior to the 1980’s, EC was broadly characterized as a single disease. However, 
observations by Lauchlan, Hendrickson et al., and Bokhman led to the description of two distinct 
types based on histologic and molecular characteristics [80, 134, 135]. Type I EC, commonly 
referred to as the endometrioid type, comprises 80%–90% of all sporadic endometrial cancers 
[11]. Histologically, these tumors can be adenocarcinoma with or without squamous 
differentiation and often are well-differentiated [17]. Furthermore, epidemiological evidence 
suggests that the multi-step carcinogenic process of Type I endometrial tumors begins with 
simple endometrial hyperplasia, progresses to complex atypia hyperplasia, and then develops 
into the precursor lesion, endometrial intraepithelial neoplasia (EIN) [63-65]. Type II EC, or 
nonendometrioid tumors, encompasses the remaining 10%-20% of sporadic endometrial tumors 
[11]. The two histologies of this subtype are uterine papillary serous carcinoma (UPSC) and 
clear cell carcinoma. Both cancers appear to progress from an atrophic endometrium to the 
precursor lesion, endometrial glandular dysplasia (EmGD) [14, 90, 136].  
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In addition to differences in histology, the etiology and survival related to these two 
subtypes are vastly different. Type I tumors are the prototypical estrogen-dependent tumors; risk 
factors that increase women’s exposure to circulating levels of estrogen are associated with 
increased risk of Type I EC. Similarly, factors that decrease progesterone are associated with 
increased risk of Type I EC. Traditionally cited risk factors for Type I EC are obesity, estrogen 
replacement therapy (ERT), nulliparity, and medical conditions that result in high estrogen 
levels, such as estrogen-secreting ovarian tumors and polycystic ovarian syndrome. In addition, 
Type I tumors are more common than Type II tumors in pre- and peri-menopausal women [11].  
The epidemiology and biology of Type II tumors are not well characterized, although a few 
studies report that Type II cases are more likely to be older, of normal-weight, multiparous, and 
African-American compared to Type I cases [10, 15, 68, 137-141]. The tumorigenesis of Type II 
EC is not thought to operate through the estrogen pathway, as normal-weight and parous women 
have decreased estrogen exposure compared to obese and nulliparous women. Low incidence of 
Type II tumors makes this subtype difficult to study.  
While the incidence of Type II tumors is low compared to Type I, excess mortality is 
associated with Type II EC. In an analysis of Surveillance, Epidemiology and End Results 
(SEER) data, Hamilton et al. reported that while 11% of endometrial cancers were Type II, 47% 
of deaths in the SEER cohort occurred in this subtype [10]. Furthermore, stage adjusted five-year 
overall survival rates for Type II tumors are significantly worse compared to Type I tumors [15]. 
Understanding the etiology of this rare, under-investigated, and deadly malignancy is important 
for the primary prevention of these cancers, early detection, and monitoring for relapse. 
Therefore, the primary goal of the present study is to compare the characteristics of Type I and 
Type II EC cases treated at Magee-Womens Hospital between 1996 and 2008. 
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4.3 METHODS 
4.3.1 Data collection 
All data for this study were retrieved from the University of Pittsburgh Medical Center (UPMC) 
Registry Information Services (RIS), a division within the UPMC Network Cancer Registry 
[142].  The UPMC Network Cancer Registry collects demographic, medical history, diagnostic 
findings, primary cancer identification, stage, grade, treatment and outcomes information on 
patients from all UPMC managed facilities. Certified cancer registrars abstract data from both 
the paper and electronic medical records into the Cancer Registry database, which is then queried 
by an RIS research specialist. This study includes cases with an International Classification of 
Diseases for Oncology (ICD-O 3rd Edition) primary site code between C54.0–C54.9 and C55.9 
who were treated at Magee-Womens Hospital between 1996 and 2008. The coding scheme of 
this data system has varied over time and current standardized coding protocols were first used in 
1996 [143]. Specific data elements include age at diagnosis, year of diagnosis, height, weight, 
race, history of additional cancer primaries, number of live births (parity), menopausal status, 
age at menopause, and tumor histology.  
4.3.2 Case ascertainment 
ECs treated between 1996 and 2008 were identified by the RIS research specialist. Histology 
subtype (Type I and Type II) was assigned by a trained gynecologic pathologist (MC) based on 
expertise and previously published literature [80, 144]. Type I EC histologies included 
adenocarcinoma, endometrioid, mucinous adenocarcinoma, and adenocarcinoma with squamous 
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differentiation (ICD-O-3 morphology codes: 8140, 8380, 8382, 8480, 8482, 8560, and 8570). 
Type II EC histologies included clear cell carcinomas and papillary serous carcinomas (ICD-O-3 
morphology codes: 8310, 8441, and 8460). Slides for nine patients with papillary 
adenocarcinoma (ICD-O-3 code: 8260) were reviewed by the pathologist and confirmed to be 
papillary serous carcinoma. 
4.3.3 Statistical analysis 
Unconditional logistic regression was used to estimate the crude and adjusted odds ratios (ORs) 
of having Type II vs. Type I EC. The factors of interest in this study were categorized as shown 
in Table 1: race was classified as white or non-white due to the low number of African-
American, Asian, and other races. Year of diagnosis was coded as 12 indicator variables. BMI 
was calculated from weight and height as (weight in pounds*703)/(height in inches)2 [145]. BMI 
was analyzed both as a continuous variable (kg/m2) and a categorical variable (i.e., underweight 
(<18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2), and obese (>30 
kg/m2)) using definitions from the Centers for Disease Control and Prevention [145]. We also 
incorporated an unknown category when height or weight was missing (N=142, 8.1%). The 
categorical BMI variable was used in the univariate and multivariable models. Parity was 
categorized as no live births, 1 live birth, 2 live births, 3 or more live births, and unknown. 
History of additional cancer primaries and postmenopausal status were coded as no, yes, or 
unknown. Age at diagnosis and age at menopause were treated as continuous variables. 
Variable selection for the multivariable logistic regression model was based on the 
association between each potential factor and the probability of having Type II EC rather than 
Type I EC using the likelihood ratio test p-value from the univariate logistic regression models. 
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A broad significance level of p<0.10 in the univariate models was used as the criterion for entry 
into the multivariable model. Pairwise multiplicative interactions between each of the covariates 
were added to the model one at a time and tested with likelihood ratio tests. Interactions between 
the covariates were tested using a two-sided alpha of 0.05. The Hosmer and Lemeshow goodness 
of fit test was performed to assess lack of fit of the final model. This study was approved by the 
University of Pittsburgh Institutional Review Board. 
4.4 RESULTS 
Between 1996 and 2008, 1,964 EC patients were diagnosed at Magee-Womens Hospital. Of 
these, the 1,752 cases with either Type I or Type II EC were included in the present report. 
Based on the pathology report, Type I tumors accounted for 90% of cases in the study group.  
Table 5 compares the frequency of potential risk factors between the tumor types. Approximately 
11% of Type II cases were non-white compared to 4% of Type I cases. Year of diagnosis was 
not significantly different between the two tumor types. A large proportion of all cases were 
overweight or obese, however 36% of Type II cases were obese compared to 55% of Type I 
cases. Forty-five percent of Type II cases had three or more live births compared to 32% of Type 
I cases. Type II cases were also more likely to have a history of additional cancer primaries 
compared to Type I cases (23.9% vs. 14.2%). Breast cancer (N=125, 47%), ovarian cancer 
(N=32, 12%), and colorectal cancer (N=26, 10%) were the three most common additional 
malignancies. Breast and colorectal cancers were more common among the Type II cases, while 
ovarian cancer was more common among the Type I cases. Menopausal status was also 
significantly related to tumor type; 86% of Type II cases were postmenopausal compared to 76% 
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of Type I cases. Finally, Type II cases were significantly older than Type II cases (median age: 
68 years vs. 60 years). 
In the univariate analyses, race, BMI, parity, history of additional primaries, menopausal 
status, and age at diagnosis were significantly associated with type of EC (Table 6). Although 
year of diagnosis was not significantly associated with tumor type, this variable was retained for 
adjustment purposes. In the adjusted models, increasing age (p<0.001), non-white race 
(p<0.001), and history of additional primaries (p=0.03) were significantly associated with 
increased odds of having Type II EC, while obesity was inversely associated with the odds of 
Type II EC (p<0.001).  The Hosmer and Lemeshow goodness of fit test indicated no lack of fit of 
this model (χ2 =6.35, p=0.61). None of the interactions considered was statistically significant. 
4.5 DISCUSSION 
This registry-based study examines the relationship between pretreatment characteristics in Type 
I and Type II ECs in a large group of patients diagnosed between 1996 and 2008. Factors 
significantly associated with Type II EC vs. Type I EC were older age, non-white race, lower 
BMI, and history of additional primaries, all of which have been identified in the published 
literature. Soslow, Hamilton, and Cirisano have reported that Type II cases are older than their 
Type I counterparts, although the age differential is most pronounced for uterine papillary serous 
carcinomas (UPSC) compared to endometrioid tumors [10, 139, 146]. Furthermore, African-
Americans make up a disproportionate number of Type II tumors in many case-series, with the 
widest differential being between the UPSC and endometrioid cases. In the Cirisano study, 34% 
of UPSC’s were African-American compared to 15% of cases with endometrioid tumors 
 59 
(p<0.0001); in the Hamilton case-series 15% of cases with UPSC tumors were African-American 
while 7% of cases with grade 3 endometrioid tumors were African-American (p<0.0001) [10, 
139]. Our study is not directly comparable to the previously mentioned studies, as we grouped all 
non-white cases together. 
 To date, obesity is the strongest risk factor for development of EC, with the underlying 
mechanism being increased estrogen exposure  [14]. Consequently, the link between obesity and 
endometrial cancer is stronger for cases with Type I tumors, the prototypical estrogen-dependent 
tumor. In the present study, compared to normal weight cases, obese cases had an OR of 2.22 of 
having Type I EC rather than Type II EC. Although this finding is consistent with the estrogen 
hypothesis, two prospective studies have reported that increasing BMI also is a risk factor for 
development of Type II EC. In the 1 million Norwegian women study, Bjorge et al. reported that 
overweight and obese women were 1.26 and 1.94 times more likely, respectively, to develop 
Type II cancer compared to normal-weight women over a 25-year follow-up [147]. Likewise, 
McCullough and colleagues reported that a BMI of 30 kg/m2 or greater was significantly 
associated with developing Type II tumors (RR: 2.87, 95% CI 1.59-5.16). Importantly, both 
studies combined grade 3 endometrioid tumors with UPSC and clear cell tumors in their 
analyses, which may explain the association between obesity and Type II tumors in these studies. 
Furthermore, both studies compared cancer cases to healthy controls. BMI may have an 
important role in the development of all ECs, however the effect appears to be stronger for Type 
I cancers compared to Type II cancers. 
In this study, Type II cases had an OR of 1.56 of having a history of an additional primary 
compared to Type I cases (p=0.03). The most common additional primary cancer in this cohort 
was breast cancer. Of the Type II cases with an additional primary, 59.5% had breast cancer, 
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compared to 44.6% for the Type I cases (p=0.07). Several hypotheses for an association between 
Type II EC and additional cancer primaries exist. First, these cancers may share similar risk 
factor profiles. Second, radiation treatment for proximate cancers may increase the incidence of 
radiation-induced ECs or vice-versa. Third, the presence of multiple cancers may be a 
manifestation of inherited cancer syndromes, such as hereditary nonpolyposis colorectal cancer 
(HNPCC) syndrome; however these genetic disorders are relatively rare in the population. 
Finally, multiple cancer primaries may be a result of mutations in unidentified cancer 
predisposing genes [68].  
Potential limitations of this study include patient selection and misclassification biases. 
Although all cases in this study received their first course of treatment at Magee-Womens 
Hospital, not all cases were diagnosed at this facility. Forty-five percent of the cases in this study 
came to Magee-Womens Hospital after being diagnosed elsewhere; these patients could be 
significantly different from the patients who were diagnosed and treated at Magee-Womens 
Hospital. The referred cases may be more advanced or suffer from multiple co-morbiditiesthat 
require specialty care at a large academic hospital such as Magee-Womens Hospital. Second, our 
use of registry data obtained through data abstraction from medical records allows for potential 
data entry errors. The UPMC Cancer RIS performs rigorous quality control on certain data 
elements, which enhances their reliability; we focused only on those variables in our analyses. 
As the UPMC Network Cancer Registry is the official source of cancer statistics for the 
Pennsylvania Department of Health and maintains a reputation of high quality, misclassification 
bias is not a major concern. 
 The major strengths of this study include a large cohort of patients, reliable data, and central 
pathology review at a single institution. Overall, this study included 1,752 EC patients, including 
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176 Type II cases. Compared to other single institution studies of EC, our study included the 
largest number of Type II cases to date. In other case-series, the numbers of Type II cases has 
ranged between 32 and 87, excluding a study which examined patients from the population-
based SEER registry [140, 146, 148, 149]. Furthermore, we only included cases that were treated 
at Magee-Womens Hospital instead of including the entire pool of EC cases available from the 
UPMC Network Cancer Registry. The fact that all cases were centrally reviewed by gynecologic 
pathologists at Magee-Womens Hospital increases confidence in the validity of the tumor type 
definitions. 
 The etiology of Type II tumors remains elusive. The findings from this study verify 
previously published reports. In our study, BMI was inversely associated with having Type II 
EC, which suggests that this carcinogenic pathway is not driven by excess estrogen exposure. 
Importantly, a large proportion of Type II cases in this study were overweight or obese (27.3% 
and 36.4%, respectively). Finally, this study adds to the growing body of literature related to an 
association between multiple cancers and Type II EC. Future studies on the etiology of the rare 
yet aggressive Type II subtype should examine risk factors that are not related to estrogen 
exposure, in order to identify novel mechanisms of endometrial carcinogenesis. 
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4.6 TABLES  
Table 3 Patient demographic and epidemiologic characteristics by tumor type (N=1,752) 
  Type I  
(N=1,576) 
Type II 
(N=176) 
p-value† 
  N (%) N (%)   
Race       
White 1511 (95.9) 157 (89.2) <0.001 
Non-white 65 (4.1) 19 (10.8) 
Year of diagnosis     
1996 108 (6.9) 15 (8.5) 0.16 
1997 83 (5.3) 18 (10.2) 
 
1998 133 (8.4) 12 (6.8) 
1999 110 (7.0) 8 (4.5) 
2000 125 (7.9) 11 (6.2) 
2001 104 6.6) 10 (5.7) 
2002 91 (5.8) 16 (9.1) 
2003 115 (7.3) 9 (5.1) 
2004 122 (7.7) 8 (4.5) 
2005 117 (7.4) 16 (9.1) 
2006 151 (9.6) 14 (7.9) 
2007 162 (10.3) 20 (11.4) 
2008 155 (9.8) 19 (10.8) 
Body Mass Index       
Underweight (<18.5 kg/m2) 12 (0.8) 7 (4.0) <0.001 
Normal (18.5-24.9 kg/m2) 238 (15.1) 44 (25.0) 
Overweight (25-<29.9 kg/m2) 326 (20.7) 48 (27.3) 
Obese (>30 kg/m2) 871 (55.3 ) 64 (36.4) 
Unknown 129 (8.2) 13 (7.4) 
Parity (# of live births)       
0 384 (24.4) 31 (17.6) 0.002 
1 230 (14.6) 14 (7.9) 
2 413 (26.2) 45 (25.6) 
3+ 511 (32.4) 80 (45.4) 
Unknown 38 (2.4) 6 (3.4) 
History of Additional Primaries       
No 1328 (84.3) 131 (74.4) 0.006 
Yes 224 (14.2) 42 (23.9) 
  Breast cancer 100 (6.3) 25 (14.2) 
  Ovarian cancer 30 (1.9) 2 (1.1) 
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  Colorectal cancer 20 (1.3) 6 (3.4) 
  Other cancers 74 (4.7) 9 (5.1) 
Unknown 24 (1.5) 2 (1.7) 
Menopausal status       
Premenopausal 289 (18.3) 15 (8.5) 0.002 
Postmenopausal 1191 (75.6) 151 (85.8) 
Unknown 96 (6.1) 10 (5.7) 
   
Median ± IQR 
 
Median ± IQR 
  
Age at diagnosis 60.0 ±  17.0 68.0 ± 15.5 <0.001 
Age at menopause 50.0  ± 5.0 50.0 ± 4.5 0.90 
† Likelihood ratio p-value 
 
 
 
Table 4 Multivariable logistic regression model to predict Type II endometrial cancer (N=176) vs. Type I 
endometrial cancer (N=1,576) 
Variable Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI)† 
Likelihood 
ratio p-value‡ 
Race      
Non-White 2.81 (1.65, 4.81) 2.95 (1.66, 5.27) <0.001 
Body Mass Index       
Underweight (<18.5 kg/m2) 3.16 (1.18, 8.46) 2.59 (0.90, 7.45) <0.001 
Overweight (>25 kg/m2 and <29.9 kg/m2) 0.80 (0.51, 1.24) 0.82 (0.52, 1.29) 
Obese (>30 kg/m2) 0.40 (0.26, 0.60) 0.45 (0.29, 0.70) 
Unknown 0.54 (0.28, 1.04) 0.48 (0.23, 0.99) 
History of Additional Primaries      
Yes 1.90 (1.31, 2.77) 1.56 (1.05, 2.32) 0.09 
Unknown 1.27 (0.38, 4.26) 1.30 (0.34, 4.94) 
Age at diagnosis* 1.04 (1.03, 1.06) 1.03 (1.01, 1.05) <0.001 
† Adjusted for year of diagnosis, race, BMI, history of additional primaries, age at diagnosis, parity, and 
menopausal status 
‡ From the adjusted model 
* Centered at 62 years 
Reference groups: white race, normal weight, no history of additional primaries, nulliparous, and premenopausal 
  
 
 
Table 3 continued 
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5.1 ABSTRACT 
Objective: The goal of this study is to identify prognostic factors for overall survival (OS) 
among low-grade Type I, high-grade Type I, and Type II endometrial cancer (EC) patients. 
Methods: We conducted a retrospective cohort study of cases treated at Magee-Womens 
Hospital between 1996 and 2008. Clinical and follow-up data were available from the University 
of Pittsburgh Medical Center Network Cancer Registry. Histology-specific Cox regression 
models were used to compare the relative importance of prognostic factors for OS among low-
grade Type I (N=1,309), high-grade Type I (N=252), and Type II cases (N=219). We also 
examined if OS differed between the subtypes in a combined model. 
Results: The prevalence of obesity, advanced stage tumors, and positive lymph node 
involvement significantly differed between all three subtypes. Increasing age and advanced stage 
were significant prognostic factors common to all three subtypes. In low-grade Type I EC cases, 
surgery plus chemotherapy was associated with a significantly increased risk of death (HR: 3.65, 
95% CI 1.33, 9.99). In high-grade Type I EC cases, surgery plus radiotherapy was significantly 
associated with reduced mortality (HR: 0.43, 95% CI 0.23, 0.81) as was surgery plus 
radiotherapy and chemotherapy (HR: 0.28, 95% CI 0.08, 0.95). In the combined model, OS did 
not differ significantly between high-grade Type I and Type II cases (HR: 1.12, 95% CI 0.79, 
1.57). 
Conclusions: Despite clinical and epidemiologic differences, high-grade Type I and Type II 
patients share similar prognostic factors and survival outcomes. Due to the higher mortality 
associated with these highly aggressive subtypes, a concerted effort to include greater numbers 
of patients with these tumors in clinical trials focusing on treatment options is warranted.  
Keywords: high-grade Type I; Type II; mortality 
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5.2 INTRODUCTION 
Endometrial cancer (EC) is a heterogeneous disease. The traditional classification system, 
originally proposed by Bokhman [80] broadly groups EC based on clinicopathologic 
characteristics. Type I ECs are estrogen-dependent, arise from endometrial hyperplasia, and are 
of adenocarcinoma histology [61]. Furthermore, Type I endometrial tumors can be further 
classified as low-grade or high-grade. Type II ECs are estrogen-independent, develop in the 
setting of an atrophic endometrium, and are either clear cell (CC) or papillary serous (PS) [95]. 
Furthermore, the survival experience between Type I and Type II ECs differs significantly. Five-
year overall survival (OS) for early stage Type I cancers ranges from 80% to 90%, whereas five-
year OS for early stage Type II cancers is approximately 60% [15, 150]. 
Despite the known poor prognosis of patients with Type II cancers, prognostic factors for 
this type of malignancy are poorly characterized. Survival analyses are hindered by small 
numbers of patients with Type II EC in single institution studies. Additionally, many studies 
exclude CC from the Type II classification, which limits the generalizability of results. Recently, 
Fader et al. [138] investigated clinicopathologic factors for OS in 206 stage I-II PS cases. Age, 
tumor depth, and treatment with platinum/taxane-based chemotherapy were significantly 
associated with all-cause mortality. Furthermore, tumors with just 5% PS histology had patterns 
of recurrence and death similar to patients with pure PS tumors, indicating the aggressiveness of 
this histology. In a single institution review of 129 PS cases, Slomovitz et al. [151] reported that 
deep myometrial invasion and nodal involvement were significantly associated with mortality. 
Additionally, the high proportion of cases with no myometrial invasion that developed 
abdominal metastases suggests that PS cases are at increased risk of extra-uterine disease even in 
the absence of myometrial invasion. Sagr et al. [141] analyzed the association between stage, 
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myometrial invasion, lymphovascular space invasion, adjuvant treatment modality (radiotherapy 
and/or chemotherapy) and OS in 45 PS patients. Only higher stage was significantly associated 
with increased mortality in this small case series. The prognostic studies that have been 
performed for the CC histology subtype were small. In the largest series of CC cases (N=181), 
disease stage and age were significantly associated with recurrence [152].  
Several studies have estimated the survival difference between high-grade Type I and Type 
II cancers. Some authors have reported significant differences in survival between these high-
grade subtypes [10, 148, 149], while others have not [140, 146, 153, 154]. These studies are 
difficult to compare because the definitions for the subtypes were not uniform and different 
statistical methods were employed.  Additionally, the number of Type II cases in the natural 
history studies ranged significantly; most included between 30 and 80 cases [140, 146, 149, 153], 
two studies included 139 and 207 cases [148, 154], and one included 1,864 Type II cases from 
the Surveillance Epidemiology and End Results database [10]. 
As few studies have examined the differences in prognostic factors between high-grade 
Type I and Type II cancers (both CC and PS), the primary goal of this study was to identify 
prognostic factors for OS among low-grade Type I, high-grade Type I, and Type II ECs using 
separate Cox proportional hazards models. We also sought to assess whether OS differed 
between the three subtypes. Understanding differences in the prognostic factors between the 
distinct histologies may improve the understanding of the underlying biology of EC and fill an 
important gap in existing research. 
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5.3 METHODS 
5.3.1 Study population 
This is a retrospective cohort study of EC cases (N=1,780) diagnosed at Magee-Womens 
Hospital between 1996 and 2008. Primary treatment included surgical intervention 
(hysterectomy with or without removal of the fallopian tubes and ovaries) in 92% (N=1,638) of 
cases. Non-surgical cases (N=142, 8%) differed significantly from surgical cases with respect to 
stage (chi-square p<0.001); 33% of non-surgical cases had late stage tumors compared to 16% of 
surgical cases.  
Clinical, pathology, and follow-up data were retrieved from the University of Pittsburgh 
Medical Center (UPMC) Network Cancer Registry using an honest broker. The UPMC Network 
Cancer Registry gathers demographic, medical history, diagnostic findings, and treatment and 
outcomes information on cancer patients treated within the network.  EC cases with an 
International Classification of Diseases for Oncology (ICD-O 3rd Edition) primary site code 
between C54.0–C54.9 and C55.9 were included in this analysis. Information on age, race, 
weight, height, stage, tumor size, post-operative therapy, tumor histology, grade (where 
applicable), date of diagnosis, and date of death was collected from electronic medical records. 
Information on the cause and date of death are supplied to the UPMC Network Cancer Registry 
with daily notifications from oncologist offices. This study was approved by the University of 
Pittsburgh Institutional Review Board. 
 Tumor histology types were classified into one of three, distinct groups: low-grade Type I, 
high-grade Type I, and Type II. Adenocarcinoma with or without squamous differentiation, 
mucinous adenocarcinoma, or endometrioid tumors were classified as Type I. Well or 
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moderately differentiated tumors were grouped as low-grade Type I while poorly differentiated 
tumors were classified as high-grade Type I. CC and PS tumors were classified as Type II. These 
classifications were based on the body of literature reporting different etiologies and outcomes 
between these subtypes. 
5.3.2 Statistical analysis 
Demographic and clinical characteristics were compared between the three histology subtypes 
with chi-square tests for categorical variables and one-way ANOVAs for continuous variables. 
Variables with a significant overall p-value were further compared using contrasts to determine 
which subtypes significantly differed. Non-surgical cases were excluded from survival analyses. 
Stage-specific Kaplan-Meier curves and log-rank tests were generated to compare OS between 
the three histology subtypes. Separate Cox proportional hazards regression models were used to 
model survival for each of the three histology subtypes. Age, race, body mass index (BMI), 
stage, tumor size, and post-operative therapy were included in each of these histology-specific 
models. BMI categories were based on the Centers for Disease Control and Prevention 
definitions: normal weight (< 24.9 kg/m2), overweight (25-29.9 kg/m2), and obese (> 30 kg/m2) 
[145]. Year of diagnosis was entered into all models as a categorical adjustment factor. OS was 
defined as the number of days between the date of diagnosis and the date of death from all 
causes. Patients lost to follow-up were censored on the last date of contact and those patients 
alive at the end of follow-up (December 31, 2008) were censored at that time.  
A combined Cox model including all cases was run in order to ascertain if OS was 
significantly different between low-grade Type I, high-grade Type I, and Type II cases adjusted 
for prognostic factors. In this model, we assessed the assumption of proportional hazards for the 
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histology types with Grambsch and Therneau’s method [155]. Interactions between histology 
subtypes and all covariates were tested using a two-sided alpha of 0.05; given that the 
interactions were non-significant the hazard ratios are based on the main-effects only model. 
5.4 RESULTS 
Of the identified 1,964 EC cases diagnosed at Magee-Womens Hospital between 1996 and 2008, 
1,864 had a diagnosis code pertaining to the three histologic cell types under investigation. 
Mixed mullerian tumors (N=82) and endometrial sarcomas (N=18) were excluded. We also 
excluded cases who were younger than 34 years of age or older than 92 years of age at the time 
of diagnosis (N=14). This age range reflects the overlap of ages for the Type I and Type II 
subtypes in our cohort; excluding cases outside of this age range was performed in an effort to 
reduce confounding by age. Cases with no information on stage (N=43), grade (N=26), or 
follow-up time (N=1) also were excluded, resulting in a final sample size of 1,780 cases.   
Distributions of demographic and clinical characteristics are shown in Table 5 by histologic 
category. Patients with low-grade Type I tumors were significantly younger than high-grade 
Type I and Type II EC cases (61 years vs. 65 and 67, respectively; p<0.001). Non-white race was 
significantly more common among Type II EC cases (10%) compared to low-grade Type I (4%) 
and high-grade Type I EC cases (6%). BMI varied significantly across subtypes, with relatively 
more low-grade Type I EC cases being obese (58%) compared to the high-grade Type I (48%) 
and Type II EC cases (40%). Stage at diagnosis significantly differed between low-grade Type I, 
high-grade Type I, and Type II EC cases; 91% vs. 65% vs. 53%, respectively, had early stage 
tumors. Positive lymph node involvement was significantly more common among Type II EC 
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cases (20%) compared to high-grade Type I EC cases (13%) which was significantly greater than 
positive lymph node involvement in low-grade Type I EC cases (5%). Tumor size significantly 
differed by subtype, although data were missing for approximately 60% of cases. Type II EC 
cases had a significantly larger proportion of large tumors (> 2 cm) compared to low-grade Type 
I EC cases (39% vs. 29%). Type of post-operative therapy differed significantly between the 
three subtypes, with approximately 50% of low-grade Type I EC cases treated with surgery only, 
compared to 18% of the high-grade Type I and 16% of the Type II EC cases. One-third of the 
Type II EC cases were treated with surgery plus chemotherapy compared to 3% of the low-grade 
Type I and 12% of the high-grade Type I EC cases.  Surgery plus radiotherapy was most 
common among the high-grade Type I EC cases (48%) compared to 38% of low-grade Type I 
and 24% of Type II EC cases.  Surgery, radiotherapy, and chemotherapy use was most common 
among Type II EC cases (17%) compared to high-grade Type I (7%) and low-grade Type I EC 
cases (3%). Finally, median follow-up time was significantly longer for the low-grade Type I EC 
cases vs. the high-grade Type I and Type II EC cases (47 months vs. 28 and 26 months, 
respectively). 
 Table 6 shows the distribution of post-operative treatments according to stage and histology 
type. In low-grade Type I cases, surgery only was more prevalent among early stage cases (53%) 
compared to late stage cases (11%). Approximately 78% of late stage low-grade Type I cases 
had chemotherapy and/or radiotherapy. Among high-grade Type I cases, 64% of early stage 
cases had radiotherapy compared to 20% of late stage cases. Chemotherapy with or without 
radiotherapy was more prevalent among late stage high-grade Type I cases (47%) compared to 
early stage high-grade Type I cases (4%). In early stage Type II cases, 25% of patients were 
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treated with surgery plus chemotherapy compared to 43% of late stage cases. Surgery plus 
radiotherapy was used in 34% of early stage cases compared to 13% of late stage cases. 
Cases that did not have surgery were excluded from survival analyses which reduced the 
sample size to 1,638 cases. Stage specific Kaplan-Meier OS curves for the three histology 
subtypes are shown in Figures 4 and 5. In early and late stage cases, low-grade Type I cases had 
significantly better OS compared to high-grade Type I and Type II cases (p<0.001), while OS 
was similar for the high-grade Type I and Type II cases (early stage: p=0.62, late stage: p=0.28). 
OS was modeled separately for cases of each histologic subtype to assess the relative 
importance of each prognostic factor (Table 7). For low-grade Type I cases, increasing age (HR: 
1.09, 95% CI: 1.07, 1.10) advanced stage (HR: 2.86, 95% CI: 1.59, 5.16), and surgery plus 
chemotherapy treatment (HR: 3.65, 95% CI 1.33, 9.99) were significantly associated with higher 
mortality. Similarly, among high-grade Type I cases increasing age (HR: 1.04 95% CI: 1.02, 
1.06) and advanced stage (HR: 2.98 95% CI: 1.56, 5.68) were significantly associated with 
worse OS. Post-operative treatment was significantly associated with better OS in high-grade 
Type I cases;  surgery plus radiotherapy was associated with an HR of 0.43 (95% CI 0.23, 0.81) 
and surgery plus radiotherapy and chemotherapy was associated with an HR of 0.28 (95% CI 
0.08, 0.95) compared to surgery only. Among Type II cases increasing age (HR: 1.03 95% CI: 
1.00, 1.05) and late stage (HR: 4.54 95% CI: 2.48, 8.32) were significantly associated with OS.  
Finally, in an adjusted Cox model including all EC cases (Table 8), low-grade Type I cases 
had significantly reduced hazards of all-cause mortality relative to the high-grade Type I (HR: 
0.48, 95% CI 0.35, 0.65) and Type II cases (HR: 0.53, 95% CI: 0.38, 0.74) adjusted for age, race, 
BMI,  stage, tumor size, post-operative therapy, and year of diagnosis. High-grade Type I cases 
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did not have significantly different OS compared to Type II cases (HR: 1.12, 95% CI: 0.79, 
1.57).  
5.5 DISCUSSION 
This study examined prognostic factors associated with OS in low-grade Type I, high-grade 
Type I, and Type II ECs. Prognostic indicators for all three subtypes were generally similar; OS 
was negatively associated with increasing age and advanced stage, which is consistent with the 
findings from other EC case series [141, 146, 149]. Post-operative treatment had different effects 
for low-grade Type I vs. high-grade Type I cases; surgery plus chemotherapy was associated 
with a significantly higher risk of death in low-grade Type I EC cases while surgery plus 
radiotherapy with or without chemotherapy was associated with better survival. 
The second goal of this study was to analyze survival differences among the high-risk 
subtypes, high-grade Type I and Type II ECs. Kaplan-Meier graphs did not show a significant 
difference in survival between high-grade Type I and Type II cases in early or late stage cases. 
We ran a Cox model including all cases to directly test whether the Type II subtype is associated 
with a higher risk of all-cause mortality than the high-grade Type I subtype. Adjusted for age, 
race, BMI, stage, post-operative treatment, tumor size, and year of diagnosis, Type II cases did 
not have a significantly higher risk of death compared to high-grade Type I cases.  
Previous studies have examined the relative survival of Type II cancers compared to high-
grade Type I. Soslow et al. [146] reported no difference in the hazard of dying comparing high-
grade Type I, PS, and CC cases despite significant differences in age, race, stage, and sites of 
metastasis among the three subtypes. Likewise, Alektiar et al. [153] compared the outcome of 42 
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Type II cases (PS and CC combined) to 41 high-grade Type I cases and reported no significant 
difference in 5-year survival rates adjusting for age, race, myometrial invasion, and cervical 
involvement. Finally, Cirisano et al. [149] reported that high-grade Type I cases had a similar 
risk of death compared to PS and CC cases combined.  
Others have reported significant survival differences between the subtypes. Hamilton et al. 
[10] compared high-grade Type I tumors vs. PS vs. CC and reported a statistically significant 
difference in OS adjusted for stage, age, race, and adjuvant radiotherapy. Similarly, Boruta and 
colleagues [148] reported OS to be significantly better in high-grade Type I cases compared to 
UPSC cases with > 50% serous histology in the tumor, adjusted for age, race, lymph vascular 
space invasion, myometrial invasion, and treatment.  
The demographic and clinical characteristics of the Magee-Womens Hospital cohort are 
similar to previously published reports [10, 139, 146]. Low-grade Type I cases were younger, 
more likely to be white, and have early stage tumors compared to the high-grade Type I and 
Type II groups. Race was not a significant predictor of mortality in the Type II subgroup. Several 
studies have reported that when diagnosed with EC, African-American women are significantly 
more likely to die compared to white women [156-160]. This difference has largely been 
attributed to the more frequent occurrence of Type II cancers in African-American women [156, 
157]. Due to small numbers of African-Americans and ‘other’ races in the UPMC Network 
Cancer Registry, all non-white races were grouped together. Therefore, this hypothesis cannot be 
tested in this dataset. Post-operative treatment also differed significantly between the three 
subtypes. Low-grade Type I tumors were less likely to be treated with radiotherapy and/or 
chemotherapy compared to high-grade Type I and Type II tumors. Disease stage may confound 
 76 
this apparent relationship, as high-grade tumors were more likely to be diagnosed in late stages 
compared to the low-grade Type I tumors. 
The major strengths of this study include reliable data from a reputable cancer registry, a 
mean follow-up of 4.3 years, and a relatively large sample size with numerous events. Other 
case-series that have explored prognosis in high-grade subtypes have generally suffered from 
small numbers of events, which limits the statistical modeling. Limitations of this study include 
the retrospective study design, lack of specific information on the post-operative therapy, and 
potential misclassification of histologic subtype. Detailed information regarding chemotherapy 
regimens (single agent vs. multimodal agents and type of agents used) would have allowed for 
interesting sub-analyses, especially in the Type II group where chemotherapy use was prevalent. 
Additionally, misclassification bias of the histology type may have occurred as the criteria for 
classification of Type II tumors has varied over time. The Gynecologic Oncology Group asserts 
that in the case of mixed histology subtypes, UPSC or CCC must comprise 50% or more of the 
tumor in order to be classified as such, which is the standard at Magee-Womens Hospital [138].  
In conclusion, high-grade Type I and Type II ECs differ from each other clinically, although 
survival following diagnosis does not significantly differ. The International Federation of 
Gynecology and Obstetrics has clearly defined disease stage, age, depth of myometrial invasion, 
and grade to be significantly associated with OS in endometrioid-type EC [161]. Whether these 
factors are prognostically relevant for high risk subtypes (high-grade Type I and Type II tumors) 
is less clear, as these tumor types make up a small proportion of all diagnosed EC cases. Due to 
the high mortality associated with these highly aggressive subtypes, an understanding of the key 
determinants will improve the current state of knowledge.  
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5.6 TABLES 
Table 5 Demographic and clinical characteristics by histology type (N=1,780) 
  
Low-grade Type I 
(N=1,309) 
High-grade Type I 
(N=252) 
Type II 
(N=219) 
p-value ¶ 
Age, mean (SD) 61 (12)† 65 (12) 67 (11) <0.001 
Race         
White 1,261 (96%)‡ 237(94%) 197 (90%) <0.001 
Non-white 48 (4%) 15 (6%) 22 (10%)   
Body Mass Index      
Normal (<24.9 kg/m2) 201 (15%)* 38 (15%) 57 (26%) <0.001 
Overweight (25-29.9 kg/m2) 250 (19%) 72 (29%) 58 (26%)  
Obese (>30 kg/m2) 757 (58%) 120 (48%) 88 (40%)  
Unknown 101 (8%) 22 (9%) 16 (8%)  
Stage      
Early (I & II) 1191 (91%)* 165 (65%) 116 (53%) <0.001 
Late (III & IV) 118 (9%) 87 (35%) 103 (47%)   
Lymph node involvement     
No nodal exam 474 (36%)* 88 (35%) 60 (27%) <0.001 
Negative 716 (55%) 123 (49%) 107 (49%)  
Positive 61 (5%) 32 (13%) 44 (20%)  
Unknown 58 (4%) 9 (4%) 8 (4%)  
Tumor size         
< 2 cm 153 (12%)‡ 20 (8%) 21 (10%) 0.01 
> 2 cm 379 (29%) 88 (35%) 86 (39%)   
Unknown 777 (59%) 144 (57%) 112 (51%)  
Post-operative therapy         
No surgery 86 (7%)§ 37 (15%) 19 (9%) <0.001 
Surgery only 642 (49%) 45 (18%) 36 (16%)  
Surgery + CT  34 (3%) 31 (12%) 73 (33%)   
Surgery + RT  504 (38%) 122 (48%) 53 (24%)   
Surgery + CT + RT 43 (3%) 17 (7%) 38 (17%)   
Follow-up (months), median (IQR) 47 (19-82)† 28 (15-55) 26 (12-51) <0.001 
† Low-grade Type I is significantly different from high-grade Type I and Type II (p<0.05) 
‡ Low-grade Type I is significantly different from Type II (p<0.05) 
* All three histologies are significantly different from one another (p<0.05) 
§ Type II is significantly different from low-grade Type I and high-grade Type I (p<0.05) 
¶ Likelihood ratio p-value for categorical variables; ANOVA p-value for continuous variables 
SD = standard deviation, CT = chemotherapy, RT = radiotherapy, IQR = Interquartile range 
 
 78 
Table 6 Post-operative therapy stratified by disease stage and histology type 
N=1,780 Early stage 
(N=1,191) 
Late stage 
(N=118) 
p-value† 
Low-grade Type I (N=1,309) 
 
  <0.001 
No surgery 73 (6%) 13 (11%)  
Surgery only 629 (53%) 13 (11%)  
Surgery + CT  15 (1%) 19 (16%)  
Surgery + RT  468 (39%) 36 (31%)  
Surgery + CT + RT 6 (1%) 37 (31%)  
High-grade Type I (N=252) 
 
  <0.001 
No surgery 17 (10%) 20 (23%)  
Surgery only 36 (22%) 9 (10%)  
Surgery + CT  4 (2%) 27 (31%)  
Surgery + RT  105 (64%) 17 (20%)  
Surgery + CT + RT 3 (2%) 14 (16%)  
Type II (N=219) 
 
  <0.001 
No surgery 5 (4%) 14 (14%)  
Surgery only 23 (20%) 13 (13%)  
Surgery + CT  29 (25%) 44 (43%)  
Surgery + RT  40 (34%) 13 (13%)  
Surgery + CT + RT 19 (16%) 19 (18%)  
† Likelihood ratio p-value 
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Table 7 Subtype-specific analyses of overall survival for low-grade Type I, high-grade Type I, and Type II ECs† 
N=1,638 
deaths=319 
Low-grade Type I 
N=1223, deaths=168 
High-grade Type I 
N=215, deaths=75 
Type II 
N=200, deaths=76 
Variable HR (95% CI) p-value‡ HR (95% CI) p-value‡ HR (95% CI) p-value‡ 
Age (years) 1.09 (1.07, 1.10) <0.001 1.04 (1.02, 1.06) <0.001 1.03 (1.00, 1.05) 0.03 
Race       
White Reference 0.22 Reference 0.13 Reference 0.99 
Non-white 1.62 (0.75, 3.50)  2.13 (0.81, 5.62)  1.00 (0.38, 2.68)  
Body Mass Index        
Normal weight Reference 0.20* (3) Reference 0.31* (3) Reference 0.16* (3) 
Overweight 0.69 (0.42, 1.15) 0.15 1.00 (0.47, 2.15) 0.99 0.45 (0.22, 0.91) 0.03 
Obese 1.05 (0.70, 1.58) 0.80 1.64 (0.82, 3.30) 0.16 0.68 (0.36, 1.29) 0.24 
Unknown 1.26 (0.67, 2.35) 0.47 1.14 (0.28, 4.62) 0.86 0.84 (0.25, 2.85) 0.78 
Stage       
Early (I & II) Reference <0.001 Reference <0.001 Reference <0.001 
Late (III & IV) 2.86 (1.59, 5.16)  2.98 (1.56, 5.68)  4.54 (2.48, 8.32)  
Tumor size       
< 2 cm Reference 0.44* (2) Reference 0.09* (2) Reference 0.46* (2) 
> 2 cm 1.25 (0.63, 2.47) 0.52 3.72 (0.98, 14.10) 0.05 2.17 (0.60, 7.82) 0.24 
Unknown 0.92 (0.49, 1.74) 0.80 2.23 (0.61, 8.19) 0.23 2.21 (0.61, 7.99) 0.23 
Post-operative therapy       
Surgery only Reference 0.03* (3) Reference 0.03* (3) Reference 0.15* (3) 
Surgery + CT  3.65 (1.33, 9.99) 0.01 0.66 (0.29, 1.51) 0.33 0.62 (0.31, 1.22) 0.17 
Surgery + RT  0.92 (0.66, 1.30) 0.65 0.43 (0.23, 0.81) 0.008 0.56 (0.25, 1.26) 0.16 
Surgery + CT + RT 0.72 (0.27, 1.93) 0.51 0.28 (0.08, 0.95) 0.04 0.27 (0.08, 0.88) 0.03 
† Adjusted for year of diagnosis 
‡ Wald p-value 
* Wald p-value for multi-parameter tests, degrees of freedom are noted in parentheses 
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Table 8 Combined overall survival model including all EC cases (N=1,638)† 
Variable HR (95% CI) p-value‡ 
Low-grade Type I vs. High-grade Type I 0.48 (0.35, 0.65) <0.001 
Low-grade Type I vs. Type II  0.53 (0.38, 0.74) <0.001 
High-grade Type I vs. Type II 1.12 (0.79, 1.57) 0.53 
   
Age (years) 1.06 (1.05, 1.07) <0.001 
Race   
White Reference 0.37 
Non-white 1.25 (0.76, 2.05)  
Body Mass Index    
Normal weight (18.5-24.9 kg/m2) Reference 0.17 (3) 
Overweight (25-29.9 kg/m2) 0.75 (0.53, 1.05) 0.09 
Obese (>30 kg/m2) 1.03 (0.78, 1.37) 0.83 
Unknown 1.04 (0.64, 1.71) 0.86 
Stage   
Early (I & II) Reference <0.001 
Late (III & IV) 3.44 (2.53, 4.68)  
Tumor size   
< 2 cm Reference 0.18 (2) 
> 2 cm 1.52 (0.90, 2.56) 0.12 
Unknown 1.20 (0.72, 2.00) 0.49 
Post-operative therapy   
Surgery only Reference 0.02 (3) 
Surgery + CT  1.11 (0.73, 1.70) 0.61 
Surgery + RT  0.79 (0.60, 1.03) 0.08 
Surgery + CT + RT 0.52 (0.29, 0.94) 0.03 
† Adjusted for year of diagnosis 
‡ Individual Wald p-value 
* Wald p-value for multi-parameter tests, degrees of freedom is noted in parentheses 
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5.7 FIGURES 
Overall log-rank p-value <0.001
High-grade Type I vs. Type II p=0.62
0.
00
0.
25
0.
50
0.
75
1.
00
K
ap
la
n-
M
ei
er
 s
ur
vi
va
l e
st
im
at
es
0 1000 2000 3000 4000 5000
overall survival (days)
Low-grade Type I High-grade Type I Type II
Early stage cases, N=1,377
 
Figure 4 Kaplan-Meier overall survival curves for low-grade Type I, high-grade Type I, and Type II 
cases: early stage (I&II) 
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Late stage cases, N=261
Overall log-rank p<0.001
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Figure 5 Kaplan-Meier overall survival curves for low-grade Type I, high-grade Type I, and Type 
II cases: late stage (III&IV) 
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6.1 ABSTRACT 
Introduction: CXCL12 is a chemotactic cytokine that plays an important role in the invasion 
and metastasis in several malignancies by interacting with its receptor CXCR4. Few studies 
examine the prognostic role of this pathway in endometrial cancer (EC), specifically in high-
grade Type I, clear cell (CC), and papillary serous (PS) ECs, all of which show a tendency for 
regional and distant spread. The goal of this study is to evaluate the association between CXCR4 
and CXCL12 expression, prognostic factors, overall survival (OS), and recurrence-free survival 
(RFS) in a cohort of low-grade Type I, high-grade Type I, CC, and PS EC cases. 
Methods: Demographic, clinical, treatment, and survival information on each EC case was 
available from the University of Pittsburgh Medical Center Network Cancer Registry. Tumor 
blocks were retrieved from the Pathology Department at Magee-Womens Hospital and sectioned 
into slides (N=199). CXCR4 and CXCL12 protein expression was measured using 
immunohistochemistry (IHC). The association between expression and clinicopathologic factors 
was assessed with chi-square tests. As CXCR4 expression did not vary substantially in the 
sample, we examined associations between CXCL12 and OS and RFS with Kaplan-Meier 
graphs, log rank tests, and Cox proportional hazards models.  
Results: CXCR4 was expressed in all ECs; 30% (n=59) and 70% (n=140) of cases showed 
moderately and strongly positive CXCR4 expression, respectively. CXCL12 expression was 
absent in 63 (32%), weakly positive in 24 (12%), moderately positive in 84 (42%), and strongly 
positive in 28 (14%) cases. Neither CXCL12 nor CXCR4 expression was significantly associated 
with race, body mass index, histology subtype, stage, lymph node involvement or tumor size. In 
multivariable analysis, we observed a significant association between CXCL12 expression, OS, 
and RFS among high-grade Type I cases; positive CXCL12 expression was associated with 
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significantly improved OS (HR: 0.17, 95% CI 0.05, 0.59) and RFS (HR: 0.10, 95% CI 0.02, 
0.57). 
Discussion: This is the first study to examine the role of CXCL12 in a histologically diverse 
cohort of EC cases. We demonstrated that CXCL12 was an independent prognostic marker 
associated with better OS and RFS in an aggressive subtype of EC. In addition to pathological 
characteristics of the primary tumor, IHC expression of CXCL12 may be clinically useful for 
assigning adjuvant treatment to EC cases. 
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6.2 INTRODUCTION  
Endometrial cancer (EC) is a heterogeneous cancer with two broad subtypes commonly 
described in the literature, Type I and Type II. Type I EC represents 80%-90% of all sporadic 
tumors and can be further subdivided by differentiation or grade of the tumor [15, 150]. Low-
grade Type I tumors (grades 1 and 2) are indolent and five-year survival is approximately 90% 
[162]. Conversely, high-grade Type I tumors have five-year survival rates ranging between 45% 
and 77% [10, 140, 146, 153]. Advanced disease stage is present in 50% of cases with high-grade 
Type I tumors [146]. The remaining 10%-20% of ECs, Type II, are characterized by invasive 
disease spread at the time of diagnosis, with survival rates ranging between 50 and 60% [15]. 
Clear cell (CC) and papillary serous (PS) are the two histology subtypes that comprise the Type 
II category. Most studies examining molecular alterations involved in EC tumorigenesis, 
invasion, and progression focus on the more prevalent Type I cases. Despite being relatively 
rare, high-grade Type I and Type II ECs are important to study due to the disproportionate 
mortality associated with these subtypes. 
As high-grade Type I, CC, and PS endometrial tumors are characterized by extensive extra-
uterine disease at the time of diagnosis, molecular mechanisms related to disease spread are 
strongly implicated in these subtypes. Previous research suggests that soluble factors secreted by 
cells of the tumor microenvironment contribute to dissemination of cancer cells from the primary 
tumor site to local and distant sites [98, 163-167]. Chemokines are a family of chemotactic 
cytokines that direct the movement of target cells that express the appropriate chemokine 
receptor. This movement occurs along a chemical gradient of the chemokine (i.e. the chemokine 
gradient) allowing cells to move towards high local concentrations of chemokines [100]. When 
chemokine ligands bind to cancer cells that aberrantly express chemokine receptors, signal 
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transduction pathways are activated which can result in several consequences, namely invasion 
and metastasis [168].  
An important and well-studied chemokine ligand-receptor pair, CXCL12 and CXCR4, is 
associated with proliferation, adhesion, and most notably chemotaxis in several malignancies, 
including breast [169], colon [170], ovarian [171], and pancreatic cancers [172]. Within the 
breast cancer literature, the roles of CXCL12 and CXCR4 on metastasis and ultimately survival 
have been examined. Muller et al. [169] demonstrated that common sites of metastasis in 
primary breast cancer patients (bone, lung, and brain) overexpress CXCL12 while the primary 
breast tumor is characterized by high levels of CXCR4. For breast cancer survival, the 
cumulative evidence points to an improved survival associated with high expression of CXCL12 
at the primary site [173-175]. Mechanistically, high levels of CXCL12 at the primary tumor site 
may saturate the receptor and inhibit progression of the tumor beyond the primary site. 
The biology of CXCR4 and CXCL12 in normal endometrial tissues and EC has been 
described. In the normal endometrium, CXCR4 gene expression is significantly higher in 
epithelial cells compared to stromal cells while CXCL12 is highly expressed in stromal cells, yet 
undetectable in normal epithelial cells [176]. Compared to normal endometrial tissues, CXCR4 
expression is significantly higher in EC cell lines and human EC tissues while CXCL12 mRNA 
is significantly higher in normal endometrial tissues compared to EC [105]. Mizokami [106] and 
Zhao [109] provided evidence that CXCL12 stimulates growth of EC cells in vitro, while 
Tsukamoto [108] demonstrated the migratory ability of CXCR4-expressing EC cells into the 
myometrial layer of the uterus which is a CXCL12-rich environment. Finally, in a murine model 
where primary EC and metastases were induced, metastatic cancer in the liver and lung were 
completely inhibited in mice treated with anti-CXCR4 antibodies compared to isotype control 
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treated mice. Despite the biological evidence supporting a role for CXCR4 and CXCL12 in EC, 
only one study has examined the prognostic value of CXCR4 and overall survival (OS) in EC. In 
Kaplan-Meier analyses, CXCR4-positive tumors had a significantly improved OS compared to 
those with CXCR4-negative tumors [107]. 
The previous research strongly suggests a potential prognostic role for CXCL12 and 
CXCR4 in EC. As epidemiologic studies of this association are lacking, we investigated 
expression of CXCL12 and CXCR4 and its relationship with clinicopathologic factors and 
survival. Our primary hypothesis was that higher expression of CXCL12 would be associated 
with better survival due to saturation of CXCR4 at the primary site, thus inhibiting migration 
beyond the uterus. 
6.3 METHODS 
6.3.1 Study sample 
The study sample was identified through an honest broker system at the University of Pittsburgh 
Medical Center Cancer Registry. The original database included 1,964 EC cases that were either 
diagnosed and/or received all or part of the first course of treatment at Magee-Womens Hospital 
between 1996 and 2008.  Demographic, clinical, treatment, and survival information was 
retrieved for each patient in the original cohort by an honest broker. In this study, Type I 
(endometrioid or adenocarcinoma) and Type II (CC or PS) EC patients comprised the target 
population. Additional exclusion criteria were applied to generate the sampling frame of 1,486 
cases from which the study sample was drawn. Information on the availability of tumor blocks 
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was obtained from the Pathology Department at Magee-Womens Hospital; of the 1,486 cases, 
1,003 (67%) were indicated as having tumor blocks available. Appendix figures 33 and 34 show 
the generation of the sampling frame (N=1,486) and the reduced sampling frame based on 
presumed tumor block availability (N=1,003), respectively. Characteristics of the sampling 
frame are available in Appendix Table 28.  
 Case selection from the reduced sampling frame was achieved with a stratified random 
sampling design. Histology type (Type I and Type II) and stage (stage I, stage II, stage III, and 
stage IV) were the two variables used to construct the sampling strata. Within each of the eight 
strata, a simple random sample was drawn using the ‘surveyselect’ procedure in SAS. A flow 
chart for case selection for this study is shown in Figure 6. Two hundred cases (25 from each 
stratum) were originally requested; however 216 cases were provided by the Pathology 
Department at Magee-Womens Hospital. Within strata where the number of available cases was 
less than 25, we made an effort to include all cases; however inadequate tissue limited our ability 
to achieve this goal. Furthermore, following slide sectioning of the selected blocks, 17 slides did 
not have evaluable tumor present, which reduced the analytic cohort to 199 EC cases. This study 
was approved by the University of Pittsburgh Institutional Review Board. 
6.3.2 Immunohistochemistry 
Formalin-fixed paraffin-embedded tissue blocks for the 216 selected cases were retrieved from 
the Pathology Department at Magee-Womens Hospital. Four μm thick slides were cut at the time 
of block retrieval and stored in a refrigerator at 4○C in order to prevent loss of antigenicity as we 
anticipated a time delay between cutting and staining of slides. The immunohistochemistry 
(IHC) protocol began with deparaffinization and hydration of the slides with xylenes and washes 
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with progressively decreasing alcohol concentrations. Endogenous peroxidase activity was 
blocked with 3% methanol peroxide. Next, antigen retrieval in 0.01 M boiling citrate buffer (pH 
6.0) in a microwave was performed followed by blocking of non-specific staining with Protein 
Block (Dako North America, Inc, Carpinteria, California). Whole tissue sections were then 
incubated for one hour at room temperature with 100 microliters of polyclonal CXCR4 antibody 
(Abcam Inc., Cambridge, MA, dilution 1:50) and polyclonal CXCL12 antibody (R&D Systems, 
Minneapolis, MN, dilution 1:200). Slides were subsequently rinsed in PBS/Tween solution for 
five minutes followed by incubation with a polymer (ImmPRESS Universal reagent, Vector 
Laboratories). Slides were again rinsed in the PBS/Tween solution followed by development 
with diaminobenzidine for detection. Counterstaining with Shandon Hematoxylin (Thermo 
Scientific), rinsing in several concentrations of alcohol solution, mounting, and viewing of the 
slides was performed. Positive and negative controls were run with each batch of slides which 
consisted of approximately 40 slides per batch. Normal heart and normal tonsil tissue were the 
positive controls for CXCR4 and CXCL12, respectively. The primary antibody was omitted from 
the negative control slides. We observed nuclear and cytoplasmic staining for CXCR4 and 
cytoplasmic and membranous staining for CXCL12.  
6.3.3 Evaluation of staining 
Expression of CXCL12 and CXCR4 was scored semi-quantitatively by incorporating the 
intensity of staining (IS) and the proportion of positive-staining cells (PS). The carcinoma and 
stromal compartments were scored separately for each case.  The PS was interpreted as 1=1-5%, 
2=6-20%, 3=21-80%, and 4=>80%, while the IS was interpreted as (1=weak, 2=moderate, 
3=strong). Slides with no positive-staining cells were coded as 0. A cumulative score was 
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calculated by summing the PS and IS.  Acceptable values of the cumulative score are 0, 2, 3, 4, 
5, 6, and 7. Interpretation of the cumulative score for a given marker is as follows: 0 (negative), 2 
(weakly positive) 3-5 (moderately positive), and 6-7 (strongly positive) [177]. Stromal 
expression of CXCL12 was absent in all cases while CXCR4 stromal expression was absent in 
98% of cases. Additionally, CXCR4 was expressed in all EC cases.  
6.3.4  Statistical analyses 
6.3.4.1 Sampling weights 
Sampling fractions (fi), the probability of case selection, were calculated as follows: stratum-
specific fraction of available tumor blocks with non-missing IHC data (Ai) * estimated case-
specific probability of tumor block availability (Bi). Calculation of Ai for the OS and RFS 
models are shown in Tables 9 and 15, respectively. The predicted probability that tumor blocks 
were available for a given case (Bi) was computed in the total target population (N=1,486) using 
a logistic regression model (Appendix Table 31). Ai and Bi were multiplied to calculate the 
probability that a case was sampled, i.e. the sampling fraction, fi. The sampling weight was 
derived by taking the inverse of the sampling fraction. All analyses applied sampling weights 
that allowed for proportions and other effect sizes to be applicable to the target population. In 
STATA 11, the svy family of commands was used to implement features of the study design into 
the analysis (StataCorp LP, College Station TX).  
6.3.4.2 Independent variables 
We hypothesized that differences in negative expression vs. positive expression at the primary 
tumor site would be clinically relevant. Therefore, we collapsed the categories of CXCL12 
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expression to represent positive expression (weak + moderate + strong cumulative scores) vs. 
negative expression. Other clinicopathologic variables of interest were age, race (white vs. non-
white), body mass index (BMI: normal, overweight, obese), additional cancer primaries (no, yes, 
unknown), histology subtype (low-grade Type I, high-grade Type I, CC, PS), stage (I & II vs. III 
& IV), lymph node involvement (no nodal involvement, positive nodal involvement, unknown 
nodal involvement, no nodal examination), tumor size (< 2 cm in the largest dimension, > 2 cm 
in the largest dimension, unknown size), post-operative treatment (surgery only, surgery + 
chemotherapy (CT), surgery + radiotherapy (RT), surgery + CT + RT), and year of diagnosis. 
6.3.4.3 Descriptive statistics  
All subsequent statistical analyses were performed using the svy family of commands in STATA 
11 (StataCorp LP, College Station TX). Survey commands take into account the stratified 
random sampling design and variance of estimators is obtained using the Taylor-linearized 
variance estimator method. For contingency tables the difference between observed and expected 
weighted cell frequencies were compared using an adjusted Wald F statistic which 
approximately follows a chi-square distribution.  
The distribution of clinicopathologic characteristics by histology subtype (low-grade Type I, 
high-grade Type I, CC, and PS) was examined with chi-square tests (svy: tabulate) for 
categorical variables. For continuous variables (i.e. age) the population mean was calculated by 
histology subtype (svy: mean) and a test command was used to test the null hypothesis that the 
means were equal across histology subtypes. The association between CXCL12 and CXCR4 
expression and clinicopathologic variables was similarly examined. All tables provide counts for 
the sample, the sample proportion, and the weighted proportion. When describing proportions in 
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the text, the weighted proportion (i.e. the proportion attributable to the target population) is 
referenced.  
6.3.4.4 Survival analysis 
OS and recurrence-free survival (RFS) were measured as the number of days between the date of 
diagnosis and the date of death from all causes or date of recurrence, respectively. Patients that 
did not experience either outcome were censored at the last date of contact or the date of last 
follow-up (December 31, 2008). For RFS analyses we only included cases that were known to 
become disease-free following the primary surgery (see Appendix Table 34 for an enumeration 
of disease recurrence in this population).  
Kaplan-Meier estimates of OS and RFS and log-rank tests were used to compare survival 
distributions by CXCL12 and CXCR4 expression status. Due to the lack of meaningful variation 
in CXCR4, only CXCL12 was examined in the multivariable survival analysis. The effect of 
CXCL12 on survival outcomes adjusted for histology subtype, stage, and age was investigated. 
A multiplicative interaction between CXCL12 and histology subtype was examined to assess 
effect modification and a p<0.05 was considered statistically significant to enter the final model. 
When the interaction was significant, hazard ratios comparing the presence vs. absence of 
CXCL12 for each histology subtype were estimated by exponentiating the following expression: 
βCXCL12 + βCXCL12*histology subtype. Stratification by year of diagnosis was performed in order to 
control for year of diagnosis without estimating coefficients for these variables. 
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6.4 RESULTS 
6.4.1 Characteristics of sample  
Table 10 shows demographic and clinical characteristics of the study sample and target 
population by histology subtype. Mean age differed significantly among the four histology 
subtypes. Low-grade Type I and high-grade Type I cases were younger (mean age: 61) compared 
to CC (mean age: 67) and PS cases (mean age: 66).  Race and BMI were borderline significantly 
different across the subtypes. Non-white race was more common among PS (17%) and CC 
(11%) cases compared to low-grade Type I (5%) and high-grade Type I cases (4%). The 
proportion of normal weight cases was lowest among high-grade Type I cases (5%), followed by 
PS (23%), low-grade Type I (26%), and CC (31%). Additional cancer primaries did not vary 
significantly by histology subtype (p=0.58). Stage was significantly different among the four 
histology types; PS cases were commonly late stage (51%), followed by high-grade Type I 
(38%), CC (29%), and low-grade Type I tumors (7%). Positive lymph node involvement was 
significantly higher in PS and high-grade Type I cases (20%) than in CC (9%) or low-grade Type 
I cases (2%).  
Finally, post-operative treatment significantly varied by histology subtype (p<0.001). Low-
grade Type I cases were most likely to have surgery only (68%) and surgery plus RT (29%). 
Among high-grade Type I cases, surgery only was most common (41%), followed by surgery 
plus RT (36%), and surgery plus RT and CT (24%). In CC cases, surgery plus RT was employed 
in almost half of the cases (47%), while PS cases had the highest proportion of a surgery plus CT 
regimen (41%). 
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6.4.2 CXCL12 and CXCR4 expression in EC patients 
CXCR4 was expressed in all ECs in the study sample. Fifty-nine of 199 (30%) cases showed 
moderately positive CXCR4 expression while 140 (70%) cases were classified as strongly 
positive CXCR4 expressers (Figures 7-8). CXCL12 expression was negative in 63 cases (32%), 
weakly positive in 24 cases (12%), moderately positive in 84 cases (42%), and strongly positive 
in 28 cases (14%) (Figures 9-12). Reclassifying CXCL12 expression as negative vs. positive 
resulted in 63 (32%) negative-expressers and 136 (68%) positive-expressers. CXCR4 and 
CXCL12 expression were not significantly associated with each other ((p=0.74, Table 11). The 
association between CXCR4, CXCL12, and clinicopathologic factors is presented in Table 12. 
Neither CXCR4 nor CXCL12 were significantly associated with race, BMI, histology subtype, 
stage, lymph node involvement, or tumor size.   
6.4.3 CXCL12/CXCR4 expression and OS  
Kaplan-Meier survival curves were produced to graphically illustrate the association between 
CXCL12 and CXCR4 expression and OS (Figure 13). Neither CXCL12 (p=0.33) nor CXCR4 
(p=0.86) were significantly associated with OS. As CXCR4 lacked variability, we only examined 
the independent effect of CXCL12 expression on OS using Cox proportional hazards models. In 
all EC patients, CXCL12 expression was not significantly associated with OS (HR: 0.72, 95% CI 
0.30, 1.72, Table 13); however we did observe a statistically significant interaction between 
CXCL12 and histology subtype (p=0.05, Table 14). The effect of CXCL12 among the histology 
subtypes is shown in Table 14. Using linear combinations to compare categories of expression, 
we observed that high-grade Type I cases with positive CXCL12 expression had a significantly 
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better OS compared to high-grade Type I cases with negative CXCL12 expression (HR: 0.17, 
95% CI 0.05, 0.59, data not shown). CXCL12 expression was not significantly associated with 
OS in low-grade Type I, CC, or PS cases. 
6.4.4 CXCL12/CXCR4 expression and RFS 
For the Kaplan-Meier analyses and the Cox proportional hazards modeling, the sampling weights 
were re-estimated to reflect the number of cases that were disease-free following the primary 
surgery (N=163, Table 15). CXCL12 and CXCR4 expression were not significantly associated 
with RFS based on the log-rank test (Figure 14). The main effect of CXCL12 adjusted for 
histology subtype, stage, and age is shown in Table 16. Although CXCL12 was not significantly 
associated with RFS in all EC cases (HR: 0.52, 95% CI 0.20, 1.34), we did observe a significant 
interaction between CXCL12 and histology subtype (p=0.01, Table 17). Among high-grade Type 
I cases, positive CXCL12 expression was significantly associated with a reduced risk of 
recurrence compared to negative CXCL12 expression (HR: 0.10, 95% CI 0.02, 0.57, data not 
shown). Among low-grade Type I cases, RFS was borderline significantly associated with 
CXCL12 expression. Risk of recurrence was reduced in low-grade Type I patients with positive 
CXCL12 expression compared to negative expression (HR: 0.23, 95% CI 0.05, 1.05).  
6.5 DISCUSSION 
In normal tissues, homeostasis is maintained through controlled interactions between epithelial 
and stromal cells. Chemokines are an important class of stromal-derived signaling proteins 
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which contribute to tissue maintenance and repair by binding specific receptors expressed by 
target cells. For a particular chemokine ligand-receptor pair, high concentrations of the ligand 
“chemoattract” cells that express the receptor through a chemokine gradient. CXCR4 is typically 
expressed by immune cells, such as hematopoietic cells, T-lymphocytes, B-lymphocytes, 
monocytes and macrophages, as well as cells of the liver, kidney, brain, lung, and colon [178]. 
Upon binding, downstream processes such as chemotaxis, cell survival and proliferation, 
increases in intracellular calcium, and gene transcription are triggered [178]. Several chemokine 
ligand-receptor pairs have been examined in the cancer literature, among which, the 
CXCL12/CXCR4 axis is the most frequently studied. During carcinogenesis, tumor cells may 
acquire CXCR4 expression as a result of hypoxic tissue conditions or activating mutations.  
Consequently, CXCR4-expressing cancer cells have the potential to metastasize to tissues which 
abundantly express CXCL12 via a chemokine gradient. By analogy, positive expression of 
CXCL12 at the primary tumor site would presumably suppress the metastasis of CXCR4-
expressing cells, which has been shown in colon [179] and breast cancer models [180]. 
We examined the role of CXCR4 and CXCL12 in a diverse sample of EC cases. CXCR4 
was highly and uniformly expressed by all cases in this study. Positive expression of CXCL12 at 
the primary tumor site was significantly associated with better OS and RFS in high-grade Type I 
cases. Furthermore, positive CXCL12 expression was borderline associated with better RFS in 
low-grade Type I cases. To our knowledge, this is the first study to demonstrate the prognostic 
significance of CXCL12 in a cohort of diverse EC subtypes. Our findings highlight additional 
molecular and prognostic differences between Type I (low-grade and high-grade) and Type II 
(CC and PS) ECs. 
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The differences in prognosis between EC subtypes associated with CXCL12 expression may 
reflect the wide-ranging effects induced by CXCL12 expression. Although high concentrations 
of CXCL12 at the primary tumor site may suppress the metastasis of tumors, mechanisms other 
than cell migration, including proliferation, immune evasion, and adhesion, may be stimulated. 
For example, in a murine melanoma model, Vianello et al. [181] reported high levels of CXCL12 
tumor expression were associated with “chemorepulsion” of effector T cells that would normally 
infiltrate the tumor and kill neoplastic cells. Consequently, these tumors were capable of evading 
the immune response. In epithelial ovarian cancer cells, expression of CXCL12 at the primary 
tumor site was associated with intraperitoneal metastasis through CXCL12-mediated adhesion to 
human peritoneal cells [171].  
Previous EC studies have investigated the association between CXCR4 and/or CXCL12 and 
tumor grade [105, 106], myometrial invasion [108], and survival [107]. Using IHC, Mizokami et 
al. [106] reported CXCR4 and CXCL12 protein expression were significantly higher in low-
grade Type I tumors (N=27) compared to high-grade Type I tumors (N=15). Conversely, 
Gelmini et al. [105] reported that IHC expression of CXCR4 showed high and uniform staining 
among 41 Type I EC tumors with different grades of differentiation [105]. In this case-series, 
CXCR4 was moderately or strongly expressed by all ECs, which agrees with the Gelmini series 
[105]. Another analysis showed that CXCR4 expression was significantly higher in endometrial 
tumors that invaded more than half of the myometrial layer compared to endometrial tumors with 
superficial invasion [108].  
Kodama and colleagues [107] investigated the prognostic association of CXCR4 expression 
on OS. Positive CXCR4 expression (defined as staining in 50% or more of cells) was associated 
with significantly better OS (log-rank p=0.04) compared to no CXCR4 expression (defined as 
 99 
less than 50% of cells stained positive), however this association was not significant in an 
adjusted regression model. In our Kaplan-Meier analysis comparing OS and RFS between 
moderately positive and strongly positive CXCR4 expressers, we did not observe a statistically 
significant association. 
Relatively few EC studies have examined CXCL12 expression. CXCL12 was highly 
variable in our sample; 32% of cases had no CXCL12 expression while the remaining 68% of 
cases had varying levels of positive CXCL12 expression. We did not observe significant 
associations between CXCL12 expression and demographic or clinical variables. A trend in 
decreasing CXCL12 expression and increasing BMI was noted, however the p-value for this 
association was 0.21. Although non-significant, this finding is particular interesting because BMI 
is typically used as a surrogate indicator for circulating estrogen exposure. As BMI increases, 
estrogen levels are also thought to increase due to the enhanced conversion of androstenedione to 
estrogen [19]. The downstream effects of estrogen action are regulated through direct interaction 
with estrogen receptors alpha and beta [182]. In normal human endometrial cell lines, Ruiz et al. 
[176] showed that CXCL12 gene expression was significantly downregulated by estrogen 
treatments, however a concurrent downregulation in CXCL12 protein expression was not 
observed. Conversely, Tsutsumi et al. [183] reported that estrogen was a potent inducer of 
CXCL12 mRNA and protein in endometrial stromal cells purified from patients with benign 
gynecologic diseases, supporting the role of a positive interaction between estrogen and 
CXCL12. The relationship between estrogen and CXCL12 expression in EC remains indefinite. 
Interestingly, stromal expression of CXCL12 was absent in this study. Based on the biology 
of CXCL12 in normal tissues [176], we anticipated that CXCL12 would be expressed by 
infiltrating stromal cells, which was not the case. However, other studies have reported CXCL12 
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and CXCR4 production in primary tumors which supports the hypothesis of autocrine signaling 
to enhance tumor proliferation [179, 180]. 
Our prognostic results are in accordance with large studies performed in breast cancer 
patients. Mirisola [173], Hassan [175], and Kobayashi [174] reported that CXCL12 expression 
was an independent and significant prognostic factor for better OS and RFS. These studies 
proposed that the CXCL12/CXCR4 axis mediates survival through inhibition of metastatic 
spread. Interestingly, studies of other cancer sites report that CXCL12 expression is a poor 
prognostic factor for RFS and OS. In stage II pancreatic ductal adenocarcinomas [184] high 
tumoral CXCL12 expression was associated with poor OS adjusted for tumor size, 
differentiation, and lymph node status. In rectal cancer patients treated with preoperative 
chemoradiotherapy, strong stromal expression of CXCL12 and CXCR4 was associated with 
shorter RFS and OS [185]. Akishima-Fukasawa et al. [186] reported that high CXCL12 
expression was significantly associated with worse OS and RFS adjusted for tumor depth, lymph 
node metastasis, and blood vessel invasion in colorectal cancer patients. These prognostic studies 
further emphasize the conflicting role CXCL12 plays in various cancers; in some cancers, a 
protective effect is observed while in others, poor outcomes are apparent. We propose that 
survival outcomes in various cancers are dependent on the dominant CXCL12 mechanism 
observed for specific cancer types. 
Several limitations with the current study should be mentioned. First, as we selected cases 
for this study from a larger population of EC cases, selection bias may play a role in the findings.  
Tumor blocks were unavailable for 33% of the target population; cases without available tumor 
blocks differed from included cases with respect to stage and histology type, two important 
prognostic factors. Second, our use of IHC as the method for protein detection is a potential 
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limitation. IHC is a subjective and semi-quantitative method used for the detection of protein 
expression.  Despite the known limitations of IHC [187], it can be argued that while IHC remains 
the gold standard in routine pathology, translational studies should utilize the molecular methods 
commonly used in clinical practice. Finally, this study lacks generalizability to EC patients of 
other races, as our study population was mostly white.   
The major strength of this clinicopathologic study was the inclusion of a large sample of 
high-grade Type I, CC, and PS tumors compared to other published case-series; it was 
particularly relevant to study this pathway in a group of aggressive ECs, as higher stage, poor 
differentiation, and metastasis are characteristic of these tumors.  Furthermore, the large sample 
size allowed us to investigate the independent prognostic significance of CXCL12 in subtypes of 
EC. Other strengths include the high quality pathology data, information on potential 
confounders, and use of archived tissue specimens.  
In conclusion, the results of this study suggest that CXCL12 expression is associated with 
better OS and RFS in a subset of EC cases. In addition to the usual pathological prognostic 
factors (stage and histology subtype), this biomarker may be relevant for identifying a subset of 
patients who will have a better outcome, and can potentially avoid adjuvant therapy. Future EC 
studies of this pathway should examine a larger sample of patients to confirm or challenge the 
findings presented in this study. Furthermore, basic science studies which examine mechanisms 
associated with CXCL12 expression in EC will add to the body of knowledge regarding this 
pathway. Future studies planned by our group include an evaluation of concurrent CXCL12 and 
estrogen receptor expression in EC cases. As CXCL12 is an estrogen receptor related target and 
estrogen exposure is etiologically the most important factor for EC development, an 
 102 
understanding of the relationship between these two proteins in a diverse group of EC cases may 
provide useful insights. 
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6.6 TABLES 
Table 9 Probability of sampling given that tumor blocks were available 
 
 
 
 
 
 
 
 
 
 
 
 Type I Type II  
Stratum Stage I Stage II Stage III Stage IV Stage I Stage II Stage III Stage IV Total 
n with tumor blocks available 691 65 85 21 62 16 34 29 1,003 
n sampled 30 28 36 16 36 9 23 21 199 
pr (sampled| tumor blocks  available)= 
(sampled/ tumor blocks ) 
0.0434 0.4308 0.4235 0.7619 0.5806 0.5625 0.6765 0.7241 
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Table 10 Demographic and clinical characteristics of the EC sample by histology subtype 
Characteristics 
N=199 
Low-grade Type I 
n=76 
High-grade Type I 
n=34 
Clear cell 
n=29 
Papillary serous 
n=60 
p* 
 n§ (%)† %‡ n§ (%)† %‡ n§ (%)† %‡ n§ (%)† %‡  
Mean age (sd) 62 (12) 61 (1.67) 62 (12) 61 (3.71) 67 (11) 67 (2.00) 66 (11) 66 (1.37) 0.04 
Race          
White 71 (93) 95 32 (94) 96 26 (90) 89 50 (83) 83 0.10 
Non-White 5 (7) 5 2 (6) 4 3 (10) 11 10 (17) 17  
Body Mass Index           
Normal (BMI < 25 kg/m2) 19 (25) 26 4 (12) 5 9 (32) 31 16 (27) 23 0.08 
Overweight (BMI 25-30 kg/m2) 20 (26) 18 10 (29) 48 10 (34) 34 18 (30) 23  
Obese (BMI > 30 kg/m2) 36 (47) 56 20 (59) 47 10 (34) 35 26 (43) 54  
Additional cancer primaries          
No 66 (87) 83 27 (79) 73 23 (79) 80 44 (74) 81 0.58 
Yes 8 (10) 14 7 (21) 27 6 (21) 20 13 (23) 16  
Unknown 2 (3) 3 0 (0) 0 0 (0) 0 2 (3) 3  
FIGO stage           
Early (I & II) 52 (68) 93 6 (18) 62 19 (66) 71 26 (43) 49 <0.001 
Late (III & IV) 24 (32) 7 28 (82) 38 10 (34) 29 34 (57) 51  
Lymph node involvement          
No nodes examined 18 (24) 39 9 (26) 27 10 (34) 34 12 (20) 20 <0.001 
None 44 (58) 57 12 (35) 53 16 (55) 57 30 (50) 52  
Positive 8 (10) 2 13 (38) 20 3 (10) 9 13 (22) 20  
Unknown 6 (8) 2 0 (0) 0 0 (0) 0 5 (8) 9  
Tumor size          
< 2 cm 11 (14) 21 4 (12) 40 3 (10) 11 8 (13) 15 0.16 
> 2 cm 34 (45) 27 20 (59) 46 14 (48) 50 27 (45) 44  
Unknown 31 (41) 52 10 (29) 14 12 (42) 39 25 (42) 41  
Post-operative treatment          
Surgery only 30 (39) 68 4 (12) 41 6 (21) 20 12 (20) 20 <0.001 
Surgery + CT 8 (11) 2 11 (32) 13 9 (31) 28 26 (43) 41  
Surgery + RT  34 (45) 29 11 (32) 36 13 (45) 47 11 (18) 20  
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Surgery + CT + RT 4 (5) 1 8 (24) 10 1 (3) 4 11 (18) 20  
§ sample count 
† proportion or mean in the study sample 
‡ proportion or mean in the target population 
* Adjusted Wald p-value  
Table10 continued 
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Table 11 Association between CXCR4 and CXCL12 expression 
N=199 CXCR4 expression 
CXCL12 expression Moderately positive  
n=59§ 
Strongly positive 
n=140§ 
p‡ 
 n§ (%)* %† n§ (%)* %†  
Negative 
n=63§ 
24 (41) 36 39 (28) 31 0.74 
Positive 
n=136§ 
35 (59) 64 101 (72) 69  
§ sample count 
* proportion in the study sample  
† proportion in the target population 
‡ Adjusted Wald p-value 
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Table 12 Association of biomarker expression with clinicopathologic characteristics 
Characteristic 
N=199 
Sample counts % Strong expression†  % Positive expression‡  
 
CXCR4§ CXCL12§ 
Race       
White 179 69 67 
Non-White 20 76 79 
p-value*   0.69 0.50 
Body Mass Index     
Normal 49 69 84 
Overweight 58 59 71 
Obese 92 71 59 
p-value*   0.92 0.21 
Histology type     
Low-grade Type I 76 66 68 
High-grade Type I 34 86 64 
Clear cell 29 73 60 
Papillary serous 60 76 71 
p-value*   0.49 0.81 
FIGO stage     
Early stage (I & II) 103 70 67 
Late stage (III & IV) 96 64 69 
p-value*   0.49 0.81 
Lymph node involvement     
None 102 70 75 
Positive 37 68 70 
No nodal exam 49 70 55 
Unknown 11 64 83 
p-value*   0.99 0.42 
Tumor size     
< 2 cm 26 84 55 
> 2 cm 95 70 62 
Unknown 78 62 77 
p-value*   0.36 0.35 
† Strong expression vs. moderate expression 
‡ Positive expression vs. negative expression 
§ Weighted percentages  
* Adjusted Wald p-value  
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Table 13 Cox proportional hazards model for OS: main effect of CXCL12  
N=199  Multivariable* 
 deaths/N HR (95% CI) p† 
CXCL12     
Negative 28/63 1.00 (Reference) 0.46 
Positive 58/136 0.72 (0.30, 1.72)  
* Adjusted for stage (early stage, late stage), histology subtype (low-grade type I, high-grade type I, clear 
cell, papillary serous), and age at diagnosis (continuous, range 34-93 years) 
Stratified by year of diagnosis (single year, 1996 through 2008) 
† Adjusted Wald p-value  
 
 
 
Table 14 Cox proportional hazards model* for OS: interaction between CXCL12 and histology subtype 
N=199 deaths/N HR (95% CI) p† 
    
Histology subtype and CXCL12 expression   0.05‡ 
Low-grade Type I and negative CXCL12 6/19  1.00 (Reference)  
Low-grade Type I and positive CXCL12 15/57  0.91 (0.20, 4.22) 0.90 
High-grade Type I and negative CXCL12 8/14  10.78 (1.53, 76.09) 0.02 
High-grade Type I and positive CXCL12 11/20  1.80 (0.25, 12.87) 0.55 
Clear cell and negative CXCL12 6/12  2.92 (0.37, 23.12) 0.31 
Clear cell and positive CXCL12 7/17  2.43 (0.57, 10.40) 0.23 
Papillary serous and negative CXCL12 8/18  2.35 (0.38, 14.69) 0.36 
Papillary serous and positive CXCL12 25/42  4.72 (0.70, 31.55) 0.11 
*Adjusted for stage (early stage, late stage) and age at diagnosis (continuous, range 34-93 years) 
Stratified by year of diagnosis (single year, 1996 through 2008) 
† Adjusted Wald p-value  
‡ p-value for interaction 
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Table 15 Probability of sampling given that tumor blocks were available in disease-free cases 
 Type I Type II  
Stratum Stage I Stage II Stage III Stage IV Stage I Stage II Stage III Stage IV Total 
n with tissue available 691 65 85 21 62 16 34 29 1,003 
n sampled 28 24 30 13 30 7 19 12 163 
pr (sampled|tissue available)= 
(sampled/tissue available) 
0.0405 0.3692 0.3529 0.6190 0.4839 0.4375 0.5588 0.4138  
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Table 16 Cox proportional hazards model for RFS: main effect of CXCL12, N=163 
N=163  Multivariable* 
 recurrences/N HR (95% CI) p† 
CXCL12     
Negative 20/55 1.00 (Reference) 0.17 
Positive 22/108 0.52 (0.20, 1.34)  
* Adjusted for stage (early stage, late stage), histology subtype (low-grade type I, high-grade type I, 
clear cell, papillary serous), and age at diagnosis (continuous, range 34-93 years) 
Stratified by year of diagnosis (single year, 1996 through 2008) 
† Adjusted Wald p-value  
 
Table 17 Cox proportional hazards model* for RFS: interaction between CXCL12 and histology subtype 
N=163 recurrences/N HR (95% CI) p† 
    
Histology subtype and CXCL12 expression   0.01‡ 
Low-grade Type I and negative CXCL12 4/17 1.00 (Reference)  
Low-grade Type I and positive CXCL12 2/50 0.23 (0.05, 1.05) 0.06 
High-grade Type I and negative CXCL12 7/12 1.66 (0.33, 8.26) 0.53 
High-grade Type I and positive CXCL12 8/16 0.16 (0.02, 1.46) 0.10 
Clear cell and negative CXCL12 2/10 0.29 (0.02, 4.30) 0.37 
Clear cell and positive CXCL12 3/13 2.84 (0.44, 18.16) 0.27 
Papillary serous and negative CXCL12 7/16 1.03 (0.18, 5.73) 0.98 
Papillary serous and positive CXCL12 9/29 1.83 (0.36, 9.17) 0.46 
* Adjusted for stage (early stage, late stage) and age at diagnosis (continuous, range 34-93 years) 
Stratified by year of diagnosis (single year, 1996 through 2008) 
† Adjusted Wald p-value  
‡ p-value for interaction 
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6.7 FIGURES 
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Figure 6 Sampling strategy for CXCL12/CXCR4 expression study 
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Figure 7 Representative IHC stain and corresponding hematoxylin and eosin stain, 40X 
magnification: Moderate CXCR4 expression 
 
 
Figure 8 Representative IHC stain and corresponding hematoxylin and eosin stain, 40X 
magnification: Strong CXCR4 expression 
 
 
Figure 9 Representative IHC stain and corresponding hematoxylin and eosin stain, 40X 
magnification: Negative CXCL12 expression 
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Figure 10 Representative IHC stain and corresponding hematoxylin and eosin stain, 40X 
magnification: Weak CXCL12 expression 
 
 
 
Figure 11 Representative IHC stain and corresponding hematoxylin and eosin stain, 40X 
magnification: Moderate CXCL12 expression 
 
 
Figure 12 Representative IHC stain and corresponding hematoxylin and eosin stain, 40X 
magnification: Strong CXCL12 expression 
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Figure 13 Kaplan-Meier overall survival curves for CXCL12 and CXCR4 
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Figure 14 Kaplan-Meier recurrence-free survival curves for CXCL12 and CXCR4 
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7.1 ABSTRACT 
Introduction: Angiogenesis plays a central role in the invasion and metastasis of many common 
cancers. Hepatocyte growth factor (HGF) is a stromal-derived, multifunctional protein that acts 
on epithelial cells through activation of the proto-oncogenic receptor, c-Met. Activation of the 
HGF/c-Met pathway is typically associated with poor cancer outcomes. Additionally, basic 
fibroblast growth factor (bFGF) is an angiogenic cytokine which induces expression of HGF and 
promotes cell proliferation and angiogenesis. The goal of this study is to determine the 
prognostic significance of HGF, c-Met, and bFGF in patients with endometrial cancer (EC). 
Methods: Tumor blocks were available for 211 EC cases diagnosed at Magee-Womens Hospital. 
Immunohistochemistry was used to detect stromal and tumor protein expression of the three 
biomarkers. The association between protein expression and clinicopathologic factors was 
examined with chi-square tests. Kaplan-Meier curves, log-rank tests, and Cox regression were 
used to investigate the association between biomarker expression, overall survival (OS), and 
recurrence-free survival (RFS). 
Results: Positive expression in the sample was as follows: tumor HGF (15%), tumor c-Met 
(27%), tumor bFGF (17%), and stromal bFGF (55%). Tumor bFGF was significantly associated 
with histology subtype (p<0.001), stage (p=0.008), lymph node involvement (p=0.002), and age 
(p=0.003). Positive tumor bFGF expression was significantly associated with worse OS (log-
rank p=0.009) and RFS (log-rank p<0.001). In the adjusted OS Cox model, a reduced risk of 
death was observed in tumor HGF positive, stromal bFGF positive patients compared to tumor 
HGF positive, stromal bFGF negative patients (HR: 0.14, 95% CI 0.03, 0.60). Tumor HGF 
positive, tumor bFGF positive patients had significantly worse RFS compared to patients with 
negative expression of both markers (HR: 9.88, 95% CI 2.63, 37.16). 
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Discussion: The present study demonstrates that interactions between tumor-derived and 
stromal-derived proteins influence survival outcomes in EC patients. Interactions between HGF 
and bFGF played an important role in OS and RFS, however the localization of bFGF 
immunostaining modified the association. Pending further investigations, tumor-derived bFGF 
may be an attractive target in EC therapy. 
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7.2 INTRODUCTION 
Angiogenesis, the formation of new vessels from preexisting parent vessels, is a critical factor in 
growth and dissemination of primary tumors [188]. Endometrial stromal cells are a highly active 
source of angiogenic cytokines, which regulate endothelial cell proliferation, migration, and 
vessel density during the proliferative and secretory phases of the menstrual cycle [189]. During 
carcinogenesis, neoplastic cells exploit the pathways controlled by angiogenic growth factors and 
their receptors, leading to cell scattering, proliferation, evasion of apoptosis, and ultimately 
metastasis [190].  
Hepatocyte growth factor (HGF), also known as scatter factor, has mitogenic and motogenic 
effects on epithelial and endothelial cells via its receptor c-Met [111]. c-Met activation by HGF 
is associated with stimulation of various signaling cascades including the ras-mitogen-activated 
protein kinase (MAPK), the phosphatidylinositol 3-kinase (PI3K), and the signal transducers and 
activators of transcription (STAT) signaling pathways; aberrant activation of these pathways can 
result in motility, protection from apoptosis, and proliferation [191]. These consequences support 
the hypothesis that HGF/c-Met interactions are associated with invasion and metastasis of human 
malignancies. c-Met is reportedly overexpressed in many cancers compared to adjacent normal 
tissue which typically correlates with worse prognosis [192]. Additionally, other angiogenic 
growth factors are known to interact with this pathway; specifically, basic fibroblast growth 
factor (bFGF) upregulates expression of HGF in EC tissues [113] and mediates angiogenesis by 
enhancing vascular permeability and proliferation of endothelial cells [193].  
The biology of HGF, c-Met, and bFGF has been examined in normal human endometrial 
tissues, EC cell lines, and human EC specimens. Sugawara et al. [118] demonstrated that HGF 
and c-Met were present in the normal endometrium; furthermore, HGF was a potent stimulator 
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of endometrial cell growth and motility.  In vitro studies using EC cell lines demonstrate the 
presence of c-Met; well-differentiated EC cell lines (HEC-1A and HEC-1B) showed higher c-
Met expression compared to moderately differentiated (RL-95) and poorly differentiated EC cell 
lines (KLE) [119]. Although HGF was not expressed by EC cell lines, addition of HGF to cell 
cultures significantly induced the invasion of EC cells, suggesting that surrounding stromal cells 
and not neoplastic cells produce the growth factor. Dai and colleagues [194] reported bFGF 
mRNA and protein expression in normal endometrial tissues, however expression was 
significantly higher in complex hyperplasia and EC specimens. In EC cell lines, tumor-derived 
bFGF was shown to increase HGF transcription, which resulted in an increased invasive and 
proliferative capacity of EC cells [111]. 
Two prognostic studies have examined HGF and c-Met expression in Type I and papillary 
serous (PS) EC patients [120, 121]. Wagatsuma et al. [120] reported positive HGF and c-Met 
expression in 90% and 63% of Type I EC patients, respectively which was higher than 
expression in normal endometrial specimens (HGF=79%; c-Met=14%). Positive c-Met 
expression was significantly associated with advanced stage, poor differentiation, and worse 
overall survival (OS) in univariate analysis, whereas HGF was significantly associated with 
advanced stage. Additionally, neither c-Met nor HGF expression were independent prognostic 
factors for survival after adjusting for stage, grade, vascular involvement, and microvessel count 
[120]. Bishop et al. [121] reported positive HGF and c-Met staining in 100% and 87% of PS EC 
patients, respectively. OS in cases with strong HGF or strong c-Met expression was significantly 
worse compared to cases with weak expression of either marker as evidenced by Kaplan-Meier 
graphs.  
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In two reports, high expression of tumor-derived bFGF protein was significantly associated 
with poor differentiation, presence of tumor necrosis, and vascular invasion [122]. Similarly, 
Fujimoto et al. [123] showed that bFGF mRNA expression was significantly higher in poorly 
differentiated and advanced stage tumors. To our knowledge, the association between bFGF 
expression and survival in EC has not been explored. The goal of this study is to expand the 
findings from the previous in vitro and prognostic studies by examining the co-expression of 
HGF, c-Met, and bFGF expression in a histologically diverse sample of EC cases. Furthermore, 
we used immunohistochemistry (IHC) to distinguish tumor and stromal expression. We 
hypothesized that positive expression of HGF, c-Met, and bFGF would be associated with worse 
survival outcomes independent of known EC prognostic factors, such as stage, histology 
subtype, and age. 
7.3 METHODS 
7.3.1 Study sample 
EC cases in this study were treated at Magee-Womens Hospital between 1996 and 2008. The 
sampling frame and sample selection methods were previously described (section 6.3.1); briefly, 
1,486 cases were eligible for inclusion in the current IHC study. Patients were classified as 
having Type I or Type II EC based on the surgical pathology report. Endometrioid or 
adenocarcinoma tumors were classified as Type I while clear cell (CC) and PS were classified as 
Type II. Tumor blocks were presumed to be available for 67% (N=1,003) of cases. Case 
selection from this reduced sampling frame was achieved using a stratified random sampling 
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design. Within the eight combinations of histology subtype and stage, we aimed to include 25 
patients from each stratum, resulting in 200 cases; however tumor blocks for 216 cases were 
retrieved. The breakdown of cases in each stratum is shown in Figure 15. Within strata where the 
number of available cases was less than 25, we made an effort to include all cases; however 
inadequate tissue limited our ability to achieve this goal. Furthermore, following slide sectioning 
of the selected blocks, 5 slides did not have evaluable tumor present, which reduced the analytic 
cohort to 211 EC cases. This study was approved by the University of Pittsburgh Institutional 
Review Board. 
7.3.2 Immunohistochemistry 
Formalin-fixed paraffin-embedded tissue blocks for the 216 selected cases were retrieved from 
the Pathology Department at Magee-Womens Hospital. Four μm thick slides were cut at the time 
of block retrieval. Deparaffinization and hydration of the slides with xylenes and washes with 
progressively decreasing alcohol concentrations was performed. Endogenous peroxidase activity 
was blocked with 3% methanol peroxide. Antigen retrieval in 0.01 M boiling citrate buffer (pH 
6.0) in a microwave was performed followed by blocking of non-specific staining with Protein 
Block (Dako North America, Inc, Carpinteria, California). Whole tissue sections were then 
incubated for one hour at room temperature with 100 microliters of polyclonal HGF antibody 
(R&D Systems, Minneapolis, MN, dilution 1:30), polyclonal c-Met antibody (Santa Cruz 
Biotechnology Inc, Santa Cruz, CA, dilution 1:75) and polyclonal basic fibroblast growth factor 
antibody (Millipore, Billerica, MA, dilution 1:1000). Slides were subsequently rinsed in 
PBS/Tween solution for five minutes followed by incubation with a polymer (ImmPRESS 
Universal reagent, Vector Laboratories). Slides were rinsed in the PBS/Tween solution followed 
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by development with diaminobenzidine for detection. Slides were counterstained with Shandon 
Hematoxylin for 2 minutes, rinsed in several concentrations of alcohol solution, mounted, and 
viewed. Positive and negative controls were run with each batch of slides, which consisted of 
approximately 40 slides per batch. Placenta, fibroadenoma, and granulation tissue were the 
positive controls for HGF, c-Met, and bFGF, respectively. The primary antibody was omitted 
from the negative control slides. Cytoplasmic and nuclear immunostaining was observed for 
HGF and bFGF; cytoplasmic staining was observed for c-Met.  
7.3.3 Evaluation of staining 
Calculation of the cumulative score was previously described (section 6.3.3).  Tumor and stromal 
expression was quantified by summing the proportionality score (PS) and the intensity score (IS). 
The PS represents the approximate proportion of positive-staining cells (1=1-5%, 2=6-20%, 
3=21-80%, and 4=>80%) while the IS represents the average intensity of positive-staining cells 
(0=none, 1=weak, 2=moderate, 3=strong). Slides with no positive-staining cells were coded as 0. 
Acceptable values of the cumulative score are 0, 2, 3, 4, 5, 6, and 7. Interpretation of the 
cumulative score for a given marker is as follows: 0 (none), 2 (weak), 3-5 (moderate), and 6-7 
(strong) [177]. Stromal expression of HGF and c-Met were negative in all cases while bFGF 
showed tumor and stromal expression.  
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7.3.4 Statistical analyses 
7.3.4.1 Sampling weights 
Sampling fractions (fi), the probability of case selection, were calculated as follows: stratum-
specific fraction of available tumor blocks with non-missing IHC data (Ai) * estimated case-
specific probability of tumor block availability (Bi). Calculation of Ai for the OS and RFS 
models are shown in Tables 18 and 25, respectively. The predicted probability that tumor blocks 
were available for a given case (Bi) was computed in the total target population (N=1,486) using 
a logistic regression model. Ai and Bi were multiplied to calculate the probability that a case was 
sampled, i.e. the sampling fraction, fi. The sampling weight was derived by taking the inverse of 
the sampling fraction. All analyses applied sampling weights that allowed for proportions and 
other effect sizes to be applicable to the target population. In STATA 11, the svy family of 
commands was used to implement features of the study design into the analysis (StataCorp LP, 
College Station TX).  
7.3.4.2 Independent variables 
As mentioned, tumor HGF, tumor c-Met, tumor bFGF, and stromal bFGF were coded as none, 
weak, moderate, or strong. These categories were further collapsed to represent positive 
expression (weak + moderate + strong cumulative scores) vs. negative expression.  
Additionally, information on age, race (white vs. non-white), body mass index (BMI: 
normal, overweight, obese), additional cancer primaries (no, yes, unknown), histology type (low-
grade Type I, high-grade Type I, CC, PS), stage (I & II vs. III & IV), lymph node involvement 
(no nodal involvement, positive nodal involvement, unknown nodal involvement, no nodal 
examination), tumor size (< 2 cm in the largest dimension, > 2 cm in the largest dimension, 
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unknown size), post-operative treatment (surgery only, surgery + chemotherapy (CT), surgery + 
radiotherapy (RT), surgery + CT + RT), and year of diagnosis was available. 
7.3.4.3 Descriptive statistics 
Contingency tables were used to examine the association between clinicopathologic factors and 
histology subtype using Pearson chi-square tests for categorical data (svy: tabulate). Means of 
continuous variables (i.e. age) by histology subtype were estimated and a test comparing the 
equality of means was performed (svy: mean). The association between tumor HGF, tumor c-
Met, tumor bFGF, stromal bFGF expression, and clinicopathologic variables was similarly 
assessed. Proportions and means for the study sample and the target population are presented, 
however statistics related to the target population are described in the text. We also examined the 
association between pairs of biomarkers using logistic regression (svy: logistic).  
7.3.4.4 Multivariable models 
The two survival outcomes of interest were OS and RFS, which were estimated as the number of 
days between the date of diagnosis and the date of death from any cause and the date of 
recurrence, respectively. Patients who did not experience either outcome were censored at the 
last date of contact or the date of last follow-up (December 31, 2008). Only cases known to be 
disease-free following the primary surgery were included in the RFS analysis (see Appendix 
Table 39 for an enumeration of disease recurrence in this sample).  
Kaplan-Meier curves were compared using the log-rank test to examine the equality of OS 
and RFS among expressers and non-expressers of the proteins of interest. Cox proportional 
hazard regression modeling was used to analyze the effect of tumor HGF, tumor c-Met, tumor 
bFGF, and stromal bFGF expression on OS and RFS controlling for histology subtype, stage, 
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and age. Year of diagnosis was included as a stratification variable. In addition to the main 
effects model, we examined pairwise interactions between the biomarkers.  
7.4 RESULTS 
7.4.1 Characteristics of study sample 
Distributions of demographic and clinical data by histology subtype are shown in Table 19.  
Mean age was significantly different between the histology subtypes; CC (67 years) and PS cases 
(66 years) were significantly older than low and high-grade Type I cases (mean age: 61 years). 
Non-white race was significantly more common among PS cases (19%) compared to CC (10%), 
low-grade Type I (4%), and high-grade Type I cases (4%). BMI and history of additional cancer 
primaries did not significantly vary across histology subtypes. Stage varied significantly between 
the four subtypes; advanced stage tumors (III & IV) were most common in PS cases (51%) 
compared to high-grade Type I (41%), CC (28%), and low-grade Type I cases (6%). Positive 
lymph node involvement was more common among high-grade Type I (22%) and PS cases 
(20%) than in CC (8%) or low-grade Type I cases (2%). Post-operative treatment was 
significantly different between the four subtypes. Surgery only was most common among low-
grade Type I cases (61%). Among high-grade Type I cases, surgery only (39%) and surgery plus 
RT (34%) were prevalent. In CC cases, surgery plus RT (51%) and surgery plus CT (27%) were 
the most common treatments received. Surgery plus CT was used in 40% of PS cases, followed 
by 21% of patients with surgery plus RT, and 21% of patients with both RT and CT. 
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7.4.2 HGF/c-Met/bFGF expression in EC patients 
Figures 16-28 show representative IHC stains for tumor HGF, tumor c-Met, tumor bFGF, and 
stromal bFGF expression. Tumor HGF expression was absent in 180 cases (85%); 16 (8%) and 
15 cases (7%) showed weakly and moderately positive tumor HGF expression, respectively. 
Tumor c-Met expression was negative in 155 (73%), weakly positive in 14 (7%), moderately 
positive in 34 (16%), and strongly positive in 8 cases (4%). bFGF expression was present in both 
the tumor and stromal compartments. Tumor bFGF expression was absent in 176 (83%), 
moderately positive in 22 (10%), and strongly positive in 13 cases (6%). Stromal bFGF 
expression was absent in 95 (45%), weakly positive in 1 (1%), moderately positive in 74 (35%), 
and strongly positive in 41 (19%) cases. As mentioned, categories of weak, moderate, and strong 
were further collapsed into positive expression vs. negative expression categories. 
Joint expression of tumor and stromal bFGF was as follows: 82 cases (39%) showed 
negative tumor bFGF and negative stromal bFGF; 13 (6%) showed positive tumor bFGF and 
negative stromal bFGF; 94 (45%) showed negative tumor bFGF and positive stromal bFGF; and 
22 (10%) showed positive expression of both tumor and stromal bFGF expression (data not 
shown in tabular format).  
The association between pairs of biomarkers was assessed using logistic regression (Table 
20). Only tumor HGF and tumor c-Met were significantly associated (OR: 9.83, 95% CI 2.28, 
42.28). Tables 21-22 show the relationship between tumor HGF, tumor c-Met, tumor bFGF, 
stromal bFGF expression and categorical and continuous factors. Positive tumor HGF expression 
was not significantly associated with race, BMI, histology subtype, stage, lymph node 
involvement, or age. A borderline significant association between tumor HGF expression and 
tumor size was observed (p=0.07); positive tumor HGF expression was more common among 
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cases with unknown tumor size (20%) compared to cases with large tumors (14%) or small 
tumors (2%). Tumor c-Met expression was not significantly associated with any 
clinicopathologic variable.  
 Tumor bFGF was significantly associated with histology subtype, stage, lymph node 
involvement, and age. Compared to low-grade Type I cases (1%), positive tumor bFGF 
expression was significantly more common in PS (16%), high-grade Type I (32%), and CC cases 
(32%). Advanced stage cases had a significantly higher proportion of positive tumor bFGF 
expression than early stage cases (18% vs. 5%). Additionally, tumor bFGF expression was 
higher in cases with positive lymph node involvement (33%) compared to no nodal involvement 
(8%) or no nodal examination (2%). Cases with positive tumor bFGF expression had a mean age 
of 69 compared to 61 in cases with negative tumor bFGF expression (Table 22). Stromal bFGF 
was borderline significantly associated with histology subtype (p=0.06). Stromal bFGF was most 
common among CC cases (70%) compared to high-grade Type I (61%), low-grade Type I 
(59%), and PS cases (44%).  
7.4.3 HGF/c-Met/bFGF expression and OS 
Kaplan-Meier curves for the association between tumor HGF, tumor c-Met, tumor bFGF, 
stromal bFGF and OS are shown in Figure 29. Positive tumor bFGF expression was significantly 
associated with worse OS compared to negative expression (p=0.009). Tumor HGF, tumor c-
Met, and stromal bFGF were not associated with OS in univariate analysis. The adjusted 
association between tumor HGF, tumor c-Met, tumor bFGF, stromal bFGF expression and OS 
were examined using Cox proportional hazards models (Table 23). The independent effect of 
each biomarker in the absence (Model 1) and presence (Model 2) of the other biomarkers is 
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reported. The main effects of the biomarkers were not significantly associated with OS in either 
model independent of histology subtype, stage, and age. 
 Pairwise interactions between the biomarkers were explored and a significant interaction 
between tumor HGF and stromal bFGF was observed (p=0.02); hazard ratios associated with this 
model are shown in Table 24. In this table all comparisons are being made to the reference 
category of tumor HGF negative, stromal bFGF negative cases. Using linear combinations to 
compare categories of expression, we observed that tumor HGF positive, stromal bFGF positive 
cases had significantly reduced risk of death compared to tumor HGF positive, stromal bFGF 
negative cases (HR: 0.14, 95% CI 0.03, 0.60, data not shown). A Kaplan-Meier graph showing 
the joint expression of these two biomarkers confirmed this relationship; tumor HGF positive, 
stromal bFGF negative cases (deaths=7, at risk=13) had a median OS time of approximately 
1,000 days (~3 years) compared to 4,000 days (~11 years) for tumor HGF negative, stromal 
bFGF positive cases (deaths=40, at risk=98). Median survival was not estimable for cases with 
negative expression of both markers or for those with positive expression of both markers 
(Figure 30). 
7.4.4 HGF/c-Met/bFGF expression and RFS 
The sampling weights for RFS were recalculated to include only disease-free cases (Table 25). 
RFS Kaplan-Meier curves for tumor HGF, tumor c-Met, tumor bFGF, and stromal bFGF are 
shown in Figure 31. Positive tumor bFGF expression was significantly associated with worse 
RFS (p<0.001), however tumor HGF, tumor c-Met, and stromal bFGF expression were not 
significantly associated with RFS.  
 130 
Two main effects models are shown in Table 26; the role of each biomarker in the absence 
(Model 1) and presence (Model 2) of the other biomarkers is shown. Tumor bFGF expression 
had a borderline significant association with RFS in both models (Model 1: p=0.08 and Model 2: 
p=0.10). Pairwise interactions between the biomarkers were investigated and a significant 
interaction between tumor HGF and tumor bFGF expression was observed (p=0.007, Table 27). 
Tumor HGF positive, tumor bFGF positive patients had a ten times higher risk of recurrence 
compared to patients with negative expression of both markers (HR: 9.88, 95% CI 2.63, 37.16). 
A Kaplan-Meier graph of these two biomarkers confirmed this relationship; tumor HGF positive, 
tumor bFGF positive patients had the shortest median RFS time (Figure 32). Additionally, tumor 
HGF positive, tumor bFGF negative patients had an improved RFS compared to the reference 
group (HR: 0.07, 95% CI 0.00, 0.81). 
7.5 DISCUSSION 
We examined immunohistochemical expression of HGF, c-Met, and bFGF in a large sample of 
EC cases and correlated expression with clinicopathologic factors and patient outcomes. OS was 
significantly associated with stromal bFGF expression in the presence of tumor HGF expression. 
Tumor HGF positive, stromal bFGF positive patients had significantly better OS compared to 
tumor HGF positive, stromal bFGF negative patients. Additionally, a significant association 
between tumor bFGF and RFS was observed, and tumor HGF expression modified this 
association. Compared to tumor HGF negative, tumor bFGF negative patients,  patients who 
were HGF positive, tumor bFGF positive had a ten times higher risk of recurrence. Additionally, 
patients who were tumor HGF positive and tumor bFGF negative had a significantly reduced risk 
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of recurrence compared to tumor HGF negative, tumor bFGF negative patients. To our 
knowledge, this is the first study to demonstrate the prognostic significance of this angiogenic 
pathway in EC patients. 
Interactions between tumor cells and tumor-associated stromal cells are hypothesized to play 
a role in aggressive cancer phenotypes. The host stromal response is initially activated to 
eliminate tumor cells; however tumor cells co-opt the functions of recruited stromal cells to 
enhance the growth and invasion of the tumor, resulting in a tumor-supportive stroma [163, 167]. 
Furthermore, as the metabolic demand for nutrients increases, tumor cells activate angiogenesis 
through secretion of various cytokines. Therefore, understanding the role of tumor and stromal-
derived angiogenic pathways is important for targeted therapy strategies [195-197].  
The underlying mechanism describing the protective role of stromal-derived bFGF is 
unknown. Based on the hypotheses regarding tumor-stromal interactions, one might assume that 
the presence of angiogenic ligands in the stroma would stimulate tumor cell proliferation and 
invasion. This study, along with others, has established that angiogenic proteins expressed in the 
stroma have a divergent prognostic role compared to tumoral expression of these proteins. In two 
independent non-small cell lung cancer (NSCLC) cohorts, stromal bFGF expression was 
inversely associated with lymph node metastasis, advanced stage, and disease-specific mortality, 
indicating a protective role of this cytokine [198, 199]. Similarly, Donnem et al. [200] showed 
that expression of several vascular endothelial growth factor (VEGF) ligands were related to 
disease-specific survival, however tumor expression was associated with worse prognosis while 
stromal expression of the same ligands was associated with better survival in NSCLC patients. 
Our findings also agree with the body of literature reporting an association between tumor bFGF 
expression, aggressive clinicopathologic characteristics, and poor prognosis [201-205]. In this 
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study, tumor bFGF was significantly associated with aggressive histology subtypes, advanced 
stage, and positive lymph node involvement, in addition to worse RFS. We propose that a 
delicate balance between tumor-inhibiting and tumor-promoting effects of bFGF exists; while 
the host stroma controls expression of bFGF, anti-cancer effects are dominant, however when the 
tumor becomes independent of stromal paracrine factors through the establishment of autocrine 
bFGF stimulation,  poor outcomes are more likely to occur.  
We explored this particular pathway as the in vitro literature indicated that HGF, c-Met, and 
bFGF are overexpressed in human EC and EC cell lines compared to normal endometrial tissues. 
Prognostic EC studies have observed that HGF, c-Met, and bFGF are significantly associated 
with poor survival in univariate analyses, yet the independent prognostic role of these biomarkers 
and their interactions were undetermined by these studies. Wagatsuma et al. [120] reported 
strong IHC expression of c-Met and HGF in Type I EC cases. In models adjusted for stage, 
differentiation, myometrial invasion, and microvessel count, an independent prognostic role of 
these biomarkers was not observed, which was similar to our study. By examining interactions 
between biomarkers, we were able to detect a significant relationship between HGF and bFGF 
co-expression and survival. This finding is further validated by an EC cell line study which 
showed that tumor-derived bFGF expression significantly increased the transcription of HGF in 
EC cells which resulted in an invasive phenotype [111]. 
We also observed a statistically significant association between tumor HGF and tumor c-
Met expression. The biological effects exerted by HGF are mediated by the c-Met receptor 
which is frequently overexpressed in many human cancers [192]. The most common mechanism 
of c-Met overexpression is through HGF-dependent autocrine/paracrine mechanisms. Upon HGF 
binding, c-Met activates a number of cellular responses, including motility or scattering of 
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epithelial cells, proliferation, and invasion [192]. Despite the importance of HGF in c-Met 
activation, most prognostic studies focus solely on the aberrant expression of c-Met. In fact, 
development of HGF antagonists lags behind the surfeit of c-Met inhibitors currently in use in 
clinical trials [206]. Evaluation of the co-expression of HGF and c-Met may lead to a better 
understanding of the overall impact this signaling pathway has in cancer prognosis. In this study, 
c-Met expression did not have a significant and independent effect on survival which may 
indicate that the presence of c-Met is a necessary but not sufficient factor in EC survival 
outcomes.  
The prevalence of positive biomarker expression in this study differs from previous EC 
studies. We observed positive HGF and c-Met expression in 15% and 22% of cases compared to 
90% and 63% of the tumors in the Wagatsuma series and 100% and 87% of PS EC cases in the 
Bishop series [120, 121]. The low positive prevalence of biomarkers in our study may reflect 
differences in commercial antibodies and IHC procedures. Regardless of the prevalence, we were 
able to identify associations between biomarker expression, clinicopathologic factors, and 
survival. 
 The major limitation of this study was the sample size. Despite including 211 EC patients, 
the number of events and number of patients at risk in each stratum for the multivariable survival 
models was low. As a result, our observed significant findings may reflect false positive results. 
Additionally, we did not have a sufficient number of cases to explore biomarker interactions 
within histology subtypes. Different associations between biomarker expression and survival 
outcomes may be apparent by histology subtype which we could not assess. The strengths of this 
study include high quality pathology data, discrimination between tumor and stromal expression 
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of bFGF, and an evaluation of the prognostic role of this biomarker pathway using multivariable 
methods. 
 In addition to validating the results of this study, future examinations of bFGF should 
examine the mechanisms that may explain the protective role observed with stromal expression. 
Functional studies that can provide a biological rationale for the associations seen here would be 
useful in recommending molecularly-targeted therapies. Recent evidence supports a role for 
therapeutic targeting of the tumor microenvironment. Compared to neoplastic cells which are 
characterized by genetic mutations, cells of the microenvironment are genetically stable which 
may provide a more attractive therapeutic target. In summary, this study revealed a significant 
interaction between HGF and bFGF expression in EC survival outcomes. The cellular 
localization of bFGF expression modified survival outcomes, which implies that angiogenic 
pathways may be differentially important in EC prognosis based on localization of expression.  
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7.6 TABLES 
Table 18 Probability of sampling given that tumor blocks were available 
 
 
 
 
 
 
 
 
 
 
 
 Type I Type II  
Stratum Stage I Stage II Stage III Stage IV Stage I Stage II Stage III Stage IV Total 
n with tumor blocks available 691 65 85 21 62 16 34 29 1,003 
n sampled 33 29 37 15 40 9 26 22 211 
pr (sampled| tumor blocks  available)= 
(sampled/ tumor blocks ) 
0.0478 0.4462 0.4353 0.7143 0.6452 0.5625 0.7647 0.7586 
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Table 19 Demographic and clinical characteristics of the EC sample by histology type 
Characteristics 
N=211 
Low-grade Type I 
n=80 
High-grade Type I 
n=34 
Clear cell 
n=31 
Papillary serous 
n=66 
p* 
 n§ (%)† %‡ n§ (%)† %‡ n§ (%)† %‡ n§ (%)† %‡  
Mean age (sd) 61 (12) 61 (1.61) 62 (12) 61 (3.56) 67 (11) 67 (1.89) 66 (11) 66 (1.34) 0.02 
Race          
White 75 (94) 96 32 (94) 96 28 (90) 90 54 (82) 81 0.05 
Non-White 5 (6) 4 2 (6) 4 3 (10) 10 12 (18) 19  
Body Mass Index           
Normal (BMI< 25 kg/m2) 22 (28) 27 5 (15) 7 9 (30) 29 19 (29) 29 0.19 
Overweight (BMI 25-30 kg/m2) 21 (26) 19 10 (29) 47 11 (35) 35 18 (27) 27  
Obese (BMI> 30 kg/m2) 37 (46) 54 19 (56) 46 11 (35) 36 29 (44) 44  
Additional cancer primaries          
No 68 (85) 79 27 (79) 73 25 (81) 81 50 (76) 76 0.76 
Yes 10 (13) 18 7 (21) 27 6 (19) 19 14 (21) 21  
Unknown 2 (2) 3 0 (0) 0 0 (0) 0 2 (3) 3  
FIGO stage           
Early (I & II) 56 (70) 94 6 (18) 59 21 (68) 72 28 (42) 49 <0.001 
Late (III & IV) 24 (30) 6 28 (82) 41 10 (32) 28 38 (58) 51  
Lymph node involvement          
No nodes examined 20 (25) 41 8 (24) 26 11 (35) 35 12 (18) 19 <0.001 
Negative 48 (58) 55 12 (35) 52 17 (55) 57 34 (51) 53  
Positive 8 (10) 2 14 (41) 22 3 (10) 8 15 (23) 20  
Unknown 6 (7) 2 0 (0) 0 0 (0) 0 3 (8) 8  
Tumor size          
< 2 cm 11 (14) 19 4 (12) 38 4 (13) 13 9 (14) 15 0.09 
> 2 cm 34 (42) 25 20 (59) 46 14 (45) 46 31 (47) 47  
Unknown 35 (44) 57 10 (29) 15 13 (42) 40 26 (39) 38  
Post-operative treatment          
Surgery only 30 (37) 61 4 (12) 39 6 (19) 19 11 (17) 17 <0.001 
Surgery + CT  8 (10) 2 12 (35) 16 9 (29) 27 28 (42) 40  
Surgery + RT  38 (48) 36 10 (29) 34 15 (49) 51 13 (20) 21  
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Surgery + CT + RT 4 (5) 1 8 (24) 11 1 3 14 (21) 21  
§ sample count 
† proportion or mean in the study sample 
‡ proportion or mean in the target population 
* Adjusted Wald p-value 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 19 continued 
 138 
Table 20 Positive biomarker expression in the study sample and target population and odds of association 
between biomarkers 
 Positive expression OR (95% CI) 
 Study Sample 
(N=211) 
Target population 
(N=1,486) 
Tumor c-Met Tumor bFGF Stromal bFGF 
Tumor HGF 15% 15% 9.83 (2.28, 42.28)* 0.65 (0.16, 2.60) 2.35 (0.53, 10.49) 
Tumor c-Met 27% 22% --- 1.00 (0.29, 3.52) 3.38 (0.97, 11.80) 
Tumor bFGF 17% 7% --- --- 2.09 (0.63, 6.98) 
Stromal bFGF 55% 59% --- --- --- 
Unadjusted logistic regression model 
* Adjusted Wald p=0.002 
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Table 21 Association of biomarker expression with clinicopathologic characteristics 
Characteristic Sample 
counts 
% Positive expression 
Tumor HGF Tumor c-Met Tumor bFGF Stromal bFGF 
Race       
White 189 15 23 7 61 
Non-White 22 4 13 8 32 
p-value*   0.18 0.45 0.88 0.29 
Body Mass Index       
Normal 55 24 33 5 49 
Overweight 60 14 28 8 52 
Obese 96 10 14 8 67 
p-value*   0.57 0.29 0.63 0.43 
Histology type       
Low-grade Type I 80 16 19 1 59 
High-grade Type I 34 2 35 32 61 
Clear cell 31 18 26 32 70 
Papillary serous 66 13 37 16 44 
p-value*   0.12 0.20 <0.001 0.06 
FIGO stage       
Early stage (I & II) 111 15 21 5 59 
Late stage (III & IV) 100 14 28 18 59 
p-value*   0.97 0.39 0.008 0.99 
Lymph node involvement       
None 109 20 22 8 59 
Positive 40 6 28 33 70 
No nodal exam 51 7 21 2 58 
Unknown 11 35 24 0 32 
p-value*   0.19 0.92 0.002 0.25 
Tumor size        
< 2 cm 28 2 26 2 51 
> 2 cm 99 14 19 17 64 
Unknown 84 20 22 3 59 
p-value*  0.07 0.90 0.14 0.77 
* Adjusted Wald p-value  
 
 
Table 22 Association between biomarker expression and age 
Mean age (standard error*) Tumor HGF Tumor c-Met Tumor bFGF Stromal bFGF 
Negative expression 60 (1.42) 61 (1.50) 61 (1.39) 61 (1.72) 
Positive expression 66 (3.50) 61 (2.97) 69 (2.38) 61 (1.93) 
p-value 0.14 0.97 0.003 0.92 
* Linearized standard error (Taylor series) 
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Table 23 Cox proportional hazards models for OS: main effects of HGF, c-Met, tumor bFGF, and stromal 
bFGF 
N=211  Model 1 Model 2 
 deaths/N HR (95% CI) p† HR (95% CI) p† 
HGF expression      
Negative 76/180 1.00 (reference) 0.97 1.00 (reference) 0.94 
Positive 11/31 0.98 (0.37, 2.62)  1.04 (0.39, 2.76)  
c-Met expression      
Negative 61/155 1.00 (reference) 0.53 1.00 (reference) 0.48 
Positive 26/56 0.75 (0.30, 1.86)  0.72 (0.29, 1.79)  
tumor bFGF expression      
Negative 67/176 1.00 (reference) 0.25 1.00 (reference) 0.20 
Positive 20/35 1.53 (0.73, 3.21)  1.59 (0.78, 3.24)  
stromal bFGF expression      
Negative 43/95 1.00 (reference) 0.44 1.00 (reference) 0.39 
Positive 44/116 0.75 (0.35, 1.58)  0.73 (0.35, 1.51)  
Model 1: Adjusted for stage (early stage, late stage), histology subtype (low-grade type I, high-grade type I, 
clear cell, papillary serous), and age at diagnosis (continuous, range 34-93 years) 
Model 2: Adjusted for other biomarkers, in addition to Model 1 factors 
Stratified by year of diagnosis 
† Adjusted Wald p-value 
 
 
Table 24 Cox proportional hazards model* for OS: interaction between HGF and stromal bFGF 
N=211 deaths/N HR (95% CI) p† 
    
HGF and stromal bFGF expression   0.02‡ 
Negative HGF and negative stromal bFGF 36/82 1.00 (Reference)  
Positive HGF and negative stromal bFGF 7/13 2.09 (0.83, 5.25) 0.12 
Negative HGF and positive stromal bFGF 40/98 1.00 (0.44, 2.28) 1.00 
Positive HGF and positive stromal bFGF 4/18 0.29 (0.06, 1.33) 0.11 
c-Met    
Negative 61/155 1.00 (Reference) 0.48 
Positive 26/56 0.73 (0.31, 1.72)  
Tumor bFGF    
Negative 67/176 1.00 (Reference) 0.27 
Positive 20/35 1.52 (0.72, 3.25)  
* Adjusted for stage (early stage, late stage), histology subtype (low-grade type I, high-grade type I, 
clear cell, papillary serous), and age at diagnosis (continuous, range 34-93 years) 
Stratified by year of diagnosis (single year, 1996 through 2008) 
† Adjusted Wald p-value  
‡ p-value for interaction 
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Table 25 Probability of sampling given that tumor blocks were available in disease-free cases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Type I Type II  
Stratum Stage I Stage II Stage III Stage IV Stage I Stage II Stage III Stage IV Total 
n with tissue available 691 65 85 21 62 16 34 29 1,003 
n sampled 31 25 31 12 33 7 22 13 174 
pr (sampled|tissue available)= 
(sampled/tissue available) 0.0448 0.3846 0.3647 0.5714 0.5322 0.4375 0.6470 0.4482  
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Table 26 Cox proportional hazards models for RFS: main effects of HGF, c-Met, tumor bFGF, and stromal 
bFGF 
N=174  Model 1 Model 2 
 recurrences/N HR (95% CI) p† HR (95% CI) p† 
HGF expression      
Negative 38/150 1.00 (reference) 0.20 1.00 (reference) 0.21 
Positive 4/24 0.40 (0.10, 1.64)  0.44 (0.12, 1.59)  
c-Met expression      
Negative 28/130 1.00 (reference) 0.78 1.00 (reference) 0.68 
Positive 14/44 0.90 (0.43, 1.89)  0.84 (0.36, 1.94)  
tumor bFGF expression      
Negative 30/147 1.00 (reference) 0.08 1.00 (reference) 0.10 
Positive 12/27 2.55 (0.90, 7.24)  2.54 (0.83, 7.82)  
stromal bFGF expression      
Negative 19/75 1.00 (reference) 0.38 1.00 (reference) 0.44 
Positive 23/99 0.68 (0.29, 1.62)  0.70 (0.29, 1.73)  
Model 1: Adjusted for stage (early stage, late stage), histology subtype (low-grade type I, high-grade type I, clear 
cell, papillary serous), and age at diagnosis (continuous, range 34-93 years) 
Model 2: Adjusted for other biomarkers, in addition to Model 1 factors 
Stratified by year of diagnosis 
† Adjusted Wald p-value 
 
 
Table 27 Cox proportional hazards model* for RFS: significant interaction between HGF and tumor bFGF 
N=174 recurrences/N HR (95% CI) p† 
    
HGF and tumor bFGF expression   0.007‡ 
Negative HGF and negative tumor bFGF 29/128 1.00 (Reference)  
Positive HGF and negative tumor bFGF 1/19 0.07 (0.00, 0.81) 0.03 
Negative HGF and positive tumor bFGF 9/22 1.56 (0.44, 5.53) 0.49 
Positive HGF and positive tumor bFGF 3/5 9.88 (2.63, 37.16) 0.001 
c-Met    
Negative 28/130 1.00 (Reference) 0.99 
Positive 14/44 1.01 (0.43, 2.33)  
Stromal bFGF    
Negative 19/75 1.00 (Reference) 0.71 
Positive 23/99 0.85 (0.35, 2.03)  
* Adjusted for stage (early stage, late stage), histology subtype (low-grade type I, high-grade type I, 
clear cell, papillary serous), and age at diagnosis (continuous, range 34-93 years) 
Stratified by year of diagnosis (single year, 1996 through 2008) 
† Adjusted Wald p-value  
‡ p-value for interaction 
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7.7  FIGURES 
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Figure 15 Sampling strategy for HGF/c-Met/bFGF expression study 
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Figure 16 Representative IHC stain and corresponding hematoxylin and eosin stain, 40X magnification: 
Negative HGF expression 
 
 
Figure 17 Representative IHC stain and corresponding hematoxylin and eosin stain, 40X magnification: 
Weak HGF expression 
 
 
Figure 18 Representative IHC stain and corresponding hematoxylin and eosin stain, 40X magnification: 
Moderate HGF expression 
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Figure 19 Representative IHC stain and corresponding hematoxylin and eosin stain, 40X magnification: 
Negative c-Met expression 
 
 
Figure 20 Representative IHC stain and corresponding hematoxylin and eosin stain, 40X 
magnification: Weak c-Met expression 
 
 
Figure 21 Representative IHC stain and corresponding hematoxylin and eosin stain, 40X magnification: 
Moderate c-Met expression 
 146 
 
Figure 22 Representative IHC stain and corresponding hematoxylin and eosin stain, 40X magnification: 
Strong c-Met expression 
 
 
 
Figure 23 Representative IHC stain and corresponding hematoxylin and eosin stain, 40X magnification: 
Negative tumor or stromal bFGF expression 
 
 
 
Figure 24 Representative IHC stain and corresponding hematoxylin and eosin stain, 40X magnification: 
Moderate tumor bFGF expression 
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Figure 25 Representative IHC stain and corresponding hematoxylin and eosin stain, 40X 
magnification: Strong tumor bFGF expression 
 
 
 
Figure 26 Representative IHC stain and corresponding hematoxylin and eosin stain, 40X magnification: 
Weak stromal bFGF expression 
 
 
 
Figure 27 Representative IHC stain and corresponding hematoxylin and eosin stain, 40X magnification: 
Moderate stromal bFGF expression 
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Figure 28 Representative IHC stain and corresponding hematoxylin and eosin stain, 40X magnification: 
Strong stromal bFGF expression 
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Figure 29 Kaplan-Meier overall survival curves for HGF, c-Met, tumor bFGF, and stromal bFGF 
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Figure 30 Kaplan-Meier overall survival curves for HGF and stromal bFGF 
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Figure 31  Kaplan-Meier recurrence-free survival curves for HGF, c-Met, tumor bFGF, and stromal bFGF 
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Figure 32 Kaplan-Meier recurrence-free survival curves for HGF and tumor bFGF 
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8.0  CONCLUSIONS AND PUBLIC HEALTH SIGNIFICANCE 
Endometrial cancer (EC) is the most common gynecologic malignancy in the United States. In 
2010, 43,470 cases were newly diagnosed and 7,950 deaths occurred. Several histology subtypes 
of EC are clinically important; low-grade Type I tumors represent approximately 72% of ECs 
and have an indolent behavior, accounting for only 26% of EC deaths each year [10]. 
Conversely, high-grade Type I, clear cell (CC), and papillary serous (PS) tumors account for less 
than 30% of EC diagnoses each year, yet collectively these subtypes are responsible for 
approximately three-quarters of deaths that occur in EC patients each year [10]. The 
disproportionate incidence and mortality associated with these subtypes emphasizes the need for 
better cancer prevention and treatment options.  
Invasion, metastasis, and sustained angiogenesis are hallmarks of aggressive cancers [190]. 
The majority of cancer-related deaths are attributable to metastases of the primary tumor; the 
ability of cancer cells to complete the metastatic process (i.e. breaking away from the primary 
tumor, invading the local stromal environment, penetrating lymph or blood vessels, surviving in 
the circulation, locating new tissues, and adapting to the new microenvironment) is dependent on 
characteristics of the primary tumor and the tumor microenvironment [207]. In recent years, the 
tumor microenvironment has come to forefront of cancer investigations which seek to examine 
the mechanisms by which tumor cells are able to achieve each step of the metastatic cascade 
[208]. 
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The tumor microenvironment refers to the surrounding non-malignant cells that interact with 
the primary tumor mass. During carcinogenesis, stromal cells react to the presence of genetically 
transformed cells by supplying paracrine factors that typically function in wound repair.  
However, unlike wounds, cancer cells are not self-limiting and respond inappropriately to 
microenvironmental signals; in fact, cancer cells exploit these signaling pathways to enhance 
growth, survival, and dissemination of the tumor. Consequently, the tumor microenvironment is 
an attractive target for therapeutic interventions in cancer control [195]. 
The goals of this dissertation project were two-fold: the first aim of this dissertation sought 
to provide an evaluation of risk factors and survival outcomes in a sample of EC patients. 
Although other studies have described these facets in EC patients, we wanted to confirm these 
findings and characterize our target population for the subsequent molecular aims of this 
dissertation.  The second goal of this study was to evaluate the role of two stromal-related 
biomarker pathways, CXCL12/CXCR4 and HGF/c-Met/bFGF, as potential prognostic 
biomarkers in EC. These pathways have been explored in other common cancers, such as breast, 
lung, and colon cancers. Furthermore, the in vitro and in vivo EC literature supported a role for 
examining the prognostic significance of these biomarkers. We sought to understand the 
association between biomarkers, the relationship between biomarker expression and 
clinicopathologic factors (race, BMI, stage, and histology subtype), and the independent 
association between biomarker expression and survival outcomes in EC patients. The ultimate 
goal of this dissertation was to add to the body of knowledge regarding the tumor 
microenvironment and EC progression. 
The first aim of this study confirms that estrogen-related characteristics are important 
characteristics of Type I EC patients. Furthermore, we demonstrated similar survival outcomes 
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for high-grade Type I and Type II EC cases, despite differing etiologies for these two subtypes. 
Future directions for research related to this aim include an examination of novel EC risk factors, 
especially for CC and PS endometrial tumors. Effective cancer prevention strategies rely on an 
understanding of the putative risk factors involved in carcinogenesis, which is lacking for CC 
and PS endometrial tumors. Specifically, future studies should explore risk factors unrelated to 
hormonal carcinogenesis.  Chronic inflammation is known to play a role in the carcinogenesis of 
many human cancers; factors such as infections, infertility, pelvic inflammatory disease, and 
other benign gynecologic conditions may contribute to an inflammatory local environment and 
should therefore be explored. Due to the rarity of these tumors, datasets with detailed 
information regarding exposures and large numbers of cases will be necessary. Moreover, a case-
control study design with a non-diseased control population will give a better estimation of risk 
factors associated with development of Type II tumors. Our study was limited as we compared 
the probability of developing one subtype of EC as opposed to another EC subtype.   
The molecular analyses in the second and third aims of this project revealed interesting 
associations between biomarker expression, clinical characteristics, and survival outcomes. 
CXCL12 was an independent prognostic marker for better overall survival (OS) and recurrence-
free survival (RFS) in high-grade Type I EC cases, however CXCL12 expression was not 
associated with prognostic factors of EC, such as stage, lymph node involvement, or histology 
subtype. We also showed that the CXCL12 receptor, CXCR4, was expressed in all EC tumors. 
Future studies regarding the role of this pathway in EC should compare a series of tissues 
including normal endometrium, hyperplasia, and precursor lesions to discern when CXCR4 
overexpression occurs in the malignant process. Additionally, the relationship between estrogen 
receptor and CXCL12 should be explored to elucidate the role of estrogen in this pathway. 
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CXCL12 is an estrogen-regulated gene in estrogen receptor-positive ovarian and breast cancer 
cells, indicating a pathway by which estrogen can induce CXCL12 production. Additional 
studies should examine larger numbers of cases with high-grade Type I, CC, and PS subtypes to 
perform well powered subgroup analyses. 
Interactions between HGF and bFGF expression had significant implications for survival 
outcomes in EC patients (Aim 3). HGF was significantly associated with OS and RFS, however 
the cellular localization of bFGF expression was an important effect modifier. Stromal 
expression of bFGF was associated with better OS, while tumoral expression of bFGF was 
associated with worse RFS. Additional studies examining the role of HGF, c-Met, and bFGF in 
EC will need to validate of the results presented in this dissertation.  Specifically, functional 
studies are needed to ascertain the mechanisms related to a positive outcome for stromal bFGF. 
The eventual goal is to provide high-quality epidemiologic data for the purpose of identifying the 
subset of biomarkers that are best targeted for patient survival. 
The public health implications of the current dissertation project include an enhanced 
understanding of EC biology and molecular epidemiology, which ultimately can inform 
prevention efforts, early detection, and treatment strategies. Discovery of additional tumor 
markers could positively impact public health by improving survival outcomes for patients with 
aggressive EC. 
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APPENDIX A: DETAILED INFORMATION REGARDING THE SAMPLING FRAME  
A.1 SCHEMATICS FOR SAMPLING FRAME 
The molecular aims of this dissertation project required sampling from a larger source 
population. One thousand nine-hundred and sixty-four cases were diagnosed at Magee-Womens 
hospital between 1996 and 2008. The target population of interest in this dissertation was Type I 
and Type II EC cases (N=1,772). In order to generate a relatively homogenous population for 
study, we applied several exclusion criteria, including overlapping age distributions between 
Type I and Type II cases, invasive cancers, surgery at Magee-Womens hospital, and known 
stage, resulting in a sampling frame of 1,486 cases (Figure 33). Characteristics of this frame are 
shown in Table 28. The distributions shown here are relatively similar to the distributions 
reported in the first aim of this dissertation. 
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Figure 33 Construction of sampling frame, N=1,486 
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Table 28 Demographic and clinical characteristics of the sampling frame 
Characteristics N=1,486 
Mean age (sd) 61 (12) 
Race N (%) 
  White 1421 (96) 
  Non-White 65 (4) 
Body Mass Index   
Normal (BMI< 25 kg/m2) 259 (17) 
Overweight (BMI 25-30 kg/m2) 324 (22) 
Obese (BMI> 30 kg/m2) 826 (55) 
  Unknown 77 (5) 
Additional cancer primaries  
  No 1247 (83) 
  Yes 222 (15) 
  Unknown 17 (1) 
Histology type  
  Low-grade Type I 1133 (76) 
  High-grade Type I 206 (14) 
  Type II 147 (10) 
FIGO stage   
  Early (I & II) 1270 (85) 
  Late (III & IV) 216 (15) 
Lymph node involvement  
  No nodes examined 462 (31) 
  Negative 857 (58) 
  Positive 109 (7) 
  Unknown 58 (4) 
Tumor size  
  < 2 cm 179 (12) 
  > 2 cm 458 (31) 
  Unknown 849 (57) 
Therapy  
  Surgery only 706 (47) 
  CT only 107 (7) 
  RT only 599 (40) 
  CT and RT 74 (5) 
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A.2 DIFFERENCES BETWEEN PATIENTS WITH AND WITHOUT TISSUE 
AVAILABLE FOR INCLUSION IN THE MOLECULAR STUDIES 
Among the cases included in the sampling frame (N=1,486), 67% of cases (n=1,003) were 
indicated as having tissue blocks available for use in the molecular studies (Figure 34). The 
numbers in red indicate the number of cases included from each stratum. Table 29 shows the 
characteristics of patients with presumed tumor block unavailability (N=483) and patients with 
presumed tumor block availability (N=1,003). Patients with potential available tissue blocks 
were slightly older (61 vs. 60 years), more likely to have stage III and IV tumors (17% vs. 10%), 
more likely to have Type II tumors (14% vs. 1%), and be diagnosed at a hospital other than 
Magee-Womens Hospital (50% vs. 42%) compared to patients without tumor blocks available. 
The unavailability of tissue might reflect depletion of specimens. As these cases patients differ 
with respect to several major characteristics, selection bias is a potential threat to the internal and 
external validity of the study.  
 Table 30 shows the selection of the study sample (N=216) from the larger sampling frame 
(N=1,486) by histology subtype and stage categories, the variables used to construct the discrete 
sampling strata. A random number procedure in SAS was used to select a random sample of 252 
cases. Although our goal was to include 200 cases in the molecular studies, we provided the 
tissue bank with 52 additional case identifiers to substitute for potential “blanks.” Blanks are 
cases thought to have available tumor blocks, however upon request of the tissue, no specimens 
were located. Of the 252 cases in our scientific random sample, 204 were located by the tissue 
bank. An additional 12 cases not included in the original random sample were provided by the 
Pathology department. Although these cases were not part of the sampling design, we assumed 
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that inclusion of these additional cases would not severely bias the internal validity of this study, 
resulting in a sample of 216 cases. 
 Once slide sectioning of the 216 cases was completed, additional cases were excluded from 
the molecular analyses of aims 2 and 3. In Aims 2 and 3, respectively, 17 and 5 cases did not 
have evaluable tumor present on the slides, resulting in sample sizes of 199 and 211. 
The subject-specific predicted probability of having tissue available for this study was 
estimated after running the logistic regression model in Table 31 in order to adjust for 
characteristics associated with selection bias. Figure 35 shows the distribution of the predicted 
probabilities according to the eight sampling strata. The narrow intervals of the predicted 
probabilities show that within the strata, cases have a similar probability of having tissue 
available for the study. Unmeasured factors do not appear to be contributing to the propensity 
that tumor blocks were available. 
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Figure 34 Reduced sampling frame based on availability of tissue, N=1,003 
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Table 29 Characteristics of cases in the sampling frame with tissue available compared to those without 
available tissue, N=1,486 
  
Presumed unavailable 
(N=483) 
Presumed available 
(N=1003) 
p 
Age, median (range) 60 (34-91) 61 (34-93) 0.05* 
BMI       
Underweight 26 (5) 67 (7) 0.31† 
Normal weight 74 (15) 172 (17)   
Overweight 99 (21) 225 (22)   
Obese 284 (59) 539 (54)   
Stage       
I 394 (82) 753 (75) 0.002† 
II 42 (9) 81 (8)   
III 38 (8) 119 (12)   
IV 9 (2) 50 (5)   
Histology type       
Type I 477 (99) 862 (86) <0.001† 
Type II 6 (1) 141 (14)   
Type of surgery       
Local tumor destruction 0 (0) 1 (0.1) 0.04‡ 
Local tumor excision 0 (0) 2 (0.2)   
Subtotal hysterectomy 0 (0) 5 (0.5)   
Total hysterectomy w/o removal of ovaries 13 (3) 17 (2)   
Total hysterectomy with removal of ovaries 395 (82) 855 (85)   
Modified radical hysterectomy 56 (11) 94 (9)   
Hysterectomy, NOS 19 (4) 21 (2)   
Pelvic exenteration 0 (0) 1 (0.1)   
Surgery, NOS 0 (0) 7 (0.7)   
Race       
White 464 (96) 957 (95) 0.62† 
Non-white 19 (4) 45 (5)   
Class of case       
Diagnosed and treated at Magee-Womens 
Hospital 280 (58) 497 (50) 0.002† 
Diagnosed elsewhere and treated at Magee-
Womens Hospital 203 (42) 506 (50)   
* Wilcoxon test p-value 
† Wald test p-value 
‡ Fishers exact test p-value  
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Table 30 Selection of the study sample (N=216) from the larger sampling frame (N=1,486) by histology subtype and stage 
  Stratum   
  Type I Type II   
  Stage 1 Stage 2 Stage 3 Stage 4 Stage 1 Stage 2 Stage 3 Stage 4 ALL 
Eligible 1082 105 122 30 65 18 35 29 1,486 
Eligible, tumor blocks assumed to be available 691 65 85 21 62 16 34 29 1,003 
Scientific random sample 33 36 33 21 50 16 34 29 252 
Blocks received from scientific sample 31 30 28 16 41 10 26 22 204 
Blanks in sample frame, N 2 6 5 5 9 6 8 7 48 
Blanks in sample frame, P 0.06 0.20 0.18 0.31 0.22 0.60 0.31 0.32 0.24 
Blocks received not in random sample 2 0 10 0 0 0 0 0 12 
Total blocks received 33 30 38 16 41 10 26 22 216 
Aim 2:  not missing IHC score 30 28 36 16 36 9 23 21 199 
Aim 3:  not missing IHC score 33 29 37 15 40 9 26 22 211 
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Table 31 Multivariable logistic regression model to predict available tumor block (N=1,003) vs. no available 
tumor block (N=483) 
Variable OR (95% CI) 
Histology type   
Type I 1.00 
Type II 11.25 (3.50 36.17) 
Stage   
Stage I 1.00 
Stage II 0.88 (0.58, 1,33) 
Stage III 1.30 (0.86, 1.95) 
Stage IV 1.33 (0.60, 2.94) 
Type * Stage interactions  
Type II, Stage II 0.39 (0.06, 2.68) 
Type II, Stage III 1.28 (0.12, 13.32) 
Type II, Stage IV >999.99 (<0.001, >999.99) 
Place of diagnosis  
Diagnosed at other facility 1.00 
Diagnosed at Magee 0.71 (0.57, 0.89) 
Age at diagnosis 1.00 (1.00, 1.01) 
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Figure 35 Distribution of predicted probability of tissue availability by sampling stratum 
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APPENDIX B: ASSOCIATION BETWEEN BIOMARKER EXPRESSION AND YEAR 
OF DIAGNOSIS 
As this was a longitudinal study, we examined the association between biomarker expression and 
year of diagnosis. Figures 36 and 37 show the proportion of positive expression in each year 
included in the study for the two biomarker aims. We did not observe any statistically significant 
trends between year of diagnosis and CXCR4 (Adjusted Wald p=0.19), CXCL12 (Adjusted 
Wald p=0.88), HGF (Adjusted Wald p=0.41), c-Met (Adjusted Wald p=0.06), tumor bFGF 
expression (Adjusted Wald p=0.27), or stromal bFGF expression (Adjusted Wald p=0.80).  
 As mentioned in the methods section of Aim 2 and Aim 3, Cox regression models stratified 
by year of diagnosis were employed to control for this variable without estimating coefficients.  
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Figure 36 Expression of CXCL12 and CXCR4 by year of diagnosis 
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Figure 37 Expression of HGF, c-Met, tumor bFGF, and stromal bFGF expression and year of 
diagnosis 
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APPENDIX C: SUPPLEMENTARY DETAILS FOR ARTICLE 3 
C.1 DIAGNOSTICS FOR THE COX PROPORTIONAL HAZARDS MODEL 
The proportional hazards assumption was examined using the postestimation stphplot command 
in STATA. The resultant log-log survival graph plots an estimate of the log-log survival vs. ln(t) 
for each level of the covariate [209]. If the proportional hazards assumption holds, the lines for 
each level of a covariate should be roughly parallel. There is some evidence that the proportional 
hazards assumption for CXCL12 in the OS model does not hold, however the model tested by 
these curves does not account for the interaction between CXCL12 and histology subtype 
(Figure 38). Similarly, in the RFS model there is evidence that the curves for negative and 
positive CXCL12 expression overlap (Figure 39). 
A limitation of using survey procedures (i.e. svy) in the setting of Cox regression modeling 
is the inability to obtain the Schoenfeld residuals which prevents the use of the analytic 
Grambsch and Therneau test. This test is useful because it investigates whether that a plot of the 
scaled Schoenfeld residuals vs. time has a slope of zero and reports an objective p-value based 
on this test. 
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Figure 38 Tests of the proportional-hazards assumption for variables in Table 13 
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Figure 39 Tests of the proportional-hazards assumption for variables in Table 16 
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C.2 POWER CALCULATIONS 
The statistical power to detect an association between CXCL12 expression and the survival 
outcomes (OS and RFS) was calculated using the stpower command in STATA. In this sample, 
the probability of death was 0.43 (86/199) and the probability of recurrence was 0.26 (42/163). 
Using an alpha of 0.05 and the log hazard ratio from the main effects model, the power to detect 
an association in the OS model was 30% and in the RFS model the statistical power was 52%.   
C.3 PROGNOSTIC ROLE OF CXCL12/CXCR4 IN SUBGROUPS OF EC CASES 
Kaplan-Meier curves and log-rank tests comparing negative vs. positive CXCL12 expression in 
subgroups of cases is shown in Figures 40-41 (OS) and Figures 42-43 (RFS). Positive CXCL12 
expression was associated with better OS in high-grade Type I cases (p=0.01) and better RFS in 
late stage cases (p=0.04). Similarly, we compared moderate and strong CXCR4 expression in 
subgroups of EC cases (OS: Figures 44-45, RFS: Figures 46-47). No significant associations 
between CXCR4 and survival outcomes were noted in these subgroups. 
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Figure 40 Association between CXCL12 and OS by histology subtype 
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Figure 41 Association between CXCL12 and OS by stage 
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Figure 42 Association between CXCL12 and RFS by histology subtype 
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Figure 43 Association between CXCL12 and RFS by stage 
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Figure 44 Association between CXCR4 and OS by histology subtype 
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Figure 45 Association between CXCR4 and OS by stage 
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Figure 46 Association between CXCR4 and RFS by histology subtype 
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Figure 47 Association between CXCR4 and RFS by stage 
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C.4 ASSOCIATION BETWEEN CXCL12/CXCR4 EXPRESSION AND METASTASIS 
As the CXCR4/CXCL12 pathway is thought to influence patient survival through directional 
movement of cancer cells, the association between CXCL12 and CXCR4 expression at the 
primary tumor site and distant metastasis was examined. Stage IV EC cases were classified as 
distant metastatic cases while stage I-III cases were classified as non-distant metastatic cases. 
Neither CXCL12 (p=0.17) nor CXCR4 expression (p=0.97) was significantly associated with 
distant metastasis (Table 32). Furthermore, a logistic regression model with distant metastasis as 
the outcome revealed that neither CXCL12 nor CXCR4 significantly predicted the odds of 
metastasis adjusted for histology type and age (Table 33).  
 
 
Table 32 Association between distant metastasis, CXCL12, and CXCR4 expression 
N=199 No metastasis (N=162) Metastasis (N=37) p‡ 
 n (%)* %† n (%)* %†  
CXCR4      
Moderate  48 (30) 31 11 (30) 31 0.97 
Strong  114 (70) 69 26 (70) 69  
CXCL12      
Negative  46 (28) 32 17 (46) 47 0.17 
Positive  116 (72) 68 20 (54) 53  
* proportion in the study sample  
† weighted proportion  
‡ Adjusted Wald p-value 
 
 
 
 
 
 175 
Table 33 Multivariable logistic regression model to predict metastasis (N=37) vs. no metastasis (N=162) 
 
C.5 AT-RISK POPULATION FOR RECURRENCE 
Only cases known to be disease-free following the primary surgery were included in analyses of 
RFS. The following tables provide information on the type of first recurrence in the sample as a 
whole and by stage. In the total sample, 61% of patients were disease-free following primary 
surgery and did not have a recurrence over the follow-up period, while 22% of cases that entered 
a state of remission following surgery recurred over the follow-up (Table 34). The remaining 
17% of cases were either never disease-free or it was unknown if they entered a state of 
remission after the primary surgery and were therefore excluded from RFS analyses. 
Furthermore, two early stage cases reportedly had a local recurrence of an invasive tumor (Table 
35) despite having a total hysterectomy with removal of both ovaries; these two cases were 
excluded as it was deemed implausible that patients without an intact uterus would have a local 
recurrence to the site. Therefore, the final sample for RFS analyses was 163. 
Variable Adjusted OR (95% CI) Wald p-value 
CXCL12      
Negative  1.00 0.20 
Positive   0.52 (0.29, 0.91)  
CXCR4    
Moderate 1.00 0.32 
Strong 0.63 (0.25, 1.57)  
Histology type   
Low-grade Type I 1.00 <0.001 
High-grade Type I 20.73 (5.06, 884.92)  
Clear cell 39.19 (11.34, 135.51)  
Papillary serous 55.82 (20.59, 151.38)  
   
Age at diagnosis 0.96 (0.93, 1.00) 0.06 
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Table 34 Type of first recurrence in the CXCR4/CXCL12 study, N=199 
Recurrence type N % 
Patient became disease-free after treatment and has not had a 
recurrence 121 61 
Local recurrence of an invasive tumor 2 1 
Regional recurrence 3 2 
Recurrence of an invasive tumor in adjacent tissue or organ 14 7 
Recurrence of an invasive tumor in regional lymph nodes only 5 3 
Recurrence of an invasive tumor in adjacent tissue or organ and in 
regional lymph node at the same time 3 2 
Distant recurrence 1 1 
Distant recurrence of an invasive tumor in the lung only 3 2 
Distant recurrence of an invasive tumor in the liver only 2 1 
Distant recurrence of an invasive tumor in bone only 2 1 
Distant recurrence of an invasive tumor in the lymph node only 2 1 
Distant recurrence of an invasive tumor in a single distant site and 
local, trocar, and or regional recurrence 
1 1 
Distance recurrence of an invasive tumor in multiple sites 4 2 
Patient has never been disease-free 17 9 
Disease has recurred but the type of recurrence is unknown 2 1 
Unknown if disease recurred or if the patient was ever disease-free. 17 9 
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Table 35 Type of first recurrence stratified by stage 
Early stage, N=103 N % 
Patient became disease-free after treatment and has not had a 
recurrence 81 79 
Local recurrence of an invasive tumor 2 2 
Recurrence of an invasive tumor in adjacent tissue or organ 5 5 
Recurrence of an invasive tumor in regional lymph nodes only 1 1 
Distant recurrence of an invasive tumor in bone only 2 2 
Patient has never been disease-free 2 2 
Unknown if disease recurred or if the patient was ever disease-free 10 10 
Late stage, N=96   
Patient became disease-free after treatment and has not had a 
recurrence 40 42 
Regional recurrence 3 3 
Recurrence of an invasive tumor in adjacent tissue or organ 9 9 
Recurrence of an invasive tumor in regional lymph nodes only 4 4 
Recurrence of an invasive tumor in adjacent tissue or organ and in 
regional lymph node at the same time 3 3 
Distant recurrence 1 1 
Distant recurrence of an invasive tumor in the lung only 3 3 
Distant recurrence of an invasive tumor in the liver only 2 2 
Distant recurrence of an invasive tumor in the lymph node only 2 2 
Distant recurrence of an invasive tumor in a single distant site and 
local, trocar, and or regional recurrence 1 1 
Distance recurrence of an invasive tumor in multiple sites 4 4 
Patient has never been disease-free 15 16 
Disease has recurred but the type of recurrence is unknown 2 2 
Unknown if disease recurred or if the patient was ever disease-free 7 7 
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APPENDIX D: SUPPLEMENTARY DETAILS FOR ARTICLE 4 
D.1 DIAGNOSTICS FOR THE COX PROPORTIONAL HAZARDS MODEL 
The proportional hazards assumption was examined using the post-estimation stphplot command 
in STATA. In the OS model there is some evidence that the proportional hazards assumption for 
HGF and stromal bFGF do not hold, however the model tested by these curves does not account 
for the interaction between HGF and stromal bFGF (Figure 48). In the RFS main effects model, 
no violations of the proportional hazards assumption were observed (Figure 49).  
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Figure 48 Tests of the proportional-hazards assumption for variables in Table 23 
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Figure 49  Tests of the proportional-hazards assumption for variables in Table 26 
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D.2 POWER CALCULATIONS 
The statistical power to detect an association between the four markers (tumor HGF, tumor c-
Met, tumor bFGF, and stromal bFGF) and survival outcomes (OS and RFS) was calculated using 
the stpower command in STATA (Table 36). The probability of death was 0.41 (87/211) and the 
probability of recurrence was 0.24 (42/174). The alpha was set at 0.05 and the log hazard ratios 
from the main effects model were specified as the effect sizes for the power calculations. 
 
 
Table 36 Power calculations for the association between biomarker expression and EC survival outcomes 
Marker Power 
Overall survival, N=211  
HGF 3% 
c-Met 27% 
Tumor bFGF 35% 
Stromal bFGF 32% 
Recurrence-free survival, N=174  
HGF 45% 
c-Met 7% 
Tumor bFGF 58% 
Stromal bFGF 20% 
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D.3 PROGNOSTIC ROLE OF HGF/C-MET/BFGF IN SUBGROUPS OF EC CASES 
OS and RFS Kaplan-Meier curves and log-rank tests comparing levels of HGF, c-Met, tumor 
bFGF, and stromal bFGF expression in subgroups of EC cases is shown in Figures 50-52. For 
space considerations, we only include graphs for associations significant at p<0.05. Positive 
HGF expression was associated with better OS in late stage cases and better RFS in low-grade 
Type I and high-grade Type I cases (Figure 50). Positive c-Met expression was significantly 
associated with worse RFS in low-grade Type I and better RFS in late stage cases (Figure 51). 
Tumor bFGF expression was significantly associated with worse OS and RFS in low-grade Type 
I cases. Additionally, tumor bFGF expression was significantly associated with worse RFS in 
early stage and late stage cases (Figure 52). Stromal bFGF expression was not significantly 
associated with either OS or RFS in any of the subgroups. 
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Figure 50 HGF in subgroups of EC cases 
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log-rank p<0.001
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Figure 51 c-Met in subgroups of EC cases 
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Figure 52 Tumor bFGF in subgroups of EC cases 
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D.4 ASSOCIATION BETWEEN HGF/C-MET/BFGF EXPRESSION AND 
METASTASIS 
HGF, c-Met, and bFGF are thought to influence cancer prognosis through metastasis and 
activation of angiogenesis. We examined the relationship between metastasis and expression of 
these biomarkers independent of their effect on prognosis. Stage IV EC cases were classified as 
distant metastatic cases while stage I-III cases were classified as non-distant metastatic cases. 
Only tumor bFGF expression was significantly associated with distant metastasis (p=0.01, Table 
37). Furthermore, a logistic regression model with distant metastasis as the outcome revealed 
that positive HGF was a significant predictor of the odds of metastasis (Table 38). Compared to 
negative HGF expression at the primary tumor site, positive HGF expression was associated with 
a higher odds of distant metastasis (OR: 3.29, 95% CI 1.06, 10.18) independent of c-Met, tumor 
bFGF, stromal bFGF, histology type, and age. 
 
Table 37 Association between metastasis, HGF, c-Met, tumor bFGF, and stromal bFGF expression 
N=211 No metastasis (N=174) Metastasis (N=37) p‡ 
 n (%)* %† n (%)* %†  
HGF     0.40 
Negative  151 (87) 86 29 (78) 78  
Positive 23 (13) 14 8 (22) 22  
c-Met     0.50 
Negative  129 (74) 78 26 (70) 72  
Positive  45 (26) 22 11 (30) 28  
Tumor bFGF     0.01 
Negative  149 (86) 94 27 (73) 76  
Positive  25 (14) 6 10 (27) 24  
Stromal bFGF     0.31 
Negative  76 (44) 40 19 (51) 52  
Positive  98 (56) 60 18 (49) 48  
* proportion in the study sample  
† weighted proportion  
‡ Adjusted Wald p-value 
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Table 38  Multivariable logistic regression model to predict metastasis (N=37) vs. no metastasis (N=174) 
 
 
 
 
 
 
 
 
 
 
Variable Adjusted OR (95% CI) Wald p-value* 
HGF      
Negative  1.00 0.04 
Positive  3.29 (1.06, 10.18)  
c-Met   
Negative  1.00 0.72 
Positive  0.84 (0.32, 2.20)  
Tumor bFGF   
Negative  1.00 0.48 
Positive  1.47 (0.50, 4.34)  
Stromal bFGF   
Negative  1.00 0.47 
Positive  0.71 (0.28, 1.80)  
Histology type   
Low-grade Type I 1.00 <0.001 
High-grade Type I 20.96 (4.49, 97.88)  
Clear cell 30.10 (8.37, 108.28)  
Papillary serous 43.79 (14.83, 129.35)  
   
Age at diagnosis 0.97 (0.93, 1.00) 0.09 
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D.5 AT-RISK POPULATION FOR RECURRENCE 
Cases known to be disease-free following the primary surgery were included in analyses of RFS. 
Tables 39 and 40 show the type of recurrence in the total cohort and stratified by stage. In the 
total sample 63% of patients were disease-free following primary surgery and did not have a 
recurrence over the follow-up period, while 20% of cases that entered a state of remission 
following surgery recurred over the follow-up. The remaining 17% of cases were either never 
disease-free or it was unknown if they entered a state of remission after the primary surgery and 
were therefore excluded from RFS analyses. Furthermore, two early stage cases reportedly had a 
local recurrence of an invasive tumor (Table 40) despite having a total hysterectomy with 
removal of both ovaries; these two cases were excluded as it was deemed implausible that 
patients without an intact uterus would have a local recurrence to the site. Therefore, the final 
sample for RFS analyses was 174. 
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Table 39 Type of first recurrence in the HGF/c-Met/bFGF study, N=211 
Recurrence type N % 
Patient became disease-free after treatment and has not had a 
recurrence 132 63 
Local recurrence of an invasive tumor 2 1 
Regional recurrence 2 1 
Recurrence of an invasive tumor in adjacent tissue or organ 14 7 
Recurrence of an invasive tumor in regional lymph nodes only 5 2 
Recurrence of an invasive tumor in adjacent tissue or organ and in 
regional lymph node at the same time 3 1 
Distant recurrence 1 0.5 
Distant recurrence of an invasive tumor in the lung only 3 1 
Distant recurrence of an invasive tumor in the liver only 2 1 
Distant recurrence of an invasive tumor in bone only 2 1 
Distant recurrence of an invasive tumor in the lymph node only 2 1 
Distant recurrence of an invasive tumor in a single distant site and 
local, trocar, and or regional recurrence 1 0.5 
Distance recurrence of an invasive tumor in multiple sites 5 2 
Patient has never been disease-free 17 8 
Disease has recurred but the type of recurrence is unknown 2 1 
Unknown if disease recurred or if the patient was ever disease -free. 18 9 
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Table 40 Type of first recurrence stratified by stage 
Early stage, N=111 N % 
Patient became disease-free after treatment and has not had a 
recurrence 87 78 
Local recurrence of an invasive tumor 2 2 
Recurrence of an invasive tumor in adjacent tissue or organ 5 5 
Recurrence of an invasive tumor in regional lymph nodes only 1 1 
Distant recurrence of an invasive tumor in bone only 2 2 
Distance recurrence of an invasive tumor in multiple sites 1 1 
Patient has never been disease-free 2 2 
Unknown if disease recurred or if the patient was ever disease -free 11 10 
Late stage, N=100   
Patient became disease-free after treatment and has not had a 
recurrence 45 45 
Regional recurrence 2 2 
Recurrence of an invasive tumor in adjacent tissue or organ 9 9 
Recurrence of an invasive tumor in regional lymph nodes only 4 4 
Recurrence of an invasive tumor in adjacent tissue or organ and in 
regional lymph node at the same time 3 3 
Distant recurrence 1 1 
Distant recurrence of an invasive tumor in the lung only 3 3 
Distant recurrence of an invasive tumor in the liver only 2 2 
Distant recurrence of an invasive tumor in the lymph node only 2 2 
Distant recurrence of an invasive tumor in a single distant site and 
local, trocar, and or regional recurrence 1 1 
Distance recurrence of an invasive tumor in multiple sites 4 4 
Patient has never been disease-free 15 15 
Disease has recurred but the type of recurrence is unknown 2 2 
Unknown if disease recurred or if the patient was ever disease -free. 7 7 
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